10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 FORM 10-Q  

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2023

OR 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 001-34950

SABRA HEALTH CARE REIT, INC.

(Exact Name of Registrant as Specified in Its Charter) 

Maryland	27-2560479
(State of Incorporation)	(I.R.S. Employer Identification No.)

18500 Von Karman Avenue, Suite 550

Irvine, CA 92612

(888) 393-8248

(Address, zip code and telephone number of Registrant)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common stock, $.01 par value	SBRA	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒

As of April 27, 2023, there were 231,195,148 shares of the registrant’s $0.01 par value Common Stock outstanding.

SABRA HEALTH CARE REIT, INC. AND SUBSIDIARIES

Index

		Page Numbers
PART I. FINANCIAL INFORMATION
Item 1.	Financial Statements:
	Consolidated Balance Sheets	4
	Consolidated Statements of (Loss) Income	5
	Consolidated Statements of Comprehensive (Loss) Income	6
	Consolidated Statements of Equity	7
	Consolidated Statements of Cash Flows	8
	Notes to Consolidated Financial Statements	9
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	26
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	37
Item 4.	Controls and Procedures	37
PART II. OTHER INFORMATION
Item 1.	Legal Proceedings	38
Item 1A.	Risk Factors	38
Item 6.	Exhibits	38
Signatures		40

1

References throughout this document to “Sabra,” “we,” “our,” “ours” and “us” refer to Sabra Health Care REIT, Inc. and its direct and indirect consolidated subsidiaries and not any other person.

STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

Certain statements in this Quarterly Report on Form 10-Q (this “10-Q”) contain “forward-looking” information as that term is defined by the Private Securities Litigation Reform Act of 1995. Any statements that do not relate to historical or current facts or matters are forward-looking statements. Examples of forward-looking statements include all statements regarding our expected future financial position, results of operations, cash flows, liquidity, financing plans, business strategy, tenants, borrowers and Senior Housing - Managed communities (as defined below), the expected amounts and timing of dividends and other distributions, projected expenses and capital expenditures, competitive position, growth opportunities, potential investments, potential dispositions, plans and objectives for future operations, and compliance with and changes in governmental regulations. You can identify some of the forward-looking statements by the use of forward-looking words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend,” “should,” “may” and other similar expressions, although not all forward-looking statements contain these identifying words.

Our actual results may differ materially from those projected or contemplated by our forward-looking statements as a result of various factors, including, among others, the following:

•pandemics or epidemics, including COVID-19, and the related impact on our tenants, borrowers and Senior Housing - Managed communities;

•increased labor costs and historically low unemployment;

•increases in market interest rates and inflation;

•operational risks with respect to our Senior Housing - Managed communities;

•competitive conditions in our industry;

•the loss of key management personnel;

•uninsured or underinsured losses affecting our properties;

•potential impairment charges and adjustments related to the accounting of our assets;

•the potential variability of our reported rental and related revenues as a result of Accounting Standards Update (“ASU”) 2016-02, Leases, as amended by subsequent ASUs;

•risks associated with our investment in our unconsolidated joint ventures;

•catastrophic weather and other natural or man-made disasters, the effects of climate change on our properties and a failure to implement sustainable and energy-efficient measures;

•increased operating costs and competition for our tenants, borrowers and Senior Housing - Managed communities;

•increased healthcare regulation and enforcement;

•our tenants’ dependency on reimbursement from governmental and other third-party payor programs;

•the effect of our tenants, operators or borrowers declaring bankruptcy or becoming insolvent;

•our ability to find replacement tenants and the impact of unforeseen costs in acquiring new properties;

•the impact of litigation and rising insurance costs on the business of our tenants;

•the impact of required regulatory approvals of transfers of healthcare properties;

•environmental compliance costs and liabilities associated with real estate properties we own;

•our tenants’, borrowers’ or operators’ failure to adhere to applicable privacy and data security laws, or a material breach of our or our tenants’, borrowers’ or operators’ information technology;

•our concentration in the healthcare property sector, particularly in skilled nursing/transitional care facilities and senior housing communities, which makes our profitability more vulnerable to a downturn in a specific sector than if we were investing in multiple industries;

•the significant amount of and our ability to service our indebtedness;

•covenants in our debt agreements that may restrict our ability to pay dividends, make investments, incur additional indebtedness and refinance indebtedness on favorable terms;

•adverse changes in our credit ratings;

•our ability to make dividend distributions at expected levels;

•our ability to raise capital through equity and debt financings;

•changes and uncertainty in macroeconomic conditions and disruptions in the financial markets;

•risks associated with our ownership of property outside the U.S., including currency fluctuations;

•the relatively illiquid nature of real estate investments;

•our ability to maintain our status as a real estate investment trust (“REIT”) under the federal tax laws;

•compliance with REIT requirements and certain tax and tax regulatory matters related to our status as a REIT;

•changes in tax laws and regulations affecting REITs;

2

•the ownership limits and takeover defenses in our governing documents and under Maryland law, which may restrict change of control or business combination opportunities; and

•the exclusive forum provisions in our bylaws.

We urge you to carefully consider these risks and review the additional disclosures we make concerning risks and other factors that may materially affect the outcome of our forward-looking statements and our future business and operating results, including those made in Part I, Item 1A, “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2022 (our “2022 Annual Report on Form 10-K”), as such risk factors may be amended, supplemented or superseded from time to time by other reports we file with the Securities and Exchange Commission (the “SEC”), including subsequent Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. We caution you that any forward-looking statements made in this 10-Q are not guarantees of future performance, events or results, and you should not place undue reliance on these forward-looking statements, which speak only as of the date of this report. We do not intend, and we undertake no obligation, to update any forward-looking information to reflect events or circumstances after the date of this 10-Q or to reflect the occurrence of unanticipated events, unless required by law to do so.

3

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

SABRA HEALTH CARE REIT, INC.

CONSOLIDATED BALANCE SHEETS

(dollars in thousands, except per share data)

	March 31, 2023		December 31, 2022
	(unaudited)
Assets
Real estate investments, net of accumulated depreciation of $952,791 and $913,345 as of March 31, 2023 and December 31, 2022, respectively	$	4,797,041	$	4,959,343
Loans receivable and other investments, net	409,079		411,396
Investment in unconsolidated joint ventures	139,402		134,962
Cash and cash equivalents	33,532		49,308
Restricted cash	5,152		4,624
Lease intangible assets, net	39,369		40,131
Accounts receivable, prepaid expenses and other assets, net	132,736		147,908
Total assets	$	5,556,311	$	5,747,672
Liabilities
Secured debt, net	$	48,754	$	49,232
Revolving credit facility	79,563		196,982
Term loans, net	533,657		526,129
Senior unsecured notes, net	1,734,644		1,734,431
Accounts payable and accrued liabilities	143,002		142,259
Lease intangible liabilities, net	40,464		42,244
Total liabilities	2,580,084		2,691,277
Commitments and contingencies (Note 12)
Equity
Preferred stock, $0.01 par value; 10,000,000 shares authorized, zero shares issued and outstanding as of March 31, 2023 and December 31, 2022	—		—
Common stock, $0.01 par value; 500,000,000 shares authorized, 231,195,148 and 231,009,295 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively	2,312		2,310
Additional paid-in capital	4,487,707		4,486,967
Cumulative distributions in excess of net income	(1,531,230)		(1,451,945)
Accumulated other comprehensive income	17,438		19,063
Total equity	2,976,227		3,056,395
Total liabilities and equity	$	5,556,311	$	5,747,672

See accompanying notes to consolidated financial statements.

4

SABRA HEALTH CARE REIT, INC.

CONSOLIDATED STATEMENTS OF (LOSS) INCOME

(dollars in thousands, except per share data)

(unaudited)

	Three Months Ended March 31,
	2023		2022
Revenues:
Rental and related revenues (Note 4)	$	95,870	$	109,886
Resident fees and services	56,721		42,227
Interest and other income	8,733		10,992
Total revenues	161,324		163,105
Expenses:
Depreciation and amortization	52,827		45,256
Interest	28,540		24,972
Triple-net portfolio operating expenses	4,168		5,011
Senior housing - managed portfolio operating expenses	43,637		33,104
General and administrative	10,502		10,396
(Recovery of) provision for loan losses and other reserves	(208)		475
Impairment of real estate	7,064		—
Total expenses	146,530		119,214
Other (expense) income:
Loss on extinguishment of debt	(1,541)		(271)
Other income	341		68
Net loss on sales of real estate	(21,515)		—
Total other expense	(22,715)		(203)
(Loss) income before loss from unconsolidated joint ventures and income tax expense	(7,921)		43,688
Loss from unconsolidated joint ventures	(838)		(2,802)
Income tax expense	(728)		(284)
Net (loss) income	$	(9,487)	$	40,602
Net (loss) income, per:
Basic common share	$	(0.04)	$	0.18
Diluted common share	$	(0.04)	$	0.18
Weighted average number of common shares outstanding, basic	231,164,876		230,859,993
Weighted average number of common shares outstanding, diluted	231,164,876		231,564,970

See accompanying notes to consolidated financial statements.

5

SABRA HEALTH CARE REIT, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME

(in thousands)

(unaudited)

	Three Months Ended March 31,
	2023		2022
Net (loss) income	$	(9,487)	$	40,602
Other comprehensive (loss) income:
Unrealized gain (loss), net of tax:
Foreign currency translation loss	(1,623)		(644)
Unrealized (loss) gain on cash flow hedges	(2)		12,339
Total other comprehensive (loss) income	(1,625)		11,695
Comprehensive (loss) income	$	(11,112)	$	52,297

See accompanying notes to consolidated financial statements.

6

SABRA HEALTH CARE REIT, INC.

CONSOLIDATED STATEMENTS OF EQUITY

(dollars in thousands, except per share data)

(unaudited)

	Three Months Ended March 31, 2022
	Common Stock			Additional Paid-in Capital		Cumulative Distributions in Excess of Net Income		Accumulated Other Comprehensive (Loss) Income		Total Equity
	Shares	Amounts
Balance, December 31, 2021	230,398,655	$	2,304	$	4,482,451	$	(1,095,204)	$	(10,021)	$	3,379,530
Net income	—	—		—		40,602		—		40,602
Other comprehensive income	—	—		—		—		11,695		11,695
Amortization of stock-based compensation	—	—		2,673		—		—		2,673
Common stock issuance, net	556,122	6		(3,490)		—		—		(3,484)
Common dividends ($0.30 per share)	—	—		—		(69,493)		—		(69,493)
Balance, March 31, 2022	230,954,777	$	2,310	$	4,481,634	$	(1,124,095)	$	1,674	$	3,361,523
	Three Months Ended March 31, 2023
	Common Stock			Additional Paid-in Capital		Cumulative Distributions in Excess of Net Income		Accumulated Other Comprehensive Income (Loss)		Total Equity
	Shares	Amounts
Balance, December 31, 2022	231,009,295	$	2,310	$	4,486,967	$	(1,451,945)	$	19,063	$	3,056,395
Net loss	—	—		—		(9,487)		—		(9,487)
Other comprehensive loss	—	—		—		—		(1,625)		(1,625)
Amortization of stock-based compensation	—	—		2,675		—		—		2,675
Common stock issuance, net	185,853	2		(1,935)		—		—		(1,933)
Common dividends ($0.30 per share)	—	—		—		(69,798)		—		(69,798)
Balance, March 31, 2023	231,195,148	$	2,312	$	4,487,707	$	(1,531,230)	$	17,438	$	2,976,227

See accompanying notes to consolidated financial statements.

7

SABRA HEALTH CARE REIT, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

	Three Months Ended March 31,
	2023		2022
Cash flows from operating activities:
Net (loss) income	$	(9,487)	$	40,602
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization	52,827		45,256
Non-cash rental and related revenues	(2,398)		(4,474)
Non-cash interest income	(392)		(547)
Non-cash interest expense	3,014		2,698
Stock-based compensation expense	2,229		2,456
Loss on extinguishment of debt	1,541		271
Provision for loan losses and other reserves	(208)		475
Net loss on sales of real estate	21,515		—
Impairment of real estate	7,064		—
Loss from unconsolidated joint ventures	838		2,802
Distributions of earnings from unconsolidated joint ventures	367		—
Changes in operating assets and liabilities:
Accounts receivable, prepaid expenses and other assets, net	(2,782)		(5,457)
Accounts payable and accrued liabilities	(5,839)		(20,968)
Net cash provided by operating activities	68,289		63,114
Cash flows from investing activities:
Acquisition of real estate	(39,630)		(20,573)
Origination and fundings of loans receivable	(1,800)		—
Origination and fundings of preferred equity investments	(6,384)		(4,074)
Additions to real estate	(19,540)		(10,803)
Escrow deposits for potential investments	—		(3,217)
Repayments of loans receivable	6,144		696
Repayments of preferred equity investments	1,433		729
Investment in unconsolidated joint ventures	(4,797)		—
Net proceeds from the sales of real estate	152,259		—
Net proceeds from sales-type lease	25,490		—
Net cash provided by (used in) investing activities	113,175		(37,242)
Cash flows from financing activities:
Net (repayments of) borrowings from revolving credit facility	(118,442)		16,577
Proceeds from term loans	12,186		—
Principal payments on term loans	—		(40,000)
Principal payments on secured debt	(490)		(16,067)
Payments of deferred financing costs	(18,127)		(6)
Issuance of common stock, net	(1,847)		(3,748)
Dividends paid on common stock	(69,351)		(69,275)
Net cash used in financing activities	(196,071)		(112,519)
Net decrease in cash, cash equivalents and restricted cash	(14,607)		(86,647)
Effect of foreign currency translation on cash, cash equivalents and restricted cash	(641)		40
Cash, cash equivalents and restricted cash, beginning of period	53,932		115,886
Cash, cash equivalents and restricted cash, end of period	$	38,684	$	29,279
Supplemental disclosure of cash flow information:
Interest paid	$	22,318	$	18,383
Supplemental disclosure of non-cash investing activities:
Decrease in loans receivable and other investments due to acquisition of real estate	$	4,644	$	5,623

See accompanying notes to consolidated financial statements.

8

SABRA HEALTH CARE REIT, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

1.     BUSINESS

Overview

Sabra Health Care REIT, Inc. (“Sabra” or the “Company”) was incorporated on May 10, 2010 as a wholly owned subsidiary of Sun Healthcare Group, Inc. (“Sun”) and commenced operations on November 15, 2010 following Sabra’s separation from Sun. Sabra elected to be treated as a real estate investment trust (“REIT”) with the filing of its United States (“U.S.”) federal income tax return for the taxable year beginning January 1, 2011. Sabra believes that it has been organized and operated, and it intends to continue to operate, in a manner to qualify as a REIT. Sabra’s primary business consists of acquiring, financing and owning real estate property to be leased to third-party tenants in the healthcare sector. Sabra primarily generates revenues by leasing properties to tenants throughout the U.S. and Canada. Sabra owns substantially all of its assets and properties and conducts its operations through Sabra Health Care Limited Partnership, a Delaware limited partnership (the “Operating Partnership”), of which Sabra is the sole general partner and a wholly owned subsidiary of Sabra is currently the only limited partner, or by subsidiaries of the Operating Partnership. The Company’s investment portfolio is primarily comprised of skilled nursing/transitional care facilities, senior housing communities (“Senior Housing - Leased”), behavioral health facilities and specialty hospitals and other facilities, in each case leased to tenants who are responsible for the operations of these facilities; senior housing communities operated by third-party property managers pursuant to property management agreements (“Senior Housing - Managed”); investments in joint ventures; investments in loans receivable; and preferred equity investments.

2.     SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation and Basis of Presentation

The accompanying consolidated financial statements include the accounts of Sabra and its wholly owned subsidiaries as of March 31, 2023 and December 31, 2022 and for the three month periods ended March 31, 2023 and 2022. All significant intercompany transactions and balances have been eliminated in consolidation.

The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information as contained within the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification and the rules and regulations of the SEC, including the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the unaudited consolidated financial statements do not include all of the information and footnotes required by GAAP for financial statements. In the opinion of management, the financial statements for the unaudited interim periods presented include all adjustments, which are of a normal and recurring nature, necessary for a fair statement of the results for such periods. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. For further information, refer to the Company’s consolidated financial statements and notes thereto for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC.

GAAP requires the Company to identify entities for which control is achieved through voting rights or other means and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). A VIE is broadly defined as an entity with one or more of the following characteristics: (a) the total equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (b) as a group, the holders of the equity investment at risk lack (i) the ability to make decisions about the entity’s activities through voting or similar rights, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity; or (c) the equity investors have voting rights that are not proportional to their economic interests, and substantially all of the entity’s activities either involve, or are conducted on behalf of, an investor that has disproportionately few voting rights. If the Company were determined to be the primary beneficiary of the VIE, the Company would consolidate investments in the VIE. The Company may change its original assessment of a VIE due to events such as modifications of contractual arrangements that affect the characteristics or adequacy of the entity’s equity investments at risk and the disposal of all or a portion of an interest held by the primary beneficiary.

The Company identifies the primary beneficiary of a VIE as the enterprise that has both: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance; and (ii) the obligation to absorb losses or

9

the right to receive benefits of the VIE that could be significant to the entity. The Company performs this analysis on an ongoing basis. As of March 31, 2023, the Company determined that it was not the primary beneficiary of any VIEs.

As it relates to investments in loans, in addition to the Company’s assessment of VIEs and whether the Company is the primary beneficiary of those VIEs, the Company evaluates the loan terms and other pertinent facts to determine whether the loan investment should be accounted for as a loan or as a real estate joint venture. If an investment has the characteristics of a real estate joint venture, including if the Company participates in the majority of the borrower’s expected residual profit, the Company would account for the investment as an investment in a real estate joint venture and not as a loan investment. Expected residual profit is defined as the amount of profit, whether called interest or another name, such as an equity kicker, above a reasonable amount of interest and fees expected to be earned by a lender. At March 31, 2023, none of the Company’s investments in loans were accounted for as real estate joint ventures.

As it relates to investments in joint ventures, the Company assesses any partners’ rights and their impact on the presumption of control of the partnership by any single partner. The Company also applies this guidance to managing member interests in limited liability companies. The Company reassesses its determination of which entity controls the joint venture if: there is a change to the terms or in the exercisability of the rights of any partners or members, the general partner or managing member increases or decreases its ownership interests, or there is an increase or decrease in the number of outstanding ownership interests. As of March 31, 2023, the Company’s determination of which entity controls its investments in joint ventures has not changed as a result of any reassessment.

Use of Estimates

The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.

3.     RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED)

During the three months ended March 31, 2023, the Company acquired one Senior Housing - Leased community and one Senior Housing - Managed community. During the three months ended March 31, 2022, the Company acquired one Senior Housing - Managed community. The Senior Housing - Managed communities acquired during the three months ended March 31, 2023 and 2022 were part of the Company’s proprietary development pipeline and were previously reflected as preferred equity investments which had a book value of $4.6 million and $5.6 million, respectively, at the time of acquisition. The consideration was allocated as follows (in thousands):

	Three Months Ended March 31,
	2023		2022
Land	$	3,415	$	3,691
Building and improvements	45,333		21,168
Tenant origination and absorption costs intangible assets	2,706		1,337
Tenant relationship intangible assets	20		—
Total consideration	$	51,474	$	26,196

The tenant origination and absorption costs intangible assets and tenant relationship intangible assets had a weighted average amortization periods as of the respective dates of acquisition of one year and 22 years, respectively, for the acquisitions completed during the three months ended March 31, 2023. The tenant origination and absorption costs intangible assets had an amortization period as of the date of acquisition of one year for the acquisition completed during the three months ended March 31, 2022.

For the three months ended March 31, 2023, the Company recognized $1.7 million of total revenues and $0.2 million of net income from the facilities acquired during the three months ended March 31, 2023. For the three months ended March 31, 2022, the Company recognized $0.9 million of total revenues and $0.1 million of net income from the facility acquired during the three months ended March 31, 2022.

The Company is required to pay additional consideration related to two Senior Housing - Managed communities if certain performance metrics are achieved, and as of March 31, 2023, based on the improved performance of these facilities, the aggregate additional consideration is estimated to be $17.4 million and is included in real estate investments, net of accumulated depreciation and accounts payable and accrued liabilities on the accompanying consolidated balance sheets.

10

4.    INVESTMENT IN REAL ESTATE PROPERTIES

The Company’s real estate properties held for investment consisted of the following (dollars in thousands):

As of March 31, 2023

Property Type	Number of Properties	Number of Beds/Units	Total Real Estate at Cost		Accumulated Depreciation		Total Real Estate Investments, Net
Skilled Nursing/Transitional Care	258	28,334	$	3,212,202	$	(518,215)	$	2,693,987
Senior Housing - Leased	47	3,600	592,119		(101,303)		490,816
Senior Housing - Managed	59	5,973	1,245,066		(227,844)		1,017,222
Behavioral Health	17	965	474,079		(61,487)		412,592
Specialty Hospitals and Other	15	392	225,443		(43,392)		182,051
	396	39,264	5,748,909		(952,241)		4,796,668
Corporate Level			923		(550)		373
			$	5,749,832	$	(952,791)	$	4,797,041

As of December 31, 2022

Property Type	Number of Properties	Number of Beds/Units	Total Real Estate at Cost		Accumulated Depreciation		Total Real Estate Investments, Net
Skilled Nursing/Transitional Care	264	29,136	$	3,385,221	$	(492,495)	$	2,892,726
Senior Housing - Leased	47	3,550	590,694		(97,716)		492,978
Senior Housing - Managed	59	5,942	1,205,283		(222,089)		983,194
Behavioral Health	17	965	465,143		(58,481)		406,662
Specialty Hospitals and Other	15	392	225,443		(42,038)		183,405
	402	39,985	5,871,784		(912,819)		4,958,965
Corporate Level			904		(526)		378
			$	5,872,688	$	(913,345)	$	4,959,343

	March 31, 2023		December 31, 2022
Building and improvements	$	4,945,404	$	5,034,470
Furniture and equipment	236,032		262,644
Land improvements	9,499		7,085
Land	558,897		568,489
Total real estate at cost	5,749,832		5,872,688
Accumulated depreciation	(952,791)		(913,345)
Total real estate investments, net	$	4,797,041	$	4,959,343

Operating Leases

As of March 31, 2023, the substantial majority of the Company’s real estate properties (excluding 59 Senior Housing - Managed communities) were leased under triple-net operating leases with expirations ranging from less than one year to 20 years. As of March 31, 2023, the leases had a weighted average remaining term of eight years. The leases generally include provisions to extend the lease terms and other negotiated terms and conditions. The Company, through its subsidiaries, retains substantially all of the risks and benefits of ownership of the real estate assets leased to the tenants. The Company may receive additional security under these operating leases in the form of letters of credit and security deposits from the lessee or guarantees from the parent of the lessee. Security deposits received in cash related to tenant leases are included in accounts payable and accrued liabilities on the accompanying consolidated balance sheets and totaled $14.0 million and $13.1 million as of March 31, 2023 and December 31, 2022, respectively, and letters of credit deposited with the Company totaled approximately $59 million and $57 million as of March 31, 2023 and December 31, 2022, respectively. In addition, the Company’s tenants have deposited with the Company $13.6 million and $13.3 million as of March 31, 2023 and December 31,

11

2022, respectively, for future real estate taxes, insurance expenditures and tenant improvements related to the Company’s properties and their operations, and these amounts are included in accounts payable and accrued liabilities on the accompanying consolidated balance sheets.

Lessor costs that are paid by the lessor and reimbursed by the lessee are included in the measurement of variable lease revenue and the associated expense. As a result, the Company recognized variable lease revenue and the associated expense of $3.8 million and $5.1 million during the three months ended March 31, 2023 and 2022, respectively.

The Company monitors the creditworthiness of its tenants by evaluating the ability of the tenants to meet their lease obligations to the Company based on the tenants’ financial performance, including, as applicable and appropriate, the evaluation of any parent guarantees (or the guarantees of other related parties) of such lease obligations. The primary basis for the Company’s evaluation of the credit quality of its tenants (and more specifically the tenant’s ability to pay their rent obligations to the Company) is the tenant’s lease coverage ratio as supplemented by the parent’s fixed charge coverage ratio for those entities with a parent guarantee. These coverage ratios include earnings before interest, taxes, depreciation, amortization and rent (“EBITDAR”) to rent and earnings before interest, taxes, depreciation, amortization, rent and management fees (“EBITDARM”) to rent at the lease level and consolidated EBITDAR to total fixed charges at the parent guarantor level when such a guarantee exists. The Company obtains various financial and operational information from the majority of its tenants each month and reviews this information in conjunction with the above-described coverage metrics to identify financial and operational trends, evaluate the impact of the industry’s operational and financial environment (including the impact of government reimbursement), and evaluate the management of the tenant’s operations. These metrics help the Company identify potential areas of concern relative to its tenants’ credit quality and ultimately the tenant’s ability to generate sufficient liquidity to meet its obligations, including its obligation to continue to pay the rent due to the Company.

During the third quarter of 2022, the Company concluded that its leases with North American Health Care, Inc. (“North American”) should no longer be accounted for on an accrual basis and wrote off $15.6 million of straight-line rent receivable balances related to these leases. The facilities were transitioned to the Ensign Group or Avamere, as applicable, effective February 1, 2023.

For the three months ended March 31, 2023, no tenant relationship represented 10% or more of the Company’s total revenues.

As of March 31, 2023, the future minimum rental payments from the Company’s properties held for investment under non-cancelable operating leases were as follows and may materially differ from actual future rental payments received (in thousands):

April 1 through December 31, 2023	$	279,989
2024	380,057
2025	375,286
2026	360,133
2027	337,235
Thereafter	1,535,962
	$	3,268,662

Senior Housing - Managed Communities

The Company’s Senior Housing - Managed communities offer residents certain ancillary services that are not contemplated in the lease with each resident (i.e., housekeeping, laundry, guest meals, etc.). These services are provided and paid for in addition to the standard services included in each resident lease (i.e., room and board, standard meals, etc.). The Company bills residents for ancillary services one month in arrears and recognizes revenue as the services are provided, as the Company has no continuing performance obligation related to those services. Resident fees and services include ancillary service revenue of $0.5 million and $0.3 million for the three months ended March 31, 2023 and 2022, respectively.

Capital and Other Expenditures

As of March 31, 2023, the Company’s aggregate commitment for future capital and other expenditures associated with facilities leased under triple-net operating leases was approximately $65 million. These commitments are principally for improvements to its facilities.

12

Investment in Unconsolidated Joint Ventures

The following is a summary of the Company’s investment in unconsolidated joint ventures (dollars in thousands):

	Property Type	Number of Properties as of March 31, 2023	Ownership as of March 31, 2023 (1)		Book Value
					March 31, 2023		December 31, 2022
Sienna Joint Venture	Senior Housing - Managed	12	50	%	$	119,824	$	120,269
Marlin Spring Joint Venture	Senior Housing - Managed	4	85	%	19,578		14,693
					$	139,402	$	134,962

(1)    These investments are not consolidated because the Company does not control, through voting rights or other means, the joint ventures.

During the three months ended March 31, 2023, the Company’s joint venture with Marlin Spring (the “Marlin Spring Joint Venture”) completed the acquisition of one additional senior housing community that is being managed by a third-party property manager. The gross investment in the additional acquisition was CAD $30.0 million, excluding acquisition costs. In addition, the Marlin Spring Joint Venture assumed and financed an aggregate CAD $23.6 million of debt associated with the additional acquisition.

During the fourth quarter of 2022, due to the confluence of labor shortages, increased labor costs, elevated interest rates and a slower than anticipated recovery in the operating performance of the underlying facilities, the Company concluded that the estimated fair value of its investment in its joint venture with affiliates of TPG Real Estate, the real estate platform of TPG (the “Enlivant Joint Venture”) had declined to zero based on updated future cash flow analyses. This decline was deemed to be other-than-temporary, and the Company recorded an impairment charge totaling $57.8 million during the three months ended December 31, 2022.

The Company has not guaranteed any obligations of and is not committed to provide any support to the Enlivant Joint Venture. The Company has discontinued applying the equity method of accounting to the Enlivant Joint Venture, in which it has a 49% equity interest, and will resume application if, during the period in which application of the equity method of accounting has been discontinued, the Company’s share of unrecognized net income exceeds its share of unrecognized net losses.

Net Investment in Sales-Type Lease

As of December 31, 2022, the Company had a $25.5 million net investment in one skilled nursing/transitional care facility leased to a tenant under a sales-type lease, as the tenant is obligated to purchase the property at the end of the lease term. During the three months ended March 31, 2023, the tenant purchased the skilled nursing/transitional care facility for net proceeds of $25.5 million as obligated under the terms of the lease.

5.    IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS

Impairment of Real Estate

During the three months ended March 31, 2023, the Company recognized $7.1 million of real estate impairment related to one skilled nursing/transitional care facility that is under contract to sell.

During the three months ended March 31, 2022, the Company recognized no real estate impairment.

To estimate the fair value of the impaired facility, the Company utilized a market approach which considered the binding sale agreement (Level 3 measurement).

The Company continues to evaluate additional assets for sale as part of its initiative to recycle capital and further improve its portfolio quality. This could lead to a shorter hold period and could result in the determination that the full amount of the Company’s investment is not recoverable, resulting in an impairment charge which could be material.

13

Dispositions

The following table summarizes the Company’s dispositions for the periods presented (dollars in millions):

	Three Months Ended March 31,
	2023		2022
Number of facilities	8		—
Consideration, net of closing costs	$	160.3	$	—
Net carrying value	181.8		—
Net loss on sale	$	(21.5)	$	—
Net (loss) income	$	(22.1)	$	0.1

The sale of the disposition facilities does not represent a strategic shift that has or will have a major effect on the Company’s operations and financial results, and therefore the results of operations attributable to these facilities have remained in continuing operations.

6.    LOANS RECEIVABLE AND OTHER INVESTMENTS

As of March 31, 2023 and December 31, 2022, the Company’s loans receivable and other investments consisted of the following (dollars in thousands):

									As of March 31, 2023
Investment	Quantity as of March 31, 2023	Property Type	Principal Balance as of March 31, 2023 (1)		Book Value as of March 31, 2023		Book Value as of December 31, 2022		Weighted Average Contractual Interest Rate / Rate of Return		Weighted Average Annualized Effective Interest Rate / Rate of Return		Maturity Date as of March 31, 2023
Loans Receivable:
Mortgage	2	Behavioral Health	$	319,000	$	319,000	$	319,000	7.6	%	7.6	%	11/01/26 - 01/31/27
Other	11	Multiple	47,200		43,768		47,936		7.1	%	6.5	%	08/31/23 - 08/31/28
	13		366,200		362,768		366,936		7.6	%	7.5	%
Allowance for loan losses			—		(6,403)		(6,611)
			$	366,200	$	356,365	$	360,325
Other Investments:
Preferred Equity	6	Skilled Nursing / Senior Housing	52,551		52,714		51,071		10.9	%	10.8	%	N/A
Total	19		$	418,751	$	409,079	$	411,396	8.0	%	7.9	%

(1)    Principal balance includes amounts funded and accrued but unpaid interest / preferred return and excludes capitalizable fees.

As of March 31, 2023, the Company has committed to provide up to $28.0 million of future funding related to two preferred equity investments and one loan receivable investment that matures in June 2024.

14

Additional information regarding the Company’s loans receivable is as follows (dollars in thousands):

	Three Months Ended March 31,
	2023		2022
Allowance for loan losses:
Balance at beginning of the period	$	6,611	$	6,344
(Recovery of) provision for loan losses	(208)		507
Balance at end of the period	$	6,403	$	6,851
	March 31, 2023		December 31, 2022
Deteriorated credit quality:
Number of loans receivable investments	1		1
Principal balance	$	1,214	$	1,214
Book value	—		—
Nonaccrual status:
Number of loans receivable investments	3		3
Book value	$	—	$	—

As of March 31, 2023 and December 31, 2022, the Company did not consider any preferred equity investments to be impaired, and no preferred equity investments were on nonaccrual status.

7.    DEBT

Secured Indebtedness

The Company’s secured debt consists of the following (dollars in thousands):

					As of March 31, 2023
Interest Rate Type	Principal Balance as of March 31, 2023 (1)		Principal Balance as of December 31, 2022 (1)		Weighted Average Interest Rate		Weighted Average Effective Interest Rate (2)		Maturity Date
Fixed Rate	$	49,633	$	50,123	2.84	%	3.34	%	May 2031 -  August 2051

(1)     Principal balance does not include deferred financing costs, net of $0.9 million as of each of March 31, 2023 and December 31, 2022.

(2)     Weighted average interest rate includes private mortgage insurance.

Senior Unsecured Notes

The Company’s senior unsecured notes consist of the following (dollars in thousands):

		Principal Balance as of
Title	Maturity Date	March 31, 2023 (1)		December 31, 2022 (1)
5.125% senior unsecured notes due 2026 (“2026 Notes”)	August 15, 2026	$	500,000	$	500,000
5.88% senior unsecured notes due 2027 (“2027 Notes”)	May 17, 2027	100,000		100,000
3.90% senior unsecured notes due 2029 (“2029 Notes”)	October 15, 2029	350,000		350,000
3.20% senior unsecured notes due 2031 (“2031 Notes”)	December 1, 2031	800,000		800,000
		$	1,750,000	$	1,750,000

(1)    Principal balance does not include discount, net of $3.7 million and deferred financing costs, net of $11.6 million as of March 31, 2023 and does not include discount, net of $3.5 million and deferred financing costs, net of $12.0 million as of December 31, 2022. In addition, the weighted average effective interest rate as of March 31, 2023 was 4.01%.

The 2026 Notes and the 2027 Notes were assumed as a result of the Company’s merger with Care Capital Properties, Inc. in 2017 and accrue interest at a rate of 5.125% and 5.88%, respectively, per annum. Interest is payable semiannually on February 15 and August 15 of each year for the 2026 Notes and on May 17 and November 17 of each year for the 2027 Notes.

15

The 2029 Notes were issued by the Operating Partnership and, until redemption of the Company’s previously outstanding 5.375% senior notes due 2023 in October 2019, Sabra Capital Corporation, wholly owned subsidiaries of the Company, and accrue interest at a rate of 3.90% per annum. Interest is payable semiannually on April 15 and October 15 of each year.

The 2031 Notes were issued by the Operating Partnership, a wholly owned subsidiary of the Company, and accrue interest at a rate of 3.20% per annum. Interest is payable semiannually on June 1 and December 1 of each year, commencing on June 1, 2022.

The obligations under the 2027 Notes are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by Sabra and one of its non-operating subsidiaries, subject to release under certain customary circumstances. The obligations under the 2026 Notes, 2029 Notes and 2031 Notes are fully and unconditionally guaranteed, on an unsecured basis, by Sabra; provided, however, that such guarantee is subject to release under certain customary circumstances.

The indentures and agreements (the “Senior Notes Indentures”) governing the 2026 Notes, 2027 Notes, 2029 Notes and 2031 Notes (collectively, the “Senior Notes”) include customary events of default and require the Company to comply with specified restrictive covenants. As of March 31, 2023, the Company was in compliance with all applicable financial covenants under the Senior Notes Indentures.

Credit Agreement

On September 9, 2019, the Operating Partnership and Sabra Canadian Holdings, LLC (together, the “Borrowers”), Sabra and the other parties thereto entered into a fifth amended and restated unsecured credit agreement (the “Prior Credit Agreement”).

The Prior Credit Agreement included a $1.0 billion revolving credit facility (the “Prior Revolving Credit Facility”), a $436.3 million U.S. dollar term loan and a CAD $125.0 million Canadian dollar term loan (collectively, the “Prior Term Loans”). Further, up to $175.0 million of the Prior Revolving Credit Facility could be used for borrowings in certain foreign currencies. The Prior Credit Agreement also contained an accordion feature that allowed for an increase in the total available borrowings to $2.75 billion, subject to terms and conditions.

During the three months ended March 31, 2022, the Company recognized $0.3 million of loss on extinguishment of debt related to write-offs of deferred financing costs in connection with the partial pay downs of the U.S. dollar Prior Term Loan.

Borrowings under the Prior Revolving Credit Facility bore interest on the outstanding principal amount at a rate equal to a ratings-based applicable interest margin plus, Canadian Dollar Offered Rate (“CDOR”) for Canadian dollar borrowings, or at the Operating Partnership’s option for U.S. dollar borrowings, either (a) LIBOR or (b) a base rate determined as the greater of (i) the federal funds rate plus 0.5%, (ii) the prime rate, and (iii) one-month LIBOR plus 1.0% (the “Prior Base Rate”). The ratings-based applicable interest margin for borrowings varied based on the Debt Ratings, as defined in the Prior Credit Agreement, and ranged from 0.775% to 1.45% per annum for CDOR or LIBOR based borrowings and 0.00% to 0.45% per annum for borrowings at the Prior Base Rate. In addition, the Operating Partnership paid a facility fee ranging between 0.125% and 0.300% per annum based on the aggregate amount of commitments under the Prior Revolving Credit Facility regardless of amounts outstanding thereunder.

The U.S. dollar Prior Term Loan bore interest on the outstanding principal amount at a rate equal to a ratings-based applicable interest margin plus, at the Operating Partnership’s option, either (a) LIBOR or (b) the Prior Base Rate. The ratings-based applicable interest margin for borrowings varied based on the Debt Ratings and ranged from 0.85% to 1.65% per annum for LIBOR based borrowings and 0.00% to 0.65% per annum for borrowings at the Prior Base Rate. The Canadian dollar Prior Term Loan bore interest on the outstanding principal amount at a rate equal to CDOR plus an interest margin that ranged from 0.85% to 1.65% depending on the Debt Ratings.

On January 4, 2023, the Borrowers, and the other parties thereto entered into a sixth amended and restated unsecured credit agreement (the “Credit Agreement”). During the three months ended March 31, 2023, the Company recorded $18.1 million of deferred financing costs related to the Credit Agreement and recognized $1.5 million of loss on extinguishment of debt related to write-offs of deferred financing costs in connection with amending and restating the Prior Credit Agreement.

The Credit Agreement includes a $1.0 billion revolving credit facility (the “Revolving Credit Facility”), a $430.0 million U.S. dollar term loan and a CAD $150.0 million Canadian dollar term loan (collectively, the “Term Loans”). Further, up to $350.0 million of the Revolving Credit Facility may be used for borrowings in certain foreign currencies. The Credit Agreement also contains an accordion feature that can increase the total available borrowings to $2.75 billion, subject to terms and conditions.

16

The Revolving Credit Facility has a maturity date of January 4, 2027, and includes two six-month extension options. The Term Loans have a maturity date of January 4, 2028.

As of March 31, 2023, there was $79.6 million (including CAD $86.0 million) outstanding under the Revolving Credit Facility and $920.4 million available for borrowing.

Borrowings under the Revolving Credit Facility bear interest on the outstanding principal amount at a rate equal to a ratings-based applicable interest margin plus, CDOR for Canadian dollar borrowings, or at the Operating Partnership’s option for U.S. dollar borrowings, either (a) Daily Simple SOFR, as defined in the Credit Agreement, or (b) a base rate determined as the greater of (i) the federal funds rate plus 0.5%, (ii) the prime rate, (iii) Term SOFR, as defined in the Credit Agreement, plus 1.0% (the “Base Rate”), and (iv) 1.00%. The ratings-based applicable interest margin for borrowings will vary based on the Debt Ratings, as defined in the Credit Agreement, and will range from 0.775% to 1.450% per annum for Daily Simple SOFR based borrowings and 0.00% to 0.450% per annum for borrowings at the Base Rate. As of March 31, 2023, the weighted average interest rate on the Revolving Credit Facility was 6.05%. In addition, the Operating Partnership pays a facility fee ranging between 0.125% and 0.300% per annum based on the aggregate amount of commitments under the Revolving Credit Facility regardless of amounts outstanding thereunder.

The U.S. dollar Term Loan bears interest on the outstanding principal amount at a ratings-based applicable interest margin plus, at the Operating Partnership’s option, either (a) Term SOFR or (b) the Base Rate. The ratings-based applicable interest margin for borrowings will vary based on the Debt Ratings and will range from 0.850% to 1.650% per annum for Term SOFR based borrowings and 0.00% to 0.650% per annum for borrowings at the Base Rate. As of March 31, 2023, the interest rate on the U.S. dollar Term Loan was 6.22%. The Canadian dollar Term Loan bears interest on the outstanding principal amount at a rate equal CDOR plus an interest margin that will range from 0.850% to 1.650% depending on the Debt Ratings. As of March 31, 2023, the interest rate on the Canadian dollar Term Loan was 6.20%.

The Company has interest rate swaps and interest rate collars that fix and set a cap and floor, respectively, for the SOFR portion of the interest rate for $430.0 million of SOFR-based borrowings under its U.S. dollar Term Loan at a weighted average rate of 1.51% and interest rate swaps that fix the CDOR portion of the interest rate for CAD $150.0 million of CDOR-based borrowings under its Canadian dollar Term Loan at a rate of 1.63%. As of March 31, 2023, the effective interest rate on the U.S. dollar and Canadian dollar Term Loans was 3.85% and 2.88%, respectively. In addition, the Canadian dollar Term Loan and the CAD $86.0 million outstanding under the Revolving Credit Facility are designated as net investment hedges. See Note 8, “Derivative and Hedging Instruments,” for further information.

The obligations of the Borrowers under the Credit Agreement are guaranteed by the Company and certain of its subsidiaries.

The Credit Agreement contains customary covenants that include restrictions or limitations on the ability to pay dividends, incur additional indebtedness, engage in non-healthcare related business activities, enter into transactions with affiliates and sell or otherwise transfer certain assets as well as customary events of default. The Credit Agreement also requires Sabra, through the Operating Partnership, to comply with specified financial covenants, which include a maximum total leverage ratio, a maximum secured debt leverage ratio, a minimum fixed charge coverage ratio, a maximum unsecured leverage ratio, a minimum tangible net worth requirement and a minimum unsecured interest coverage ratio. As of March 31, 2023, the Company was in compliance with all applicable financial covenants under the Credit Agreement.

Interest Expense

The Company incurred interest expense of $28.5 million and $25.0 million during the three months ended March 31, 2023 and 2022, respectively. Interest expense includes non-cash interest expense of $3.0 million and $2.7 million for the three months ended March 31, 2023 and 2022, respectively. As of March 31, 2023 and December 31, 2022, the Company had $21.4 million and $18.2 million, respectively, of accrued interest included in accounts payable and accrued liabilities on the accompanying consolidated balance sheets.

17

Maturities

The following is a schedule of maturities for the Company’s outstanding debt as of March 31, 2023 (in thousands): 

	Secured Indebtedness		Revolving Credit     Facility (1)		Term Loans		Senior Notes		Total
April 1 through December 31, 2023	$	1,489	$	—	$	—	$	—	$	1,489
2024	2,034		—		—		—		2,034
2025	2,089		—		—		—		2,089
2026	2,147		—		—		500,000		502,147
2027	2,206		79,563		—		100,000		181,769
Thereafter	39,668		—		540,865		1,150,000		1,730,533
Total Debt	49,633		79,563		540,865		1,750,000		2,420,061
Discount, net	—		—		—		(3,719)		(3,719)
Deferred financing costs, net	(879)		—		(7,208)		(11,637)		(19,724)
Total Debt, Net	$	48,754	$	79,563	$	533,657	$	1,734,644	$	2,396,618

(1)    Revolving Credit Facility is subject to two six-month extension options.

8.    DERIVATIVE AND HEDGING INSTRUMENTS

The Company is exposed to various market risks, including the potential loss arising from adverse changes in interest rates and foreign exchange rates. The Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates and foreign exchange rates. The Company’s derivative financial instruments are used to manage differences in the amount of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s investments and borrowings.

Certain of the Company’s foreign operations expose the Company to fluctuations of foreign interest rates and exchange rates. These fluctuations may impact the value in the Company’s functional currency, the U.S. dollar, of the Company’s investment in foreign operations, the cash receipts and payments related to these foreign operations and payments of interest and principal under Canadian dollar denominated debt. The Company enters into derivative financial instruments to protect the value of its foreign investments and fix a portion of the interest payments for certain debt obligations. The Company does not enter into derivatives for speculative purposes.

Cash Flow Hedges

The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish these objectives, the Company primarily uses interest rate swaps and collars as part of its interest rate risk management strategy. As of March 31, 2023, approximately $5.4 million of gains, which are included in accumulated other comprehensive income, are expected to be reclassified into earnings in the next 12 months.

Net Investment Hedges

The Company is exposed to fluctuations in foreign exchange rates on investments it holds in Canada. The Company uses cross currency interest rate swaps to hedge its exposure to changes in foreign exchange rates on these foreign investments.

18

The following presents the notional amount of derivative instruments as of the dates indicated (in thousands):

	March 31, 2023		December 31, 2022
Derivatives designated as cash flow hedges:
Denominated in U.S. Dollars (1)	$	753,750	$	436,250
Denominated in Canadian Dollars (2)	$	300,000	$	125,000
Derivatives designated as net investment hedges:
Denominated in Canadian Dollars	$	56,300	$	55,991
Financial instruments designated as net investment hedges:
Denominated in Canadian Dollars	$	236,000	$	329,500
Derivatives not designated as net investment hedges:
Denominated in Canadian Dollars	$	—	$	309

(1) Balance as of March 31, 2023 includes two forward starting interest rate swaps with an effective date of August 2024 and an aggregate notional amount of $323.8 million.

(2)    Balance as of March 31, 2023 includes two forward starting interest rate swaps with an effective date of September 2024 and an aggregate notional amount of CAD $150.0 million.

Derivative and Financial Instruments Designated as Hedging Instruments

The following is a summary of the derivative and financial instruments designated as hedging instruments held by the Company at March 31, 2023 and December 31, 2022 (dollars in thousands):    

		Count as of March 31, 2023	Fair Value as of				Maturity Dates
Type	Designation		March 31, 2023		December 31, 2022			Balance Sheet Location
Assets:
Interest rate swaps	Cash flow	5	$	8,753	$	11,004	2024 - 2028	Accounts receivable, prepaid expenses and other assets, net
Interest rate collars	Cash flow	2	5,308		6,622		2024	Accounts receivable, prepaid expenses and other assets, net
Forward starting interest rate swaps	Cash flow	4	1,977		—		2028	Accounts receivable, prepaid expenses and other assets, net
Cross currency interest rate swaps	Net investment	2	3,785		3,851		2025	Accounts receivable, prepaid expenses and other assets, net
			$	19,823	$	21,477
Liabilities:
CAD borrowings under Revolving Credit Facility	Net investment	1	63,563		150,982		2027	Revolving credit facility
CAD Term Loan	Net investment	1	110,865		92,288		2028	Term loans, net
			$	174,428	$	243,270

19

The following presents the effect of the Company’s derivative and financial instruments designated as hedging instruments on the consolidated statements of (loss) income and the consolidated statements of equity for the three months ended March 31, 2023 and 2022 (in thousands):

	Gain (Loss) Recognized in Other Comprehensive Income
	Three Months Ended March 31,
	2023		2022
Cash Flow Hedges:
Interest rate products	$	1,565	$	9,652
Net Investment Hedges:
Foreign currency products	(14)		(986)
CAD borrowings under Revolving Credit Facility	(1,026)		—
CAD term loan	(140)		(1,513)
	$	385	$	7,153

		Loss Reclassified from Accumulated Other Comprehensive Income into Income
		Three Months Ended March 31,
	Income Statement Location	2023		2022
Cash Flow Hedges:
Interest rate products	Interest expense	$	1,572	$	(2,704)

During the three months ended March 31, 2023 and 2022, no cash flow hedges were determined to be ineffective.

Derivatives Not Designated as Hedging Instruments

As of March 31, 2023, the Company’s derivatives were all designated as hedging instruments. During the three months ended March 31, 2022, the Company recorded $0.1 million of other expense related to the portion of derivatives not designated as hedging instruments and no such expense was recorded during the three months ended March 31, 2023.

Offsetting Derivatives

The Company enters into master netting arrangements, which reduce credit risk by permitting net settlement of transactions with the same counterparty. The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of March 31, 2023 and December 31, 2022 (in thousands):

	As of March 31, 2023
	Gross Amounts of Recognized Assets / Liabilities		Gross Amounts Offset in the Balance Sheet		Net Amounts of Assets / Liabilities presented in the Balance Sheet		Gross Amounts Not Offset in the Balance Sheet
							Financial Instruments		Cash Collateral Received		Net Amount
Offsetting Assets:
Derivatives	$	19,823	$	—	$	19,823	$	—	$	—	$	19,823
Offsetting Liabilities:
Derivatives	$	—	$	—	$	—	$	—	$	—	$	—

	As of December 31, 2022
	Gross Amounts of Recognized Assets / Liabilities		Gross Amounts Offset in the Balance Sheet		Net Amounts of Assets / Liabilities presented in the Balance Sheet		Gross Amounts Not Offset in the Balance Sheet
							Financial Instruments		Cash Collateral Received		Net Amount
Offsetting Assets:
Derivatives	$	21,477	$	—	$	21,477	$	—	$	—	$	21,477
Offsetting Liabilities:
Derivatives	$	—	$	—	$	—	$	—	$	—	$	—

20

Credit Risk-related Contingent Features

The Company has agreements with each of its derivative counterparties that contain a provision pursuant to which the Company could be declared in default on the derivative obligation if the Company defaults on any of its indebtedness, including a default where repayment of the indebtedness has not been accelerated by the lender. As of March 31, 2023, the Company had no derivatives in a net liability position related to these agreements.

9.    FAIR VALUE DISCLOSURES

Under GAAP, the Company is required to measure certain financial instruments at fair value on a recurring basis. In addition, the Company is required to measure other financial instruments and balances at fair value on a non-recurring basis (e.g., carrying value of impaired loans receivable and long-lived assets). Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The GAAP fair value framework uses a three-tiered approach. Fair value measurements are classified and disclosed in one of the following three categories:

•Level 1: unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets or liabilities;

•Level 2: quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which significant inputs and significant value drivers are observable in active markets; and

•Level 3: prices or valuation techniques where little or no market data is available that requires inputs that are both significant to the fair value measurement and unobservable.

Financial Instruments

The fair value for certain financial instruments is derived using a combination of market quotes, pricing models and other valuation techniques that involve significant management judgment. The price transparency of financial instruments is a key determinant of the degree of judgment involved in determining the fair value of the Company’s financial instruments.

Financial instruments for which actively quoted prices or pricing parameters are available and whose markets contain orderly transactions will generally have a higher degree of price transparency than financial instruments whose markets are inactive or consist of non-orderly trades. The Company evaluates several factors when determining if a market is inactive or when market transactions are not orderly. The carrying values of cash and cash equivalents, restricted cash, accounts payable, accrued liabilities and the Credit Agreement are reasonable estimates of fair value because of the short-term maturities of these instruments. Fair values for other financial instruments are derived as follows:

Loans receivable: These instruments are presented on the accompanying consolidated balance sheets at their amortized cost and not at fair value. The fair values of the loans receivable were estimated using an internal valuation model that considered the expected cash flows for the loans receivable, as well as the underlying collateral value and other credit enhancements as applicable. The Company utilized discount rates ranging from 7% to 16% with a weighted average rate of 7% in its fair value calculation. As such, the Company classifies these instruments as Level 3.

Preferred equity investments: These instruments are presented on the accompanying consolidated balance sheets at their cost and not at fair value. The fair values of the preferred equity investments were estimated using an internal valuation model that considered the expected future cash flows for the preferred equity investments, the underlying collateral value and other credit enhancements. The Company utilized discount rates ranging from 10% to 15% with a weighted average rate of 11% in its fair value calculation. As such, the Company classifies these instruments as Level 3.

Derivative instruments: The Company’s derivative instruments are presented at fair value on the accompanying consolidated balance sheets. The Company estimates the fair value of derivative instruments, including its interest rate swaps, interest rate collars and cross currency swaps, using the assistance of a third party using inputs that are observable in the market, which include forward yield curves and other relevant information. Although the Company has determined that the majority of the inputs used to value its derivative financial instruments fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with its derivative financial instruments utilize Level 3 inputs, such as estimates of current credit spreads, to evaluate the likelihood of default by itself and its counterparties. The Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of its derivative financial instruments. As a result, the

21

Company has determined that its derivative financial instruments valuations in their entirety are classified in Level 2 of the fair value hierarchy.

Senior Notes: These instruments are presented on the accompanying consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Senior Notes were determined using third-party market quotes derived from orderly trades. As such, the Company classifies these instruments as Level 2.

Secured indebtedness: These instruments are presented on the accompanying consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Company’s secured debt were estimated using a discounted cash flow analysis based on management’s estimates of current market interest rates for instruments with similar characteristics, including remaining loan term, loan-to-value ratio, type of collateral and other credit enhancements. The Company utilized a rate of 6% in its fair value calculation. As such, the Company classifies these instruments as Level 3.

The following are the face values, carrying amounts and fair values of the Company’s financial instruments as of March 31, 2023 and December 31, 2022 whose carrying amounts do not approximate their fair value (in thousands):

	As of March 31, 2023						As of December 31, 2022
	Face Value (1)		Carrying Amount (2)		Fair Value		Face Value (1)		Carrying Amount (2)		Fair Value
Financial assets:
Loans receivable	$	366,200	$	356,365	$	370,048	$	370,364	$	360,325	$	370,188
Preferred equity investments	52,551		52,714		54,156		50,902		51,071		51,995
Financial liabilities:
Senior Notes	1,750,000		1,734,644		1,436,036		1,750,000		1,734,431		1,463,041
Secured indebtedness	49,633		48,754		37,583		50,123		49,232		38,149

(1)    Face value represents amounts contractually due under the terms of the respective agreements.

(2)    Carrying amount represents the book value of financial instruments, including unamortized premiums/discounts and deferred financing costs.

The Company determined the fair value of financial instruments as of March 31, 2023 whose carrying amounts do not approximate their fair value with valuation methods utilizing the following types of inputs (in thousands):

			Fair Value Measurements Using
	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Financial assets:
Loans receivable	$	370,048	$	—	$	—	$	370,048
Preferred equity investments	54,156		—		—		54,156
Financial liabilities:
Senior Notes	1,436,036		—		1,436,036		—
Secured indebtedness	37,583		—		—		37,583

Disclosure of the fair value of financial instruments is based on pertinent information available to the Company at the applicable dates and requires a significant amount of judgment. Transaction volume for certain of the Company’s financial instruments remains relatively low, which has made the estimation of fair values difficult. Therefore, both the actual results and the Company’s estimate of fair value at a future date could be materially different.

22

Items Measured at Fair Value on a Recurring Basis

During the three months ended March 31, 2023, the Company recorded the following amounts measured at fair value (in thousands):

			Fair Value Measurements Using
	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Recurring Basis:
Financial assets:
Interest rate swaps	$	8,753	$	—	$	8,753	$	—
Interest rate collars	5,308		—		5,308		—
Forward starting interest rate swaps	1,977		—		1,977		—
Cross currency interest rate swaps	3,785		—		3,785		—

10.    EQUITY

Common Stock

On February 23, 2023, the Company established an at-the-market equity offering program (the “ATM Program”) pursuant to which shares of its common stock having an aggregate gross sales price of up to $500.0 million may be sold from time to time (i) by the Company through a consortium of banks acting as sales agents or directly to the banks acting as principals or (ii) by a consortium of banks acting as forward sellers on behalf of any forward purchasers pursuant to a forward sale agreement. The use of a forward sale agreement would allow the Company to lock in a share price on the sale of shares at the time the agreement is effective, but defer receiving the proceeds from the sale of the shares until a later date. The Company may also elect to cash settle or net share settle all or a portion of its obligations under any forward sale agreement. The forward sale agreements have a one year term during which time the Company may settle the forward sales by delivery of physical shares of common stock to the forward purchasers or, at the Company’s election, in cash or net shares. The forward sale price that the Company expects to receive upon settlement will be the initial forward price established upon the effective date, subject to adjustments for (i) the forward purchasers’ stock borrowing costs and (ii) certain fixed price reductions during the term of the agreement.

During the three months ended March 31, 2023, no shares were sold under the ATM Program and the Company did not utilize the forward feature of the ATM Program. As of March 31, 2023, the Company had $500.0 million available under the ATM Program.

The following table lists the cash dividends on common stock declared and paid by the Company during the three months ended March 31, 2023:

Declaration Date	Record Date	Amount Per Share		Dividend Payable Date
February 1, 2023	February 13, 2023	$	0.30	February 28, 2022

During the three months ended March 31, 2023, the Company issued 0.2 million shares of common stock as a result of restricted stock unit vestings.

Upon any payment of shares to team members as a result of restricted stock unit vestings, the team members’ related tax withholding obligation will generally be satisfied by the Company reducing the number of shares to be delivered by a number of shares necessary to satisfy the related applicable tax withholding obligation. During the three months ended March 31, 2023 and 2022, the Company incurred $1.4 million and $3.3 million, respectively, in tax withholding obligations on behalf of its team members that were satisfied through a reduction in the number of shares delivered to those participants.

23

Accumulated Other Comprehensive Income

The following is a summary of the Company’s accumulated other comprehensive income (in thousands):

	March 31, 2023		December 31, 2022
Foreign currency translation (loss) gain	$	(455)	$	1,168
Unrealized gain on cash flow hedges	17,893		17,895
Total accumulated other comprehensive income	$	17,438	$	19,063

11.    EARNINGS PER COMMON SHARE

The following table illustrates the computation of basic and diluted earnings per share for the three months ended March 31, 2023 and 2022 (in thousands, except share and per share amounts):

	Three Months Ended March 31,
	2023		2022
Numerator
Net (loss) income	$	(9,487)	$	40,602
Denominator
Basic weighted average common shares and common equivalents	231,164,876		230,859,993
Dilutive restricted stock units	—		704,977
Diluted weighted average common shares	231,164,876		231,564,970
Net (loss) income, per:
Basic common share	$	(0.04)	$	0.18
Diluted common share	$	(0.04)	$	0.18

During the three months ended March 31, 2023 and 2022, approximately 0.7 million and 13,100 restricted stock units, respectively, were not included in computing diluted earnings per share because they were considered anti-dilutive.

12.    COMMITMENTS AND CONTINGENCIES

Environmental

As an owner of real estate, the Company is subject to various environmental laws of federal, state and local governments. The Company is not aware of any environmental liability that could have a material adverse effect on its financial condition or results of operations. However, changes in applicable environmental laws and regulations, the uses and conditions of properties in the vicinity of the Company’s properties, the activities of its tenants and other environmental conditions of which the Company is unaware with respect to the properties could result in future environmental liabilities. As of March 31, 2023, the Company does not expect that compliance with existing environmental laws will have a material adverse effect on the Company’s financial condition and results of operations.

Legal Matters

From time to time, the Company and its subsidiaries are party to legal proceedings that arise in the ordinary course of its business. Management is not aware of any legal proceedings where the likelihood of a loss contingency is reasonably possible and the amount or range of reasonably possible losses is material to the Company’s results of operations, financial condition or cash flows.

13.    SUBSEQUENT EVENTS

The Company evaluates subsequent events up until the date the consolidated financial statements are issued.

24

Dividend Declaration

On May 3, 2023, the Company’s board of directors declared a quarterly cash dividend of $0.30 per share of common stock. The dividend will be paid on May 31, 2023 to common stockholders of record as of the close of business on May 16, 2023.

25

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The discussion below contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those which are discussed in the “Risk Factors” section in Part I, Item 1A of our 2022 Annual Report on Form 10-K. Also see “Statement Regarding Forward-Looking Statements” preceding Part I.

The following discussion and analysis should be read in conjunction with our accompanying consolidated financial statements and the notes thereto.

Our Management’s Discussion and Analysis of Financial Condition and Results of Operations is organized as follows:

•Overview

•Critical Accounting Policies and Estimates

•Recently Issued Accounting Standards Update

•Results of Operations

•Liquidity and Capital Resources

•Concentration of Credit Risk

•Skilled Nursing Facility Reimbursement Rates

Overview

We operate as a self-administered, self-managed REIT that, through our subsidiaries, owns and invests in real estate serving the healthcare industry.

Our primary business consists of acquiring, financing and owning real estate property to be leased to third party tenants in the healthcare sector. We primarily generate revenues by leasing properties to tenants and owning properties operated by third-party property managers throughout the United States (“U.S.”) and Canada.

Our investment portfolio is primarily comprised of skilled nursing/transitional care facilities, senior housing communities (“Senior Housing - Leased”), behavioral health facilities, and specialty hospitals and other facilities, in each case leased to third-party operators; senior housing communities operated by third-party property managers pursuant to property management agreements (“Senior Housing - Managed”); investments in joint ventures; loans receivable; and preferred equity investments.

We expect to grow our investment portfolio while diversifying our portfolio by tenant, facility type and geography within the healthcare sector. We plan to achieve these objectives primarily through making investments directly or indirectly in healthcare real estate, including the development of purpose-built healthcare facilities with select developers. We also intend to achieve our objective of diversifying our portfolio by tenant and facility type through select asset sales and other arrangements with our tenants.

We employ a disciplined approach in our healthcare real estate investment strategy by investing in assets that provide attractive opportunities for dividend growth and appreciation of asset values, while maintaining balance sheet strength and liquidity, thereby creating long-term stockholder value.

We elected to be treated as a REIT with the filing of our U.S. federal income tax return for the taxable year beginning January 1, 2011. We believe that we have been organized and have operated, and we intend to continue to operate, in a manner to qualify as a REIT. We operate through an umbrella partnership, commonly referred to as an UPREIT structure, in which substantially all of our properties and assets are held by Sabra Health Care Limited Partnership, a Delaware limited partnership (the “Operating Partnership”), of which we are the sole general partner and a wholly owned subsidiary of ours is currently the only limited partner, or by subsidiaries of the Operating Partnership.

Market Trends and Uncertainties

Our operations have been and are expected to continue to be impacted by economic and market conditions. Together with the ongoing impact of COVID-19, increases in interest rates, labor shortages, supply chain disruptions, high inflation and increased volatility in public equity and fixed income markets have led to increased costs and limited the availability of capital. If our tenants, borrowers and Senior Housing - Managed communities experience increased costs or financing difficulties due to

26

these macroeconomic conditions, our tenants and borrowers may be unable to meet their financial obligations to us and our results of operations may be adversely affected.

The above factors have resulted in decreased occupancy and increased operating costs for our tenants and borrowers, which have negatively impacted their operating results and may adversely impact their ability to make full and timely rental payments and debt service payments, respectively, to us. Our Senior Housing - Managed portfolio has been similarly impacted, and we expect that decreased occupancy and increased operating costs will continue to negatively impact the operating results of these investments. While our tenants, borrowers and Senior Housing - Managed portfolio have experienced some recent increases in occupancy, those occupancy rates are still below pre-pandemic levels. Similarly, while our tenants, borrowers and Senior Housing - Managed portfolio have more recently experienced small, incremental improvements in both labor availability and overall labor costs, labor supply remains lower and costs remain higher than pre-pandemic levels. In some cases, we may have to restructure or temporarily defer tenants’ long-term rent obligations and may not be able to do so on terms that are as favorable to us as those currently in place. Reduced or modified rental and debt service amounts could result in the determination that the full amounts of our investments are not recoverable, which could result in an impairment charge. If our tenants and borrowers default on these obligations, such defaults could materially and adversely affect our results of operations and liquidity, in addition to resulting in potential impairment charges. Further, prolonged deterioration in the operating results for our investments in our Senior Housing - Managed portfolio could result in the determination that the full amounts of our investments are not recoverable, which could result in an impairment charge.

We regularly monitor the effects of economic and market conditions and COVID-19 on our operations and financial position, as well as on the operations and financial position of our tenants and borrowers, in order to respond and adapt to the ongoing changes in our operating environment.

Investment in Unconsolidated Joint Venture

During the three months ended March 31, 2023, our joint venture with Marlin Spring (the “Marlin Spring Joint Venture”) completed the acquisition of one additional senior housing community with a gross investment of CAD $30.0 million, excluding acquisition costs. In addition, the Marlin Spring Joint Venture assumed and financed an aggregate CAD $23.6 million of debt associated with the additional acquisition. Our equity investment in the additional acquisition was CAD $6.1 million. See Note 4, “Investment in Real Estate Properties—Investment in Unconsolidated Joint Ventures,” in the Notes to Consolidated Financial Statements for additional information regarding this investment.

Acquisitions

During the three months ended March 31, 2023, we acquired one Senior Housing - Leased community and one Senior Housing - Managed community for aggregate consideration of $51.5 million, including acquisition costs. See Note 3, “Recent Real Estate Acquisitions,” in the Notes to Consolidated Financial Statements for additional information regarding these acquisitions.

Dispositions

During the three months ended March 31, 2023, we completed the sale of seven skilled nursing/transitional care facilities (including one leased to a tenant under a sales-type lease) and two senior housing communities for aggregate consideration, net of closing costs, of $185.8 million. The net carrying value of the assets and liabilities of these facilities was $207.3 million, which resulted in an aggregate $21.5 million net loss on sale. We continue to evaluate additional assets for sale as part of our initiative to recycle capital and further improve our portfolio quality.

Credit Agreement

Effective on January 4, 2023, we and certain of our subsidiaries entered into the Credit Agreement. See “—Liquidity and Capital Resources—Material Cash Requirements—Credit Agreement.”

At-The-Market Common Stock Offering Program

On February 23, 2023, we established the ATM Program (as defined below) pursuant to which shares of our common stock having an aggregate gross sales price of up to $500.0 million may be sold from time to time. See “—Liquidity and Capital Resources.”

Critical Accounting Policies and Estimates

Our consolidated interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and in conjunction with the rules and regulations of the SEC. The preparation of our financial statements requires significant management judgments, assumptions and estimates about matters that are inherently uncertain. These

27

judgments affect the reported amounts of assets and liabilities and our disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. With different estimates or assumptions, materially different amounts could be reported in our financial statements. Additionally, other companies may utilize different estimates that may impact the comparability of our results of operations to those of companies in similar businesses. A discussion of the accounting policies that management considers critical in that they involve significant management judgments and assumptions, require estimates about matters that are inherently uncertain and because they are important for understanding and evaluating our reported financial results is included in Part II, Item 7 of our 2022 Annual Report on Form 10-K filed with the SEC. There have been no significant changes to our critical accounting policies during the three months ended March 31, 2023.

Recently Issued Accounting Standards Update

See Note 2, “Summary of Significant Accounting Policies,” in the Notes to Consolidated Financial Statements for information concerning recently issued accounting standards updates.

Results of Operations

As of March 31, 2023, our investment portfolio consisted of 396 real estate properties held for investment, 13 investments in loans receivable, six preferred equity investments and three investments in unconsolidated joint ventures. As of March 31, 2022, our investment portfolio consisted of 416 real estate properties held for investment, one asset held for sale, one investment in a sales-type lease, 16 investments in loans receivable, seven preferred equity investments and one investment in an unconsolidated joint venture. In general, we expect that income and expenses related to our portfolio will fluctuate in future periods in comparison to the corresponding prior periods as a result of investment and disposition activity and anticipated future changes in our portfolio. The results of operations presented are not directly comparable due to ongoing acquisition and disposition activity, including our capital recycling initiative.

28

Comparison of results of operations for the three months ended March 31, 2023 versus the three months ended March 31, 2022 (dollars in thousands):

	Three Months Ended March 31,				Increase / (Decrease)		Percentage Difference		Variance due to Acquisitions, Originations and Dispositions (1)		Remaining Variance (2)
	2023		2022
Revenues:
Rental and related revenues	$	95,870	$	109,886	$	(14,016)	(13)	%	$	(5,704)	$	(8,312)
Resident fees and services	56,721		42,227		14,494		34	%	6,239		8,255
Interest and other income	8,733		10,992		(2,259)		(21)	%	(2,598)		339
Expenses:
Depreciation and amortization	52,827		45,256		7,571		17	%	(1,180)		8,751
Interest	28,540		24,972		3,568		14	%	—		3,568
Triple-net portfolio operating expenses	4,168		5,011		(843)		(17)	%	(243)		(600)
Senior housing - managed portfolio operating expenses	43,637		33,104		10,533		32	%	4,096		6,437
General and administrative	10,502		10,396		106		1	%	—		106
(Recovery of) provision for loan losses and other reserves	(208)		475		(683)		(144)	%	48		(731)
Impairment of real estate	7,064		—		7,064		100	%	—		7,064
Other income (expense):
Loss on extinguishment of debt	(1,541)		(271)		(1,270)		469	%	—		(1,270)
Other income	341		68		273		401	%	—		273
Net loss on sales of real estate	(21,515)		—		(21,515)		100	%	(21,515)		—
Loss from unconsolidated joint ventures	(838)		(2,802)		1,964		(70)	%	(838)		2,802
Income tax expense	(728)		(284)		(444)		156	%	—		(444)

(1)    Represents the dollar amount increase (decrease) for the three months ended March 31, 2023 compared to the three months ended March 31, 2022 as a result of investments/dispositions made after January 1, 2022.

(2)    Represents the dollar amount increase (decrease) for the three months ended March 31, 2023 compared to the three months ended March 31, 2022 that is not a direct result of investments/dispositions made after January 1, 2022.

Rental and Related Revenues

During the three months ended March 31, 2023, we recognized $95.9 million of rental income compared to $109.9 million for the three months ended March 31, 2022. The $14.0 million net decrease in rental income is related to (i) a $6.9 million net decrease related to leases that are no longer accounted for on an accrual basis, (ii) a $5.8 million decrease from properties disposed of after January 1, 2022, (iii) a $1.9 million decrease from properties that were transitioned to new operators and (iv) a $0.4 million decrease from properties transitioned from triple-net lease to Senior Housing - Managed communities. The $6.9 million net decrease related to leases that are not accounted for on an accrual basis includes (i) a $2.9 million decrease in earned cash rents primarily due to the Avamere lease amendment effective February 1, 2022, (ii) a $1.5 million decrease in Genesis excess rents in accordance with the terms of the memorandum of understanding entered into in 2017, (iii) a $1.1 million decrease in earned cash rents, (iv) a $0.8 million decrease in operating expense recoveries and (v) a $0.6 million decrease in non-cash rental revenue. These decreases are partially offset by a $0.6 million increase due to lease amendments and annual increases associated with a Consumer Price Index component.

Our reported rental and related revenues may be subject to increased variability in the future as a result of lease accounting standards. If at any time we cannot determine that it is probable that substantially all rents over the life of a lease are collectible, rental revenue will be recognized only to the extent of payments received and all receivables associated with the lease will be written off, irrespective of amounts expected to be collectible. However, there can be no assurances regarding the timing and amount of these revenues. Amounts due under the terms of all of our lease agreements are subject to contractual increases, and contingent rental income may be derived from certain lease agreements. No material contingent rental income was derived during the three months ended March 31, 2023 and 2022.

29

Resident Fees and Services

During the three months ended March 31, 2023, we recognized $56.7 million of resident fees and services compared to $42.2 million for the three months ended March 31, 2022. The $14.5 million increase is due to (i) a $6.3 million increase from four Senior Housing - Managed communities acquired after January 1, 2022, (ii) a $5.6 million increase related to seven facilities that were transitioned to Senior Housing - Managed communities after January 1, 2022 and (iii) a $2.6 million increase related to increased occupancy and an increase in rates.

Interest and Other Income

Interest and other income primarily consists of income earned on our loans receivable investments, preferred returns earned on our preferred equity investments and income on the sales-type lease. During the three months ended March 31, 2023, we recognized $8.7 million of interest and other income compared to $11.0 million for the three months ended March 31, 2022. The net decrease of $2.3 million is due to a $2.3 million lease termination payment related to one skilled nursing/transitional care facility that sold in 2022 and a $0.7 million decrease in income from investments repaid after January 1, 2022, partially offset by a $0.5 million increase from investments made after January 1, 2022.

Depreciation and Amortization

During the three months ended March 31, 2023, we incurred $52.8 million of depreciation and amortization expense compared to $45.3 million for the three months ended March 31, 2022. The net increase of $7.6 million is due to (i) an $8.0 million increase due to accelerating the remaining useful life of a facility that will be demolished, (ii) a $0.9 million increase due to the acceleration of lease intangible amortization related to facilities transitioned to new operators and lease terminations, (iii) a $1.6 million increase from properties acquired after January 1, 2022 and (iv) a $0.3 million increase from additions to real estate. These increases are partially offset by a $2.8 million decrease from properties disposed of after January 1, 2022.

Interest Expense

We incur interest expense comprised of costs of borrowings plus the amortization of deferred financing costs related to our indebtedness. During the three months ended March 31, 2023, we incurred $28.5 million of interest expense compared to $25.0 million for the three months ended March 31, 2022. The $3.6 million net increase is primarily related to an increase in interest expense due to an increase in the borrowings outstanding under the Credit Agreement (as defined below) and an increase in interest rates.

Triple-Net Portfolio Operating Expenses

During each of the three months ended March 31, 2023, we recognized $4.2 million of triple-net portfolio operating expenses compared to $5.0 million during the three months ended March 31, 2022. The $0.8 million net decrease is related to a $0.2 million decrease due to properties disposed of after January 1, 2022 and the remaining decrease is primarily due to facilities that have since been transitioned to new operators who are now paying the property taxes directly.

Senior Housing - Managed Portfolio Operating Expenses

During the three months ended March 31, 2023, we recognized $43.6 million of Senior Housing - Managed portfolio operating expenses compared to $33.1 million for the three months ended March 31, 2022. The $10.5 million net increase is due to (i) a $5.5 million increase related to seven facilities that were transitioned to Senior Housing - Managed communities after January 1, 2022, (ii) a $4.3 million increase related to four Senior Housing - Managed communities acquired after January 1, 2022, (iii) a $0.7 million increase in employee compensation primarily due to increased labor rates and staffing and (iv) a $0.2 million increase in management fees and dining expenses due to increased occupancy. The increases are partially offset by a $0.2 million decrease related to one Senior Housing - Managed community disposed of after January 1, 2022.

General and Administrative Expenses

General and administrative expenses include compensation-related expenses as well as professional services, office costs, other costs associated with asset management, and merger and acquisition costs. During the three months ended March 31, 2023, general and administrative expenses were $10.5 million compared to $10.4 million during the three months ended March 31, 2022. The $0.1 million net increase is related to a $0.4 million increase in compensation for our team members as a result of increased staffing and annual salary adjustments, partially offset by a $0.3 million decrease in tax preparation fees due to adjusting our estimates.

30

Recovery of (Provision for) Loan Losses and Other Reserves

During the three months ended March 31, 2023 and 2022, we recognized a $0.2 million recovery of and $0.5 million provision for loan losses and other reserves, respectively, primarily associated with our loans receivable investments.

Impairment of Real Estate

During the three months ended March 31, 2023, we recognized $7.1 million of impairment of real estate related to one skilled nursing/transitional care facility that is under contract to sell. See Note 5, “Impairment of Real Estate and Dispositions,” in the Notes to Consolidated Financial Statements for additional information regarding this impairment. No impairment of real estate was recognized during the three months ended March 31, 2022.

Loss on Extinguishment of Debt

During the three months ended March 31, 2023, we recognized a $1.5 million loss on extinguishment of debt related to write-offs of deferred financing costs in connection with amending and restating the Prior Credit Agreement (as defined below). During the three months ended March 31, 2022, we recognized a $0.3 million loss on extinguishment of debt related to write-offs of deferred financing costs in connection with the partial pay downs of the U.S. dollar Prior Term Loan (as defined below).

Other Income

During the three months ended March 31, 2023, we recognized $0.3 million of other income primarily due to the sale of licensed beds. During the three months ended March 31, 2022, we recognized $0.1 million of other income primarily related to a settlement payment received related to a legacy Care Capital Properties investment.

Net Loss on Sales of Real Estate

During the three months ended March 31, 2023, we recognized an aggregate net loss on the sales of real estate of $21.5 million related to the disposition of six skilled nursing/transitional care facilities, one Senior Housing - Leased community and one Senior Housing - Managed community. We did not have any sales of real estate during the three months ended March 31, 2022.

Loss from Unconsolidated Joint Ventures

During the three months ended March 31, 2023, we recognized $0.8 million of loss, including $2.0 million of depreciation expense, related to 16 senior housing communities acquired by two joint ventures after January 1, 2022.

During the three months ended March 31, 2022, we recognized $2.8 million of loss from our joint venture with affiliates of TPG Real Estate, the real estate platform of TPG (the “Enlivant Joint Venture”), consisting primarily of $4.6 million of depreciation and amortization expense and $1.6 million of interest expense, partially offset by $3.5 million of net operating income. As of December 31, 2022, we concluded that the estimated fair value of our investment in the Enlivant Joint Venture had declined to zero and that the decline was other-than-temporary. As such, we have discontinued applying the equity method of accounting to the Enlivant Joint Venture and no loss was recognized during the three months ended March 31, 2023. We will resume application if, during the period in which application of the equity method of accounting has been discontinued, our share of unrecognized net income exceeds our share of unrecognized net losses.

Income Tax Expense

During the three months ended March 31, 2023, we recognized $0.7 million of income tax expense compared to $0.3 million for the three months ended March 31, 2022. The $0.4 million increase is due to adjusting our estimates related to state income taxes.

Funds from Operations and Adjusted Funds from Operations

We believe that net income as defined by GAAP is the most appropriate earnings measure. We also believe that funds from operations (“FFO”), as defined in accordance with the definition used by the National Association of Real Estate Investment Trusts (“Nareit”), and adjusted funds from operations (“AFFO”) (and related per share amounts) are important non-GAAP supplemental measures of our operating performance. Because the historical cost accounting convention used for real estate assets requires straight-line depreciation (except on land), such accounting presentation implies that the value of real estate assets diminishes predictably over time. However, since real estate values have historically risen or fallen with market and other conditions, presentations of operating results for a REIT that use historical cost accounting for depreciation could be less informative. Thus, Nareit created FFO as a supplemental measure of operating performance for REITs that excludes historical cost depreciation and amortization, among other items, from net income, as defined by GAAP. FFO is defined as net

31

income, computed in accordance with GAAP, excluding gains or losses from real estate dispositions and our share of gains or losses from real estate dispositions related to our unconsolidated joint ventures, plus real estate depreciation and amortization, net of amounts related to noncontrolling interests, plus our share of depreciation and amortization related to our unconsolidated joint ventures, and real estate impairment charges of both consolidated and unconsolidated entities when the impairment is directly attributable to decreases in the value of the depreciable real estate held by the entity. AFFO is defined as FFO excluding merger and acquisition costs, stock-based compensation expense, non-cash rental and related revenues, non-cash interest income, non-cash interest expense, non-cash portion of loss on extinguishment of debt, provision for loan losses and other reserves, non-cash lease termination income and deferred income taxes, as well as other non-cash revenue and expense items (including ineffectiveness gain/loss on derivative instruments, and non-cash revenue and expense amounts related to noncontrolling interests) and our share of non-cash adjustments related to our unconsolidated joint ventures. We believe that the use of FFO and AFFO (and the related per share amounts), combined with the required GAAP presentations, improves the understanding of our operating results among investors and makes comparisons of operating results among REITs more meaningful. We consider FFO and AFFO to be useful measures for reviewing comparative operating and financial performance because, by excluding the applicable items listed above, FFO and AFFO can help investors compare our operating performance between periods or as compared to other companies. While FFO and AFFO are relevant and widely used measures of operating performance of REITs, they do not represent cash flows from operations or net income as defined by GAAP and should not be considered an alternative to those measures in evaluating our liquidity or operating performance. FFO and AFFO also do not consider the costs associated with capital expenditures related to our real estate assets nor do they purport to be indicative of cash available to fund our future cash requirements. Further, our computation of FFO and AFFO may not be comparable to FFO and AFFO reported by other REITs that do not define FFO in accordance with the current Nareit definition or that interpret the current Nareit definition or define AFFO differently than we do.

The following table reconciles our calculations of FFO and AFFO for the three months ended March 31, 2023 and 2022, to net income, the most directly comparable GAAP financial measure, for the same periods (in thousands, except share and per share amounts):

	Three Months Ended March 31,
	2023		2022
Net (loss) income	$	(9,487)	$	40,602
Depreciation and amortization of real estate assets	52,827		45,256
Depreciation, amortization and impairment of real estate assets related to unconsolidated joint ventures	2,048		4,633
Net loss on sales of real estate	21,515		—
Impairment of real estate	7,064		—
FFO	73,967		90,491
Stock-based compensation expense	2,229		2,456
Non-cash rental and related revenues	(2,398)		(4,474)
Non-cash interest income	(392)		(547)
Non-cash interest expense	3,014		2,698
Non-cash portion of loss on extinguishment of debt	1,541		271
(Recovery of) provision for loan losses and other reserves	(208)		475
Other adjustments related to unconsolidated joint ventures	69		(986)
Other adjustments	106		183
AFFO	$	77,928	$	90,567
FFO per diluted common share	$	0.32	$	0.39
AFFO per diluted common share	$	0.33	$	0.39
Weighted average number of common shares outstanding, diluted:
FFO	231,892,769		231,564,970
AFFO	233,168,932		232,484,734

32

The following table sets forth additional information related to certain other items included in net income above, and the portions of each that are included in FFO and AFFO, which may be helpful in assessing our operating results. Please refer to “—Results of Operations” above for additional information regarding these items (in millions):

	Three Months Ended March 31,
	2023		2022		2023		2022		2023		2022
	Net (Loss) Income				FFO				AFFO
Rental and related revenues:
Non-cash rental and related revenue write-offs	$	0.5	$	(0.2)	$	0.5	$	(0.2)	$	—	$	—
Interest and other income:
Lease termination income	—		2.3		—		2.3		—		2.3
(Recovery of) provision for loan losses and other reserves	(0.2)		0.5		(0.2)		0.5		—		—
Loss on extinguishment of debt	1.5		0.3		1.5		0.3		—		—
Other income	0.3		0.1		0.3		0.1		0.3		0.2
Loss from unconsolidated joint ventures:
Deferred income tax benefit	—		0.1		—		0.1		—		—

Liquidity and Capital Resources

As of March 31, 2023, we had approximately $954.0 million in liquidity, consisting of unrestricted cash and cash equivalents of $33.5 million and available borrowings under our Revolving Credit Facility (as defined below) of $920.4 million. The Credit Agreement also contains an accordion feature that can increase the total available borrowings to $2.75 billion (from U.S. $1.4 billion plus CAD $150.0 million), subject to terms and conditions.

We have filed a shelf registration statement with the SEC that expires in November 2025, which allows us to offer and sell shares of common stock, preferred stock, warrants, rights, units, and certain of our subsidiaries to offer and sell debt securities, through underwriters, dealers or agents or directly to purchasers, on a continuous or delayed basis, in amounts, at prices and on terms we determine at the time of the offering, subject to market conditions.

On February 23, 2023, we established an at-the-market equity offering program (the “ATM Program”) pursuant to which shares of our common stock having an aggregate gross sales price of up to $500.0 million may be sold from time to time (i) by us through a consortium of banks acting as sales agents or directly to the banks acting as principals or (ii) by a consortium of banks acting as forward sellers on behalf of any forward purchasers pursuant to a forward sale agreement.

During the three months ended March 31, 2023, no shares were sold under the ATM Program and we did not utilize the forward feature of the ATM Program. As of March 31, 2023, we had $500.0 million available under the ATM Program.

Our short-term liquidity requirements consist primarily of operating expenses, including our planned capital expenditures and funding commitments, interest expense, scheduled debt service payments under our loan agreements, dividend requirements, general and administrative expenses and other requirements described under “Material Cash Requirements” below. Based on our current assessment, we believe that our available cash, operating cash flows and borrowings available to us under our Revolving Credit Facility provide sufficient funds for such requirements for the next twelve months. In addition, we do not believe that the restrictions under our Senior Notes Indentures (as defined below) or Credit Agreement significantly limit our ability to use our available liquidity for these purposes.

Our long-term liquidity requirements consist primarily of future investments in properties, including any improvements or renovations of current or newly-acquired properties, as well as scheduled debt maturities. We expect to meet these liquidity needs using the sources above as well as the proceeds from issuances of common stock, preferred stock, debt or other securities, additional borrowings, including mortgage debt or a new or refinanced credit facility, and proceeds from the sale of properties. In addition, we may seek financing from U.S. government agencies, including through Fannie Mae, Freddie Mac and the U.S. Department of Housing and Urban Development, in appropriate circumstances in connection with acquisitions.

Cash Flows from Operating Activities

Net cash provided by operating activities was $68.3 million for the three months ended March 31, 2023. Operating cash inflows were derived primarily from the rental payments received under our lease agreements, resident fees and services net of the corresponding operating expenses and interest payments from borrowers under our loan and preferred equity investments. Operating cash outflows consisted primarily of interest payments on borrowings and payment of general and administrative expenses, including corporate overhead. Increases to operating cash flows primarily relate to completed investment activity, and

33

decreases to operating cash flows primarily relate to disposition activity and interest expense from increased borrowing activity and higher interest rates. In addition, the change in operating cash flows was impacted by the timing of collections from our tenants and borrowers and fluctuations in the operating results of our Senior Housing - Managed communities. We expect our annualized cash flows provided by operating activities to fluctuate as a result of such activity.

Cash Flows from Investing Activities

During the three months ended March 31, 2023, net cash provided by investing activities was $113.2 million and included $152.3 million of net proceeds from the sales of real estate, $25.5 million of net proceeds from the sale of a facility under a sales-type lease, $6.1 million in repayments of loans receivable and $1.4 million in repayments of preferred equity investments, partially offset by $39.6 million used for the acquisition of two facilities, $19.5 million used for additions to real estate, $6.4 million used to provide funding for preferred equity investments, $4.8 million used for the investment in an unconsolidated joint venture and $1.8 million used to provide funding for loans receivable.

Cash Flows from Financing Activities

During the three months ended March 31, 2023, net cash used in financing activities was $196.1 million and included $118.4 million of net repayments of our Revolving Credit Facility, $69.4 million of dividends paid to stockholders, $18.1 million of payments of deferred financing costs related to the Credit Agreement, $1.8 million of net costs related to payroll tax payments related to the issuance of common stock pursuant to equity compensation arrangements and our ATM Program, and $0.5 million of principal repayments on secured debt, partially offset by $12.2 million of proceeds from Term Loans (as defined below).

Please see the accompanying consolidated statements of cash flows for details of our operating, investing and financing cash activities.

Material Cash Requirements

Our material cash requirements include the following contractual and other obligations.

Senior Unsecured Notes. Our senior unsecured notes consisted of the following (collectively, the “Senior Notes”) as of March 31, 2023 (dollars in thousands):

Title	Maturity Date	Principal Balance (1)
5.125% senior unsecured notes due 2026 (the “2026 Notes”)	August 15, 2026	$	500,000
5.88% senior unsecured notes due 2027 (the “2027 Notes”)	May 17, 2027	100,000
3.90% senior unsecured notes due 2029 (the “2029 Notes”)	October 15, 2029	350,000
3.20% senior unsecured notes due 2031 (the “2031 Notes”)	December 1, 2031	800,000
		$	1,750,000

(1)    Principal balance does not include discount, net of $3.7 million and deferred financing costs, net of $11.6 million as of March 31, 2023.

See Note 7, “Debt,” in the Notes to Consolidated Financial Statements and “Subsidiary Issuer and Guarantor Financial Information” below for additional information concerning the Senior Notes, including information regarding the indentures and agreements governing the Senior Notes (the “Senior Notes Indentures”). As of March 31, 2023, we were in compliance with all applicable covenants under the Senior Notes Indentures.

Credit Agreement. Effective January 4, 2023, the Operating Partnership and Sabra Canadian Holdings, LLC (together, the “Borrowers”), and the other parties thereto entered into a sixth amended and restated unsecured credit agreement (the “Credit Agreement”). The Credit Agreement includes a $1.0 billion revolving credit facility (the “Revolving Credit Facility”), a $430.0 million U.S. dollar term loan and a CAD $150.0 million Canadian dollar term loan (collectively, the “Term Loans”). Further, up to $350.0 million of the Revolving Credit Facility may be used for borrowings in certain foreign currencies. The Credit Agreement also contains an accordion feature that can increase the total available borrowings to $2.75 billion, subject to terms and conditions.

The Revolving Credit Facility has a maturity date of January 4, 2027, and includes two six-month extension options. The Term Loans have a maturity date of January 4, 2028.

The obligations of the Borrowers under the Credit Agreement are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by us and one of our non-operating subsidiaries, subject to release under certain customary circumstances.

34

See Note 7, “Debt,” in the Notes to Consolidated Financial Statements for additional information concerning the Credit Agreement, including information regarding covenants contained in the Credit Agreement. As of March 31, 2023, we were in compliance with all applicable covenants under the Credit Agreement.

Secured Indebtedness. As of March 31, 2023, eight of our properties held for investment were subject to secured indebtedness to third parties, and our secured debt consisted of the following (dollars in thousands):

Interest Rate Type	Principal Balance (1)		Weighted Average Interest Rate		Maturity Date
Fixed Rate	$	49,633	2.84	%	May 2031 -  August 2051

(1)    Principal balance does not include deferred financing costs, net of $0.9 million as of March 31, 2023.

Interest. Our estimated interest and facility fee payments based on principal amounts of debt outstanding as of March 31, 2023, applicable interest rates in effect as of March 31, 2023, and including the impact of interest rate swaps and collars are $79.7 million for the remainder of 2023, $100.4 million in 2024, $102.0 million in 2025, $102.0 million in 2026, $66.0 million in 2027 and $141.5 million thereafter.

Capital and Other Expenditures and Funding Commitments. For the three months ended March 31, 2023 and 2022, our aggregate capital expenditures were $19.5 million and $10.8 million, respectively. As of March 31, 2023, our aggregate commitment for future capital and other expenditures related to facilities leased under triple-net operating leases was approximately $65 million, of which $57 million will directly result in incremental rental income, and approximately $45 million will be spent over the next 12 months. Additionally, as of March 31, 2023, anticipated capital expenditures related to our Senior Housing - Managed communities was approximately $54 million, of which we expect to spend approximately $36 million over the next 12 months.

In addition, as of March 31, 2023, we have committed to provide up to $28.0 million of future funding related to two preferred equity investments and one loan receivable investment that matures in June 2024.

Dividends. To maintain REIT status, we are required each year to distribute to stockholders at least 90% of our annual REIT taxable income after certain adjustments. All distributions will be made by us at the discretion of our board of directors and will depend on our financial position, results of operations, cash flows, capital requirements, debt covenants (which include limits on distributions by us), applicable law, and other factors as our board of directors deems relevant.

We paid dividends of $69.4 million on our common stock during the three months ended March 31, 2023. On May 3, 2023, our board of directors declared a quarterly cash dividend of $0.30 per share of common stock. The dividend will be paid on May 31, 2023 to common stockholders of record as of May 16, 2023.

Subsidiary Issuer and Guarantor Financial Information. In connection with the Operating Partnership’s assumption of the 2026 Notes, we have fully and unconditionally guaranteed the 2026 Notes. The 2029 Notes and 2031 Notes are issued by the Operating Partnership and guaranteed, fully and unconditionally, by us.

These guarantees are subordinated to all existing and future senior debt and senior guarantees of us, as guarantor, and are unsecured. We conduct all of our business through and derive virtually all of our income from our subsidiaries. Therefore, our ability to make required payments with respect to our indebtedness (including the Senior Notes) and other obligations depends on the financial results and condition of our subsidiaries and our ability to receive funds from our subsidiaries.

35

In accordance with Regulation S-X, the following aggregate summarized financial information is provided for Sabra and the Operating Partnership. This aggregate summarized financial information has been prepared from the books and records maintained by us and the Operating Partnership. The aggregate summarized financial information does not include the investments in, nor the earnings from, subsidiaries other than the Operating Partnership and therefore is not necessarily indicative of the results of operations or financial position had the Operating Partnership operated as an independent entity. Intercompany transactions have been eliminated. The aggregate summarized balance sheet information as of March 31, 2023 and December 31, 2022 and aggregate summarized statement of loss information for the three months ended March 31, 2023 is as follows (in thousands):

	March 31, 2023		December 31, 2022
Total assets	$	68,745	$	74,063
Total liabilities	2,227,420		2,275,511
	Three Months Ended March 31, 2023
Total revenues	$	18
Total expenses	32,905
Net loss	(35,020)

Concentration of Credit Risk

Concentrations of credit risk arise when a number of tenants or obligors related to our investments are engaged in similar business activities, or activities in the same geographic region, or have similar economic features that would cause their ability to meet contractual obligations, including those to us, to be similarly affected by changes in economic conditions. We regularly monitor our portfolio to assess potential concentrations of risks.

Management believes our current portfolio is reasonably diversified across healthcare related real estate and geographical location and does not contain any other significant concentration of credit risks. Our portfolio of 396 real estate properties held for investment as of March 31, 2023 is diversified by location across the U.S. and Canada.

For the three months ended March 31, 2023, no tenant relationship represented 10% or more of our total revenues.

Skilled Nursing Facility Reimbursement Rates

For the three months ended March 31, 2023, 43.0% of our revenues was derived directly or indirectly from skilled nursing/transitional care facilities. Medicare reimburses skilled nursing facilities for Medicare Part A services under the Prospective Payment System (“PPS”), as implemented pursuant to the Balanced Budget Act of 1997 and modified pursuant to subsequent laws, most recently the Patient Protection and Affordable Care Act of 2010. PPS regulations predetermine a payment amount per patient, per day, based on a market basket index calculated for all covered costs.

On October 1, 2019, a case-mix classification system called the skilled nursing facility Patient-Driven Payment Model (“PDPM”) became effective pursuant to a Centers for Medicare & Medicaid Services (“CMS”) final rule. PDPM focuses on clinically relevant factors, rather than volume-based service, for determining Medicare payment. PDPM adjusts Medicare payments based on each aspect of a resident’s care, most notably for non-therapy ancillaries, which are items and services not related to the provision of therapy such as drugs and medical supplies, thereby more accurately addressing costs associated with medically complex patients. It further adjusts the skilled nursing facility per diem payments to reflect varying costs throughout the stay and incorporates safeguards against potential financial incentives to ensure that beneficiaries receive care consistent with their unique needs and goals.

On July 29, 2022, CMS issued a final rule regarding fiscal year 2023 Medicare rates for skilled nursing facilities providing an estimated net increase of 2.7% compared to fiscal year 2022 comprised of an increase as a result of an update to the payment rates of 5.1% (which is based on (i) a market basket increase of 3.9% plus (ii) a market basket forecast error adjustment of 1.5% and less (iii) a productivity adjustment of 0.3%), partially offset by the recalibrated PDPM parity adjustment of 2.3% (the total PDPM parity adjustment is 4.6%, and it is being phased in over a two-year period). These figures do not incorporate any of the estimated value-based purchasing reductions for skilled nursing facilities. The new payment rates became effective on October 1, 2022.

On April 4, 2023, CMS issued a proposed rule regarding fiscal year 2024 Medicare rates for skilled nursing facilities providing an estimated net increase of 3.7% compared to fiscal year 2023 comprised of an increase as a result of an update to the payment rates of 6.1% (which is based on (i) a market basket increase of 2.7% plus (ii) a market basket forecast error

36

adjustment of 3.6% and less (iii) a productivity adjustment of 0.2%), partially offset by the second phase of the recalibrated PDPM parity adjustment of 2.3%. These figures do not incorporate any of the estimated value-based purchasing reductions for skilled nursing facilities. The proposed payment rates would become effective on October 1, 2023.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There have been no material changes to the quantitative and qualitative disclosures about market risk set forth in our 2022 Annual Report on Form 10-K.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

As of the end of the period covered by this report, management, including our chief executive officer and chief financial officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures. Based upon, and as of the date of, the evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective as of March 31, 2023 to ensure that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our chief executive officer and our chief financial officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended March 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

37

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

None of the Company or any of its subsidiaries is a party to, and none of their respective property is the subject of, any material legal proceeding, although we are from time to time party to legal proceedings that arise in the ordinary course of our business.

ITEM 1A. RISK FACTORS

There have been no material changes in our assessment of our risk factors from those set forth in Part I, Item 1A of our 2022 Annual Report on Form 10-K.

ITEM 6. EXHIBITS

Ex.	Description
3.1	Articles of Amendment and Restatement of Sabra Health Care REIT, Inc., dated October 20, 2010, filed with the State Department of Assessments and Taxation of the State of Maryland on October 21, 2010 (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed by Sabra Health Care REIT, Inc. on October 26, 2010).
3.1.1	Articles of Amendment to the Articles of Amendment and Restatement of Sabra Health Care REIT, Inc., dated as of July 31, 2017 (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed by Sabra Health Care REIT, Inc. on July 31, 2017).
3.1.2	Articles of Amendment to the Articles of Amendment and Restatement of Sabra Health Care REIT, Inc., dated as of June 9, 2020 (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed by Sabra Health Care REIT, Inc. on June 12, 2020).
3.1.3	Articles Supplementary of Sabra Health Care REIT, Inc., dated as of December 15, 2022 (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed by Sabra Health Care REIT, Inc. on December 16, 2022).
3.2	Amended and Restated Bylaws of Sabra Health Care REIT, Inc. (incorporated by reference to Exhibit 3.2 of the Current Report on Form 8-K filed by Sabra Health Care REIT, Inc. on December 16, 2022).
10.1	Sixth Amended and Restated Credit Agreement, dated January 4, 2023, among Sabra Health Care Limited Partnership and Sabra Canadian Holdings, LLC, as Borrowers; Sabra Health Care REIT, Inc., as a guarantor; the other guarantors party thereto; the lenders party thereto; Bank of America, N.A., as Administrative Agent and L/C Issuer; Citizens Bank, National Association, Crédit Agricole Corporate and Investment Bank and Wells Fargo Bank, National Association, as Co-Syndication Agents and L/C Issuers; The Bank of Nova Scotia, Fifth Third Bank, JPMorgan Chase Bank, N.A., Keybank National Association, Mizuho Bank, Ltd., and Truist Bank, as Co-Documentation Agents; BofA Securities, Inc., as Joint Lead Arranger and Sole Bookrunner; and Citizens Bank, National Association, Crédit Agricole Corporate and Investment Bank and Wells Fargo Securities, LLC, as Joint Lead Arrangers (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed by Sabra Health Care REIT, Inc. on January 5, 2023).
10.2	Equity Distribution Agreement, dated February 23, 2023, among the Company, the Sales Agents party thereto, and the Forward Purchasers party thereto (incorporated by reference to Exhibit 1.1 of the Current Report on Form 8-K filed by Sabra Health Care REIT, Inc. on February 23, 2023).
22.1	List of Subsidiary Issuers and Guarantors of Sabra Health Care REIT, Inc. (incorporated by reference to Exhibit 22.1 of the Annual Report on 10-K filed by Sabra Health Care REIT, Inc. on February 22, 2022).
31.1*	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**	Certification of Chief Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**	Certification of Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

38

Ex.	Description
101.INS*	XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH*	XBRL Taxonomy Extension Schema Document.
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*	XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document.
104*	Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

*	Filed herewith.
**	Furnished herewith.

39

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	SABRA HEALTH CARE REIT, INC.
Date: May 3, 2023	By:	/S/    RICHARD K. MATROS
		Richard K. Matros
		Chief Executive Officer, President and Chair
		(Principal Executive Officer)
Date: May 3, 2023	By:	/S/    MICHAEL COSTA
		Michael Costa
		Chief Financial Officer, Secretary and Executive Vice President
		(Principal Financial Officer)

40

EX-31.1

Exhibit 31.1

Certification of Chief Executive Officer pursuant to

Section 302 of the Sarbanes-Oxley Act of 2002

I, Richard K. Matros, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Sabra Health Care REIT, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 3, 2023

/S/    RICHARD K. MATROS

Richard K. Matros

Chief Executive Officer, President and Chair

EX-31.2

Exhibit 31.2

Certification of Chief Financial Officer pursuant to

Section 302 of the Sarbanes-Oxley Act of 2002

I, Michael Costa, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Sabra Health Care REIT, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: 

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 3, 2023

/S/    MICHAEL COSTA

Michael Costa

Chief Financial Officer, Secretary and Executive Vice President

EX-32.1

Exhibit 32.1

Certification pursuant to 18 U.S.C. Section 1350,

as Adopted pursuant to Section 906 of the

Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q of Sabra Health Care REIT, Inc. (the “Registrant”) for the three months ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Richard K. Matros, as Chief Executive Officer, President and Chair of the Registrant, hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

Date: May 3, 2023

/S/    RICHARD K. MATROS

Richard K. Matros

Chief Executive Officer, President and Chair

EX-32.2

Exhibit 32.2

Certification pursuant to 18 U.S.C. Section 1350,

as Adopted pursuant to Section 906 of the

Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q of Sabra Health Care REIT, Inc. (the “Registrant”) for the three months ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Michael Costa, as Chief Financial Officer, Secretary and Executive Vice President of the Registrant, hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

Date: May 3, 2023

/S/    MICHAEL COSTA

Michael Costa

Chief Financial Officer, Secretary and Executive Vice President

XML

Cover - shares	3 Months Ended
	Mar. 31, 2023	Apr. 27, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	001-34950
Entity Registrant Name	SABRA HEALTH CARE REIT, INC.
Entity Incorporation, State or Country Code	MD
Entity Tax Identification Number	27-2560479
Entity Address, Address Line One	18500 Von Karman Avenue, Suite 550
Entity Address, City or Town	Irvine
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92612
City Area Code	888
Local Phone Number	393-8248
Title of 12(b) Security	Common stock, $.01 par value
Trading Symbol	SBRA
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		231,195,148
Entity Central Index Key	0001492298
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Amendment Flag	false

XML

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Assets
Real estate investments, net of accumulated depreciation of $952,791 and $913,345 as of March 31, 2023 and December 31, 2022, respectively	$ 4,797,041	$ 4,959,343
Loans receivable and other investments, net	409,079	411,396
Investment in unconsolidated joint ventures	139,402	134,962
Cash and cash equivalents	33,532	49,308
Restricted cash	5,152	4,624
Lease intangible assets, net	39,369	40,131
Accounts receivable, prepaid expenses and other assets, net	132,736	147,908
Total assets	5,556,311	5,747,672
Liabilities
Secured debt, net	48,754	49,232
Revolving credit facility	79,563	196,982
Term loans, net	533,657	526,129
Senior unsecured notes, net	1,734,644	1,734,431
Accounts payable and accrued liabilities	143,002	142,259
Lease intangible liabilities, net	40,464	42,244
Total liabilities	2,580,084	2,691,277
Commitments and contingencies (Note 12)
Equity
Preferred stock, $0.01 par value; 10,000,000 shares authorized, zero shares issued and outstanding as of March 31, 2023 and December 31, 2022	0	0
Common stock, $0.01 par value; 500,000,000 shares authorized, 231,195,148 and 231,009,295 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively	2,312	2,310
Additional paid-in capital	4,487,707	4,486,967
Cumulative distributions in excess of net income	(1,531,230)	(1,451,945)
Accumulated other comprehensive income	17,438	19,063
Total equity	2,976,227	3,056,395
Total liabilities and equity	$ 5,556,311	$ 5,747,672

XML

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Assets
Accumulated depreciation	$ 952,791	$ 913,345
Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]
Par value (in dollars per share)	$ 0.01	$ 0.01
Shares authorized (in shares)	10,000,000	10,000,000
Shares issued (in shares)	0	0
Shares outstanding (in shares)	0	0
Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]
Par value (in dollars per share)	$ 0.01	$ 0.01
Shares authorized (in shares)	500,000,000	500,000,000
Shares issued (in shares)	231,195,148	231,009,295
Shares outstanding (in shares)	231,195,148	231,009,295

XML

CONSOLIDATED STATEMENTS OF (LOSS) INCOME - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenues:
Rental and related revenues (Note 4)	$ 95,870	$ 109,886
Resident fees and services	56,721	42,227
Interest and other income	8,733	10,992
Total revenues	161,324	163,105
Expenses:
Depreciation and amortization	52,827	45,256
Interest	28,540	24,972
General and administrative	10,502	10,396
(Recovery of) provision for loan losses and other reserves	(208)	475
Impairment of real estate	7,064	0
Total expenses	146,530	119,214
Other (expense) income:
Loss on extinguishment of debt	(1,541)	(271)
Other income	341	68
Net loss on sales of real estate	(21,515)	0
Total other expense	(22,715)	(203)
(Loss) income before loss from unconsolidated joint ventures and income tax expense	(7,921)	43,688
Loss from unconsolidated joint ventures	(838)	(2,802)
Income tax expense	(728)	(284)
Net (loss) income	$ (9,487)	$ 40,602
Net (loss) income, per:
Basic common share (in dollars per share)	$ (0.04)	$ 0.18
Diluted common share (in dollars per share)	$ (0.04)	$ 0.18
Weighted average number of common shares outstanding, basic (in shares)	231,164,876	230,859,993
Weighted average number of common shares outstanding, diluted (in shares)	231,164,876	231,564,970
Revenue, type, extensible enumeration	Health Care, Resident Service [Member]	Health Care, Resident Service [Member]
Triple-net portfolio
Expenses:
Operating expenses	$ 4,168	$ 5,011
Senior housing - managed
Expenses:
Operating expenses	$ 43,637	$ 33,104

XML

CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Statement of Comprehensive Income [Abstract]
Net (loss) income	$ (9,487)	$ 40,602
Unrealized gain (loss), net of tax:
Foreign currency translation loss	(1,623)	(644)
Unrealized (loss) gain on cash flow hedges	(2)	12,339
Total other comprehensive (loss) income	(1,625)	11,695
Comprehensive (loss) income	$ (11,112)	$ 52,297

XML

CONSOLIDATED STATEMENTS OF EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Cumulative Distributions in Excess of Net Income	Accumulated Other Comprehensive (Loss) Income
Beginning balance (in shares) at Dec. 31, 2021		230,398,655
Beginning balance at Dec. 31, 2021	$ 3,379,530	$ 2,304	$ 4,482,451	$ (1,095,204)	$ (10,021)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	40,602			40,602
Other comprehensive income (loss)	11,695				11,695
Amortization of stock-based compensation	2,673		2,673
Common stock issuance, net (in shares)		556,122
Common stock issuance, net	(3,484)	$ 6	(3,490)
Common dividends	(69,493)			(69,493)
Ending balance (in shares) at Mar. 31, 2022		230,954,777
Ending balance at Mar. 31, 2022	3,361,523	$ 2,310	4,481,634	(1,124,095)	1,674
Beginning balance (in shares) at Dec. 31, 2022		231,009,295
Beginning balance at Dec. 31, 2022	3,056,395	$ 2,310	4,486,967	(1,451,945)	19,063
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(9,487)			(9,487)
Other comprehensive income (loss)	(1,625)				(1,625)
Amortization of stock-based compensation	2,675		2,675
Common stock issuance, net (in shares)		185,853
Common stock issuance, net	(1,933)	$ 2	(1,935)
Common dividends	(69,798)			(69,798)
Ending balance (in shares) at Mar. 31, 2023		231,195,148
Ending balance at Mar. 31, 2023	$ 2,976,227	$ 2,312	$ 4,487,707	$ (1,531,230)	$ 17,438

XML

CONSOLIDATED STATEMENTS OF EQUITY (Parenthetical) - USD ($) $ in Thousands		3 Months Ended
	Feb. 01, 2023	Mar. 31, 2023	Mar. 31, 2022
Statement of Stockholders' Equity [Abstract]
Common dividends (in dollars per share)	$ 0.30	$ 0.30	$ 0.30
Common stock issuance, net		$ (1,933)	$ (3,484)

XML

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net (loss) income	$ (9,487)	$ 40,602
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization	52,827	45,256
Non-cash rental and related revenues	(2,398)	(4,474)
Non-cash interest income	(392)	(547)
Non-cash interest expense	3,014	2,698
Stock-based compensation expense	2,229	2,456
Loss on extinguishment of debt	1,541	271
Provision for loan losses and other reserves	(208)	475
Net loss on sales of real estate	21,515	0
Impairment of real estate	7,064	0
Loss from unconsolidated joint ventures	838	2,802
Distributions of earnings from unconsolidated joint ventures	367	0
Changes in operating assets and liabilities:
Accounts receivable, prepaid expenses and other assets, net	(2,782)	(5,457)
Accounts payable and accrued liabilities	(5,839)	(20,968)
Net cash provided by operating activities	68,289	63,114
Cash flows from investing activities:
Acquisition of real estate	(39,630)	(20,573)
Origination and fundings of loans receivable	(1,800)	0
Origination and fundings of preferred equity investments	(6,384)	(4,074)
Additions to real estate	(19,540)	(10,803)
Escrow deposits for potential investments	0	(3,217)
Repayments of loans receivable	6,144	696
Repayments of preferred equity investments	1,433	729
Investment in unconsolidated joint ventures	(4,797)	0
Net proceeds from the sales of real estate	152,259	0
Net proceeds from sales-type lease	25,490	0
Net cash provided by (used in) investing activities	113,175	(37,242)
Cash flows from financing activities:
Net (repayments of) borrowings from revolving credit facility	(118,442)	16,577
Proceeds from term loans	12,186	0
Principal payments on term loans	0	(40,000)
Principal payments on secured debt	(490)	(16,067)
Payments of deferred financing costs	(18,127)	(6)
Issuance of common stock, net	(1,847)	(3,748)
Dividends paid on common stock	(69,351)	(69,275)
Net cash used in financing activities	(196,071)	(112,519)
Net decrease in cash, cash equivalents and restricted cash	(14,607)	(86,647)
Effect of foreign currency translation on cash, cash equivalents and restricted cash	(641)	40
Cash, cash equivalents and restricted cash, beginning of period	53,932	115,886
Cash, cash equivalents and restricted cash, end of period	38,684	29,279
Supplemental disclosure of cash flow information:
Interest paid	22,318	18,383
Supplemental disclosure of non-cash investing activities:
Decrease in loans receivable and other investments due to acquisition of real estate	$ 4,644	$ 5,623

XML

BUSINESS

3 Months Ended

Mar. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

BUSINESS

BUSINESS

Overview

Sabra Health Care REIT, Inc. (“Sabra” or the “Company”) was incorporated on May 10, 2010 as a wholly owned subsidiary of Sun Healthcare Group, Inc. (“Sun”) and commenced operations on November 15, 2010 following Sabra’s separation from Sun. Sabra elected to be treated as a real estate investment trust (“REIT”) with the filing of its United States (“U.S.”) federal income tax return for the taxable year beginning January 1, 2011. Sabra believes that it has been organized and operated, and it intends to continue to operate, in a manner to qualify as a REIT. Sabra’s primary business consists of acquiring, financing and owning real estate property to be leased to third-party tenants in the healthcare sector. Sabra primarily generates revenues by leasing properties to tenants throughout the U.S. and Canada. Sabra owns substantially all of its assets and properties and conducts its operations through Sabra Health Care Limited Partnership, a Delaware limited partnership (the “Operating Partnership”), of which Sabra is the sole general partner and a wholly owned subsidiary of Sabra is currently the only limited partner, or by subsidiaries of the Operating Partnership. The Company’s investment portfolio is primarily comprised of skilled nursing/transitional care facilities, senior housing communities (“Senior Housing - Leased”), behavioral health facilities and specialty hospitals and other facilities, in each case leased to tenants who are responsible for the operations of these facilities; senior housing communities operated by third-party property managers pursuant to property management agreements (“Senior Housing - Managed”); investments in joint ventures; investments in loans receivable; and preferred equity investments.

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Mar. 31, 2023

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation and Basis of Presentation

The accompanying consolidated financial statements include the accounts of Sabra and its wholly owned subsidiaries as of March 31, 2023 and December 31, 2022 and for the three month periods ended March 31, 2023 and 2022. All significant intercompany transactions and balances have been eliminated in consolidation.

The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information as contained within the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification and the rules and regulations of the SEC, including the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the unaudited consolidated financial statements do not include all of the information and footnotes required by GAAP for financial statements. In the opinion of management, the financial statements for the unaudited interim periods presented include all adjustments, which are of a normal and recurring nature, necessary for a fair statement of the results for such periods. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. For further information, refer to the Company’s consolidated financial statements and notes thereto for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC.

GAAP requires the Company to identify entities for which control is achieved through voting rights or other means and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). A VIE is broadly defined as an entity with one or more of the following characteristics: (a) the total equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (b) as a group, the holders of the equity investment at risk lack (i) the ability to make decisions about the entity’s activities through voting or similar rights, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity; or (c) the equity investors have voting rights that are not proportional to their economic interests, and substantially all of the entity’s activities either involve, or are conducted on behalf of, an investor that has disproportionately few voting rights. If the Company were determined to be the primary beneficiary of the VIE, the Company would consolidate investments in the VIE. The Company may change its original assessment of a VIE due to events such as modifications of contractual arrangements that affect the characteristics or adequacy of the entity’s equity investments at risk and the disposal of all or a portion of an interest held by the primary beneficiary.

The Company identifies the primary beneficiary of a VIE as the enterprise that has both: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance; and (ii) the obligation to absorb losses or

the right to receive benefits of the VIE that could be significant to the entity. The Company performs this analysis on an ongoing basis. As of March 31, 2023, the Company determined that it was not the primary beneficiary of any VIEs.

As it relates to investments in loans, in addition to the Company’s assessment of VIEs and whether the Company is the primary beneficiary of those VIEs, the Company evaluates the loan terms and other pertinent facts to determine whether the loan investment should be accounted for as a loan or as a real estate joint venture. If an investment has the characteristics of a real estate joint venture, including if the Company participates in the majority of the borrower’s expected residual profit, the Company would account for the investment as an investment in a real estate joint venture and not as a loan investment. Expected residual profit is defined as the amount of profit, whether called interest or another name, such as an equity kicker, above a reasonable amount of interest and fees expected to be earned by a lender. At March 31, 2023, none of the Company’s investments in loans were accounted for as real estate joint ventures.

As it relates to investments in joint ventures, the Company assesses any partners’ rights and their impact on the presumption of control of the partnership by any single partner. The Company also applies this guidance to managing member interests in limited liability companies. The Company reassesses its determination of which entity controls the joint venture if: there is a change to the terms or in the exercisability of the rights of any partners or members, the general partner or managing member increases or decreases its ownership interests, or there is an increase or decrease in the number of outstanding ownership interests. As of March 31, 2023, the Company’s determination of which entity controls its investments in joint ventures has not changed as a result of any reassessment.

Use of Estimates

The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.

XML

RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED)

3 Months Ended

Mar. 31, 2023

Business Combination and Asset Acquisition [Abstract]

RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED)

RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED)

During the three months ended March 31, 2023, the Company acquired one Senior Housing - Leased community and one Senior Housing - Managed community. During the three months ended March 31, 2022, the Company acquired one Senior Housing - Managed community. The Senior Housing - Managed communities acquired during the three months ended March 31, 2023 and 2022 were part of the Company’s proprietary development pipeline and were previously reflected as preferred equity investments which had a book value of $4.6 million and $5.6 million, respectively, at the time of acquisition. The consideration was allocated as follows (in thousands):

	Three Months Ended March 31,
	2023		2022
Land	$	3,415	$	3,691
Building and improvements	45,333		21,168
Tenant origination and absorption costs intangible assets	2,706		1,337
Tenant relationship intangible assets	20		—
Total consideration	$	51,474	$	26,196

The tenant origination and absorption costs intangible assets and tenant relationship intangible assets had a weighted average amortization periods as of the respective dates of acquisition of one year and 22 years, respectively, for the acquisitions completed during the three months ended March 31, 2023. The tenant origination and absorption costs intangible assets had an amortization period as of the date of acquisition of one year for the acquisition completed during the three months ended March 31, 2022.

For the three months ended March 31, 2023, the Company recognized $1.7 million of total revenues and $0.2 million of net income from the facilities acquired during the three months ended March 31, 2023. For the three months ended March 31, 2022, the Company recognized $0.9 million of total revenues and $0.1 million of net income from the facility acquired during the three months ended March 31, 2022.

The Company is required to pay additional consideration related to two Senior Housing - Managed communities if certain performance metrics are achieved, and as of March 31, 2023, based on the improved performance of these facilities, the aggregate additional consideration is estimated to be $17.4 million and is included in real estate investments, net of accumulated depreciation and accounts payable and accrued liabilities on the accompanying consolidated balance sheets.

XML

INVESTMENT IN REAL ESTATE PROPERTIES

3 Months Ended

Mar. 31, 2023

Real Estate [Abstract]

INVESTMENT IN REAL ESTATE PROPERTIES

INVESTMENT IN REAL ESTATE PROPERTIES

The Company’s real estate properties held for investment consisted of the following (dollars in thousands):

As of March 31, 2023

Property Type	Number of Properties	Number of Beds/Units	Total Real Estate at Cost		Accumulated Depreciation		Total Real Estate Investments, Net
Skilled Nursing/Transitional Care	258	28,334	$	3,212,202	$	(518,215)	$	2,693,987
Senior Housing - Leased	47	3,600	592,119		(101,303)		490,816
Senior Housing - Managed	59	5,973	1,245,066		(227,844)		1,017,222
Behavioral Health	17	965	474,079		(61,487)		412,592
Specialty Hospitals and Other	15	392	225,443		(43,392)		182,051
	396	39,264	5,748,909		(952,241)		4,796,668
Corporate Level			923		(550)		373
			$	5,749,832	$	(952,791)	$	4,797,041

As of December 31, 2022

Property Type	Number of Properties	Number of Beds/Units	Total Real Estate at Cost		Accumulated Depreciation		Total Real Estate Investments, Net
Skilled Nursing/Transitional Care	264	29,136	$	3,385,221	$	(492,495)	$	2,892,726
Senior Housing - Leased	47	3,550	590,694		(97,716)		492,978
Senior Housing - Managed	59	5,942	1,205,283		(222,089)		983,194
Behavioral Health	17	965	465,143		(58,481)		406,662
Specialty Hospitals and Other	15	392	225,443		(42,038)		183,405
	402	39,985	5,871,784		(912,819)		4,958,965
Corporate Level			904		(526)		378
			$	5,872,688	$	(913,345)	$	4,959,343

	March 31, 2023		December 31, 2022
Building and improvements	$	4,945,404	$	5,034,470
Furniture and equipment	236,032		262,644
Land improvements	9,499		7,085
Land	558,897		568,489
Total real estate at cost	5,749,832		5,872,688
Accumulated depreciation	(952,791)		(913,345)
Total real estate investments, net	$	4,797,041	$	4,959,343

Operating Leases

As of March 31, 2023, the substantial majority of the Company’s real estate properties (excluding 59 Senior Housing - Managed communities) were leased under triple-net operating leases with expirations ranging from less than one year to 20 years. As of March 31, 2023, the leases had a weighted average remaining term of eight years. The leases generally include provisions to extend the lease terms and other negotiated terms and conditions. The Company, through its subsidiaries, retains substantially all of the risks and benefits of ownership of the real estate assets leased to the tenants. The Company may receive additional security under these operating leases in the form of letters of credit and security deposits from the lessee or guarantees from the parent of the lessee. Security deposits received in cash related to tenant leases are included in accounts payable and accrued liabilities on the accompanying consolidated balance sheets and totaled $14.0 million and $13.1 million as of March 31, 2023 and December 31, 2022, respectively, and letters of credit deposited with the Company totaled approximately $59 million and $57 million as of March 31, 2023 and December 31, 2022, respectively. In addition, the Company’s tenants have deposited with the Company $13.6 million and $13.3 million as of March 31, 2023 and December 31,

2022, respectively, for future real estate taxes, insurance expenditures and tenant improvements related to the Company’s properties and their operations, and these amounts are included in accounts payable and accrued liabilities on the accompanying consolidated balance sheets.

Lessor costs that are paid by the lessor and reimbursed by the lessee are included in the measurement of variable lease revenue and the associated expense. As a result, the Company recognized variable lease revenue and the associated expense of $3.8 million and $5.1 million during the three months ended March 31, 2023 and 2022, respectively.

The Company monitors the creditworthiness of its tenants by evaluating the ability of the tenants to meet their lease obligations to the Company based on the tenants’ financial performance, including, as applicable and appropriate, the evaluation of any parent guarantees (or the guarantees of other related parties) of such lease obligations. The primary basis for the Company’s evaluation of the credit quality of its tenants (and more specifically the tenant’s ability to pay their rent obligations to the Company) is the tenant’s lease coverage ratio as supplemented by the parent’s fixed charge coverage ratio for those entities with a parent guarantee. These coverage ratios include earnings before interest, taxes, depreciation, amortization and rent (“EBITDAR”) to rent and earnings before interest, taxes, depreciation, amortization, rent and management fees (“EBITDARM”) to rent at the lease level and consolidated EBITDAR to total fixed charges at the parent guarantor level when such a guarantee exists. The Company obtains various financial and operational information from the majority of its tenants each month and reviews this information in conjunction with the above-described coverage metrics to identify financial and operational trends, evaluate the impact of the industry’s operational and financial environment (including the impact of government reimbursement), and evaluate the management of the tenant’s operations. These metrics help the Company identify potential areas of concern relative to its tenants’ credit quality and ultimately the tenant’s ability to generate sufficient liquidity to meet its obligations, including its obligation to continue to pay the rent due to the Company.

During the third quarter of 2022, the Company concluded that its leases with North American Health Care, Inc. (“North American”) should no longer be accounted for on an accrual basis and wrote off $15.6 million of straight-line rent receivable balances related to these leases. The facilities were transitioned to the Ensign Group or Avamere, as applicable, effective February 1, 2023.

For the three months ended March 31, 2023, no tenant relationship represented 10% or more of the Company’s total revenues.

As of March 31, 2023, the future minimum rental payments from the Company’s properties held for investment under non-cancelable operating leases were as follows and may materially differ from actual future rental payments received (in thousands):

April 1 through December 31, 2023	$	279,989
2024	380,057
2025	375,286
2026	360,133
2027	337,235
Thereafter	1,535,962
	$	3,268,662

Senior Housing - Managed Communities

The Company’s Senior Housing - Managed communities offer residents certain ancillary services that are not contemplated in the lease with each resident (i.e., housekeeping, laundry, guest meals, etc.). These services are provided and paid for in addition to the standard services included in each resident lease (i.e., room and board, standard meals, etc.). The Company bills residents for ancillary services one month in arrears and recognizes revenue as the services are provided, as the Company has no continuing performance obligation related to those services. Resident fees and services include ancillary service revenue of $0.5 million and $0.3 million for the three months ended March 31, 2023 and 2022, respectively.

Capital and Other Expenditures

As of March 31, 2023, the Company’s aggregate commitment for future capital and other expenditures associated with facilities leased under triple-net operating leases was approximately $65 million. These commitments are principally for improvements to its facilities.

Investment in Unconsolidated Joint Ventures

The following is a summary of the Company’s investment in unconsolidated joint ventures (dollars in thousands):

	Property Type	Number of Properties as of March 31, 2023	Ownership as of March 31, 2023 (1)		Book Value
					March 31, 2023		December 31, 2022
Sienna Joint Venture	Senior Housing - Managed	12	50	%	$	119,824	$	120,269
Marlin Spring Joint Venture	Senior Housing - Managed	4	85	%	19,578		14,693
					$	139,402	$	134,962

(1)    These investments are not consolidated because the Company does not control, through voting rights or other means, the joint ventures.

During the three months ended March 31, 2023, the Company’s joint venture with Marlin Spring (the “Marlin Spring Joint Venture”) completed the acquisition of one additional senior housing community that is being managed by a third-party property manager. The gross investment in the additional acquisition was CAD $30.0 million, excluding acquisition costs. In addition, the Marlin Spring Joint Venture assumed and financed an aggregate CAD $23.6 million of debt associated with the additional acquisition.

During the fourth quarter of 2022, due to the confluence of labor shortages, increased labor costs, elevated interest rates and a slower than anticipated recovery in the operating performance of the underlying facilities, the Company concluded that the estimated fair value of its investment in its joint venture with affiliates of TPG Real Estate, the real estate platform of TPG (the “Enlivant Joint Venture”) had declined to zero based on updated future cash flow analyses. This decline was deemed to be other-than-temporary, and the Company recorded an impairment charge totaling $57.8 million during the three months ended December 31, 2022.

The Company has not guaranteed any obligations of and is not committed to provide any support to the Enlivant Joint Venture. The Company has discontinued applying the equity method of accounting to the Enlivant Joint Venture, in which it has a 49% equity interest, and will resume application if, during the period in which application of the equity method of accounting has been discontinued, the Company’s share of unrecognized net income exceeds its share of unrecognized net losses.

Net Investment in Sales-Type Lease

As of December 31, 2022, the Company had a $25.5 million net investment in one skilled nursing/transitional care facility leased to a tenant under a sales-type lease, as the tenant is obligated to purchase the property at the end of the lease term. During the three months ended March 31, 2023, the tenant purchased the skilled nursing/transitional care facility for net proceeds of $25.5 million as obligated under the terms of the lease.

XML

IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS

3 Months Ended

Mar. 31, 2023

Discontinued Operations and Disposal Groups [Abstract]

IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS

IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS

Impairment of Real Estate

During the three months ended March 31, 2023, the Company recognized $7.1 million of real estate impairment related to one skilled nursing/transitional care facility that is under contract to sell.

During the three months ended March 31, 2022, the Company recognized no real estate impairment.

To estimate the fair value of the impaired facility, the Company utilized a market approach which considered the binding sale agreement (Level 3 measurement).

The Company continues to evaluate additional assets for sale as part of its initiative to recycle capital and further improve its portfolio quality. This could lead to a shorter hold period and could result in the determination that the full amount of the Company’s investment is not recoverable, resulting in an impairment charge which could be material.

Dispositions

The following table summarizes the Company’s dispositions for the periods presented (dollars in millions):

	Three Months Ended March 31,
	2023		2022
Number of facilities	8		—
Consideration, net of closing costs	$	160.3	$	—
Net carrying value	181.8		—
Net loss on sale	$	(21.5)	$	—
Net (loss) income	$	(22.1)	$	0.1

The sale of the disposition facilities does not represent a strategic shift that has or will have a major effect on the Company’s operations and financial results, and therefore the results of operations attributable to these facilities have remained in continuing operations.

XML

LOANS RECEIVABLE AND OTHER INVESTMENTS

3 Months Ended

Mar. 31, 2023

Receivables [Abstract]

LOANS RECEIVABLE AND OTHER INVESTMENTS

LOANS RECEIVABLE AND OTHER INVESTMENTS

As of March 31, 2023 and December 31, 2022, the Company’s loans receivable and other investments consisted of the following (dollars in thousands):

									As of March 31, 2023
Investment	Quantity as of March 31, 2023	Property Type	Principal Balance as of March 31, 2023 (1)		Book Value as of March 31, 2023		Book Value as of December 31, 2022		Weighted Average Contractual Interest Rate / Rate of Return		Weighted Average Annualized Effective Interest Rate / Rate of Return		Maturity Date as of March 31, 2023
Loans Receivable:
Mortgage	2	Behavioral Health	$	319,000	$	319,000	$	319,000	7.6	%	7.6	%	11/01/26 - 01/31/27
Other	11	Multiple	47,200		43,768		47,936		7.1	%	6.5	%	08/31/23 - 08/31/28
	13		366,200		362,768		366,936		7.6	%	7.5	%
Allowance for loan losses			—		(6,403)		(6,611)
			$	366,200	$	356,365	$	360,325
Other Investments:
Preferred Equity	6	Skilled Nursing / Senior Housing	52,551		52,714		51,071		10.9	%	10.8	%	N/A
Total	19		$	418,751	$	409,079	$	411,396	8.0	%	7.9	%

(1)    Principal balance includes amounts funded and accrued but unpaid interest / preferred return and excludes capitalizable fees.

As of March 31, 2023, the Company has committed to provide up to $28.0 million of future funding related to two preferred equity investments and one loan receivable investment that matures in June 2024.

Additional information regarding the Company’s loans receivable is as follows (dollars in thousands):

	Three Months Ended March 31,
	2023		2022
Allowance for loan losses:
Balance at beginning of the period	$	6,611	$	6,344
(Recovery of) provision for loan losses	(208)		507
Balance at end of the period	$	6,403	$	6,851
	March 31, 2023		December 31, 2022
Deteriorated credit quality:
Number of loans receivable investments	1		1
Principal balance	$	1,214	$	1,214
Book value	—		—
Nonaccrual status:
Number of loans receivable investments	3		3
Book value	$	—	$	—

As of March 31, 2023 and December 31, 2022, the Company did not consider any preferred equity investments to be impaired, and no preferred equity investments were on nonaccrual status.

XML

DEBT

3 Months Ended

Mar. 31, 2023

Debt Disclosure [Abstract]

DEBT

DEBT

Secured Indebtedness

The Company’s secured debt consists of the following (dollars in thousands):

					As of March 31, 2023
Interest Rate Type	Principal Balance as of March 31, 2023 (1)		Principal Balance as of December 31, 2022 (1)		Weighted Average Interest Rate		Weighted Average Effective Interest Rate (2)		Maturity Date
Fixed Rate	$	49,633	$	50,123	2.84	%	3.34	%	May 2031 -  August 2051

(1)     Principal balance does not include deferred financing costs, net of $0.9 million as of each of March 31, 2023 and December 31, 2022.

(2)     Weighted average interest rate includes private mortgage insurance.

Senior Unsecured Notes

The Company’s senior unsecured notes consist of the following (dollars in thousands):

		Principal Balance as of
Title	Maturity Date	March 31, 2023 (1)		December 31, 2022 (1)
5.125% senior unsecured notes due 2026 (“2026 Notes”)	August 15, 2026	$	500,000	$	500,000
5.88% senior unsecured notes due 2027 (“2027 Notes”)	May 17, 2027	100,000		100,000
3.90% senior unsecured notes due 2029 (“2029 Notes”)	October 15, 2029	350,000		350,000
3.20% senior unsecured notes due 2031 (“2031 Notes”)	December 1, 2031	800,000		800,000
		$	1,750,000	$	1,750,000

(1)    Principal balance does not include discount, net of $3.7 million and deferred financing costs, net of $11.6 million as of March 31, 2023 and does not include discount, net of $3.5 million and deferred financing costs, net of $12.0 million as of December 31, 2022. In addition, the weighted average effective interest rate as of March 31, 2023 was 4.01%.

The 2026 Notes and the 2027 Notes were assumed as a result of the Company’s merger with Care Capital Properties, Inc. in 2017 and accrue interest at a rate of 5.125% and 5.88%, respectively, per annum. Interest is payable semiannually on February 15 and August 15 of each year for the 2026 Notes and on May 17 and November 17 of each year for the 2027 Notes.

The 2029 Notes were issued by the Operating Partnership and, until redemption of the Company’s previously outstanding 5.375% senior notes due 2023 in October 2019, Sabra Capital Corporation, wholly owned subsidiaries of the Company, and accrue interest at a rate of 3.90% per annum. Interest is payable semiannually on April 15 and October 15 of each year.

The 2031 Notes were issued by the Operating Partnership, a wholly owned subsidiary of the Company, and accrue interest at a rate of 3.20% per annum. Interest is payable semiannually on June 1 and December 1 of each year, commencing on June 1, 2022.

The obligations under the 2027 Notes are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by Sabra and one of its non-operating subsidiaries, subject to release under certain customary circumstances. The obligations under the 2026 Notes, 2029 Notes and 2031 Notes are fully and unconditionally guaranteed, on an unsecured basis, by Sabra; provided, however, that such guarantee is subject to release under certain customary circumstances.

The indentures and agreements (the “Senior Notes Indentures”) governing the 2026 Notes, 2027 Notes, 2029 Notes and 2031 Notes (collectively, the “Senior Notes”) include customary events of default and require the Company to comply with specified restrictive covenants. As of March 31, 2023, the Company was in compliance with all applicable financial covenants under the Senior Notes Indentures.

Credit Agreement

On September 9, 2019, the Operating Partnership and Sabra Canadian Holdings, LLC (together, the “Borrowers”), Sabra and the other parties thereto entered into a fifth amended and restated unsecured credit agreement (the “Prior Credit Agreement”).

The Prior Credit Agreement included a $1.0 billion revolving credit facility (the “Prior Revolving Credit Facility”), a $436.3 million U.S. dollar term loan and a CAD $125.0 million Canadian dollar term loan (collectively, the “Prior Term Loans”). Further, up to $175.0 million of the Prior Revolving Credit Facility could be used for borrowings in certain foreign currencies. The Prior Credit Agreement also contained an accordion feature that allowed for an increase in the total available borrowings to $2.75 billion, subject to terms and conditions.

During the three months ended March 31, 2022, the Company recognized $0.3 million of loss on extinguishment of debt related to write-offs of deferred financing costs in connection with the partial pay downs of the U.S. dollar Prior Term Loan.

Borrowings under the Prior Revolving Credit Facility bore interest on the outstanding principal amount at a rate equal to a ratings-based applicable interest margin plus, Canadian Dollar Offered Rate (“CDOR”) for Canadian dollar borrowings, or at the Operating Partnership’s option for U.S. dollar borrowings, either (a) LIBOR or (b) a base rate determined as the greater of (i) the federal funds rate plus 0.5%, (ii) the prime rate, and (iii) one-month LIBOR plus 1.0% (the “Prior Base Rate”). The ratings-based applicable interest margin for borrowings varied based on the Debt Ratings, as defined in the Prior Credit Agreement, and ranged from 0.775% to 1.45% per annum for CDOR or LIBOR based borrowings and 0.00% to 0.45% per annum for borrowings at the Prior Base Rate. In addition, the Operating Partnership paid a facility fee ranging between 0.125% and 0.300% per annum based on the aggregate amount of commitments under the Prior Revolving Credit Facility regardless of amounts outstanding thereunder.

The U.S. dollar Prior Term Loan bore interest on the outstanding principal amount at a rate equal to a ratings-based applicable interest margin plus, at the Operating Partnership’s option, either (a) LIBOR or (b) the Prior Base Rate. The ratings-based applicable interest margin for borrowings varied based on the Debt Ratings and ranged from 0.85% to 1.65% per annum for LIBOR based borrowings and 0.00% to 0.65% per annum for borrowings at the Prior Base Rate. The Canadian dollar Prior Term Loan bore interest on the outstanding principal amount at a rate equal to CDOR plus an interest margin that ranged from 0.85% to 1.65% depending on the Debt Ratings.

On January 4, 2023, the Borrowers, and the other parties thereto entered into a sixth amended and restated unsecured credit agreement (the “Credit Agreement”). During the three months ended March 31, 2023, the Company recorded $18.1 million of deferred financing costs related to the Credit Agreement and recognized $1.5 million of loss on extinguishment of debt related to write-offs of deferred financing costs in connection with amending and restating the Prior Credit Agreement.

The Credit Agreement includes a $1.0 billion revolving credit facility (the “Revolving Credit Facility”), a $430.0 million U.S. dollar term loan and a CAD $150.0 million Canadian dollar term loan (collectively, the “Term Loans”). Further, up to $350.0 million of the Revolving Credit Facility may be used for borrowings in certain foreign currencies. The Credit Agreement also contains an accordion feature that can increase the total available borrowings to $2.75 billion, subject to terms and conditions.

The Revolving Credit Facility has a maturity date of January 4, 2027, and includes two six-month extension options. The Term Loans have a maturity date of January 4, 2028.

As of March 31, 2023, there was $79.6 million (including CAD $86.0 million) outstanding under the Revolving Credit Facility and $920.4 million available for borrowing.

Borrowings under the Revolving Credit Facility bear interest on the outstanding principal amount at a rate equal to a ratings-based applicable interest margin plus, CDOR for Canadian dollar borrowings, or at the Operating Partnership’s option for U.S. dollar borrowings, either (a) Daily Simple SOFR, as defined in the Credit Agreement, or (b) a base rate determined as the greater of (i) the federal funds rate plus 0.5%, (ii) the prime rate, (iii) Term SOFR, as defined in the Credit Agreement, plus 1.0% (the “Base Rate”), and (iv) 1.00%. The ratings-based applicable interest margin for borrowings will vary based on the Debt Ratings, as defined in the Credit Agreement, and will range from 0.775% to 1.450% per annum for Daily Simple SOFR based borrowings and 0.00% to 0.450% per annum for borrowings at the Base Rate. As of March 31, 2023, the weighted average interest rate on the Revolving Credit Facility was 6.05%. In addition, the Operating Partnership pays a facility fee ranging between 0.125% and 0.300% per annum based on the aggregate amount of commitments under the Revolving Credit Facility regardless of amounts outstanding thereunder.

The U.S. dollar Term Loan bears interest on the outstanding principal amount at a ratings-based applicable interest margin plus, at the Operating Partnership’s option, either (a) Term SOFR or (b) the Base Rate. The ratings-based applicable interest margin for borrowings will vary based on the Debt Ratings and will range from 0.850% to 1.650% per annum for Term SOFR based borrowings and 0.00% to 0.650% per annum for borrowings at the Base Rate. As of March 31, 2023, the interest rate on the U.S. dollar Term Loan was 6.22%. The Canadian dollar Term Loan bears interest on the outstanding principal amount at a rate equal CDOR plus an interest margin that will range from 0.850% to 1.650% depending on the Debt Ratings. As of March 31, 2023, the interest rate on the Canadian dollar Term Loan was 6.20%.

The Company has interest rate swaps and interest rate collars that fix and set a cap and floor, respectively, for the SOFR portion of the interest rate for $430.0 million of SOFR-based borrowings under its U.S. dollar Term Loan at a weighted average rate of 1.51% and interest rate swaps that fix the CDOR portion of the interest rate for CAD $150.0 million of CDOR-based borrowings under its Canadian dollar Term Loan at a rate of 1.63%. As of March 31, 2023, the effective interest rate on the U.S. dollar and Canadian dollar Term Loans was 3.85% and 2.88%, respectively. In addition, the Canadian dollar Term Loan and the CAD $86.0 million outstanding under the Revolving Credit Facility are designated as net investment hedges. See Note 8, “Derivative and Hedging Instruments,” for further information.

The obligations of the Borrowers under the Credit Agreement are guaranteed by the Company and certain of its subsidiaries.

The Credit Agreement contains customary covenants that include restrictions or limitations on the ability to pay dividends, incur additional indebtedness, engage in non-healthcare related business activities, enter into transactions with affiliates and sell or otherwise transfer certain assets as well as customary events of default. The Credit Agreement also requires Sabra, through the Operating Partnership, to comply with specified financial covenants, which include a maximum total leverage ratio, a maximum secured debt leverage ratio, a minimum fixed charge coverage ratio, a maximum unsecured leverage ratio, a minimum tangible net worth requirement and a minimum unsecured interest coverage ratio. As of March 31, 2023, the Company was in compliance with all applicable financial covenants under the Credit Agreement.

Interest Expense

The Company incurred interest expense of $28.5 million and $25.0 million during the three months ended March 31, 2023 and 2022, respectively. Interest expense includes non-cash interest expense of $3.0 million and $2.7 million for the three months ended March 31, 2023 and 2022, respectively. As of March 31, 2023 and December 31, 2022, the Company had $21.4 million and $18.2 million, respectively, of accrued interest included in accounts payable and accrued liabilities on the accompanying consolidated balance sheets.

Maturities

The following is a schedule of maturities for the Company’s outstanding debt as of March 31, 2023 (in thousands): 

	Secured Indebtedness		Revolving Credit     Facility (1)		Term Loans		Senior Notes		Total
April 1 through December 31, 2023	$	1,489	$	—	$	—	$	—	$	1,489
2024	2,034		—		—		—		2,034
2025	2,089		—		—		—		2,089
2026	2,147		—		—		500,000		502,147
2027	2,206		79,563		—		100,000		181,769
Thereafter	39,668		—		540,865		1,150,000		1,730,533
Total Debt	49,633		79,563		540,865		1,750,000		2,420,061
Discount, net	—		—		—		(3,719)		(3,719)
Deferred financing costs, net	(879)		—		(7,208)		(11,637)		(19,724)
Total Debt, Net	$	48,754	$	79,563	$	533,657	$	1,734,644	$	2,396,618

(1)    Revolving Credit Facility is subject to two six-month extension options.

XML

DERIVATIVE AND HEDGING INSTRUMENTS

3 Months Ended

Mar. 31, 2023

Derivative Instruments and Hedging Activities Disclosure [Abstract]

DERIVATIVE AND HEDGING INSTRUMENTS

DERIVATIVE AND HEDGING INSTRUMENTS

The Company is exposed to various market risks, including the potential loss arising from adverse changes in interest rates and foreign exchange rates. The Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates and foreign exchange rates. The Company’s derivative financial instruments are used to manage differences in the amount of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s investments and borrowings.

Certain of the Company’s foreign operations expose the Company to fluctuations of foreign interest rates and exchange rates. These fluctuations may impact the value in the Company’s functional currency, the U.S. dollar, of the Company’s investment in foreign operations, the cash receipts and payments related to these foreign operations and payments of interest and principal under Canadian dollar denominated debt. The Company enters into derivative financial instruments to protect the value of its foreign investments and fix a portion of the interest payments for certain debt obligations. The Company does not enter into derivatives for speculative purposes.

Cash Flow Hedges

The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish these objectives, the Company primarily uses interest rate swaps and collars as part of its interest rate risk management strategy. As of March 31, 2023, approximately $5.4 million of gains, which are included in accumulated other comprehensive income, are expected to be reclassified into earnings in the next 12 months.

Net Investment Hedges

The Company is exposed to fluctuations in foreign exchange rates on investments it holds in Canada. The Company uses cross currency interest rate swaps to hedge its exposure to changes in foreign exchange rates on these foreign investments.

The following presents the notional amount of derivative instruments as of the dates indicated (in thousands):

	March 31, 2023		December 31, 2022
Derivatives designated as cash flow hedges:
Denominated in U.S. Dollars (1)	$	753,750	$	436,250
Denominated in Canadian Dollars (2)	$	300,000	$	125,000
Derivatives designated as net investment hedges:
Denominated in Canadian Dollars	$	56,300	$	55,991
Financial instruments designated as net investment hedges:
Denominated in Canadian Dollars	$	236,000	$	329,500
Derivatives not designated as net investment hedges:
Denominated in Canadian Dollars	$	—	$	309

(1) Balance as of March 31, 2023 includes two forward starting interest rate swaps with an effective date of August 2024 and an aggregate notional amount of $323.8 million.

(2)    Balance as of March 31, 2023 includes two forward starting interest rate swaps with an effective date of September 2024 and an aggregate notional amount of CAD $150.0 million.

Derivative and Financial Instruments Designated as Hedging Instruments

The following is a summary of the derivative and financial instruments designated as hedging instruments held by the Company at March 31, 2023 and December 31, 2022 (dollars in thousands):    

		Count as of March 31, 2023	Fair Value as of				Maturity Dates
Type	Designation		March 31, 2023		December 31, 2022			Balance Sheet Location
Assets:
Interest rate swaps	Cash flow	5	$	8,753	$	11,004	2024 - 2028	Accounts receivable, prepaid expenses and other assets, net
Interest rate collars	Cash flow	2	5,308		6,622		2024	Accounts receivable, prepaid expenses and other assets, net
Forward starting interest rate swaps	Cash flow	4	1,977		—		2028	Accounts receivable, prepaid expenses and other assets, net
Cross currency interest rate swaps	Net investment	2	3,785		3,851		2025	Accounts receivable, prepaid expenses and other assets, net
			$	19,823	$	21,477
Liabilities:
CAD borrowings under Revolving Credit Facility	Net investment	1	63,563		150,982		2027	Revolving credit facility
CAD Term Loan	Net investment	1	110,865		92,288		2028	Term loans, net
			$	174,428	$	243,270

The following presents the effect of the Company’s derivative and financial instruments designated as hedging instruments on the consolidated statements of (loss) income and the consolidated statements of equity for the three months ended March 31, 2023 and 2022 (in thousands):

	Gain (Loss) Recognized in Other Comprehensive Income
	Three Months Ended March 31,
	2023		2022
Cash Flow Hedges:
Interest rate products	$	1,565	$	9,652
Net Investment Hedges:
Foreign currency products	(14)		(986)
CAD borrowings under Revolving Credit Facility	(1,026)		—
CAD term loan	(140)		(1,513)
	$	385	$	7,153

		Loss Reclassified from Accumulated Other Comprehensive Income into Income
		Three Months Ended March 31,
	Income Statement Location	2023		2022
Cash Flow Hedges:
Interest rate products	Interest expense	$	1,572	$	(2,704)

During the three months ended March 31, 2023 and 2022, no cash flow hedges were determined to be ineffective.

Derivatives Not Designated as Hedging Instruments

As of March 31, 2023, the Company’s derivatives were all designated as hedging instruments. During the three months ended March 31, 2022, the Company recorded $0.1 million of other expense related to the portion of derivatives not designated as hedging instruments and no such expense was recorded during the three months ended March 31, 2023.

Offsetting Derivatives

The Company enters into master netting arrangements, which reduce credit risk by permitting net settlement of transactions with the same counterparty. The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of March 31, 2023 and December 31, 2022 (in thousands):

	As of March 31, 2023
	Gross Amounts of Recognized Assets / Liabilities		Gross Amounts Offset in the Balance Sheet		Net Amounts of Assets / Liabilities presented in the Balance Sheet		Gross Amounts Not Offset in the Balance Sheet
							Financial Instruments		Cash Collateral Received		Net Amount
Offsetting Assets:
Derivatives	$	19,823	$	—	$	19,823	$	—	$	—	$	19,823
Offsetting Liabilities:
Derivatives	$	—	$	—	$	—	$	—	$	—	$	—

	As of December 31, 2022
	Gross Amounts of Recognized Assets / Liabilities		Gross Amounts Offset in the Balance Sheet		Net Amounts of Assets / Liabilities presented in the Balance Sheet		Gross Amounts Not Offset in the Balance Sheet
							Financial Instruments		Cash Collateral Received		Net Amount
Offsetting Assets:
Derivatives	$	21,477	$	—	$	21,477	$	—	$	—	$	21,477
Offsetting Liabilities:
Derivatives	$	—	$	—	$	—	$	—	$	—	$	—

Credit Risk-related Contingent Features

The Company has agreements with each of its derivative counterparties that contain a provision pursuant to which the Company could be declared in default on the derivative obligation if the Company defaults on any of its indebtedness, including a default where repayment of the indebtedness has not been accelerated by the lender. As of March 31, 2023, the Company had no derivatives in a net liability position related to these agreements.

XML

FAIR VALUE DISCLOSURES

3 Months Ended

Mar. 31, 2023

Fair Value Disclosures [Abstract]

FAIR VALUE DISCLOSURES

FAIR VALUE DISCLOSURES

Under GAAP, the Company is required to measure certain financial instruments at fair value on a recurring basis. In addition, the Company is required to measure other financial instruments and balances at fair value on a non-recurring basis (e.g., carrying value of impaired loans receivable and long-lived assets). Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The GAAP fair value framework uses a three-tiered approach. Fair value measurements are classified and disclosed in one of the following three categories:

•Level 1: unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets or liabilities;

•Level 2: quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which significant inputs and significant value drivers are observable in active markets; and

•Level 3: prices or valuation techniques where little or no market data is available that requires inputs that are both significant to the fair value measurement and unobservable.

Financial Instruments

The fair value for certain financial instruments is derived using a combination of market quotes, pricing models and other valuation techniques that involve significant management judgment. The price transparency of financial instruments is a key determinant of the degree of judgment involved in determining the fair value of the Company’s financial instruments.

Financial instruments for which actively quoted prices or pricing parameters are available and whose markets contain orderly transactions will generally have a higher degree of price transparency than financial instruments whose markets are inactive or consist of non-orderly trades. The Company evaluates several factors when determining if a market is inactive or when market transactions are not orderly. The carrying values of cash and cash equivalents, restricted cash, accounts payable, accrued liabilities and the Credit Agreement are reasonable estimates of fair value because of the short-term maturities of these instruments. Fair values for other financial instruments are derived as follows:

Loans receivable: These instruments are presented on the accompanying consolidated balance sheets at their amortized cost and not at fair value. The fair values of the loans receivable were estimated using an internal valuation model that considered the expected cash flows for the loans receivable, as well as the underlying collateral value and other credit enhancements as applicable. The Company utilized discount rates ranging from 7% to 16% with a weighted average rate of 7% in its fair value calculation. As such, the Company classifies these instruments as Level 3.

Preferred equity investments: These instruments are presented on the accompanying consolidated balance sheets at their cost and not at fair value. The fair values of the preferred equity investments were estimated using an internal valuation model that considered the expected future cash flows for the preferred equity investments, the underlying collateral value and other credit enhancements. The Company utilized discount rates ranging from 10% to 15% with a weighted average rate of 11% in its fair value calculation. As such, the Company classifies these instruments as Level 3.

Derivative instruments: The Company’s derivative instruments are presented at fair value on the accompanying consolidated balance sheets. The Company estimates the fair value of derivative instruments, including its interest rate swaps, interest rate collars and cross currency swaps, using the assistance of a third party using inputs that are observable in the market, which include forward yield curves and other relevant information. Although the Company has determined that the majority of the inputs used to value its derivative financial instruments fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with its derivative financial instruments utilize Level 3 inputs, such as estimates of current credit spreads, to evaluate the likelihood of default by itself and its counterparties. The Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of its derivative financial instruments. As a result, the

Company has determined that its derivative financial instruments valuations in their entirety are classified in Level 2 of the fair value hierarchy.

Senior Notes: These instruments are presented on the accompanying consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Senior Notes were determined using third-party market quotes derived from orderly trades. As such, the Company classifies these instruments as Level 2.

Secured indebtedness: These instruments are presented on the accompanying consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Company’s secured debt were estimated using a discounted cash flow analysis based on management’s estimates of current market interest rates for instruments with similar characteristics, including remaining loan term, loan-to-value ratio, type of collateral and other credit enhancements. The Company utilized a rate of 6% in its fair value calculation. As such, the Company classifies these instruments as Level 3.

The following are the face values, carrying amounts and fair values of the Company’s financial instruments as of March 31, 2023 and December 31, 2022 whose carrying amounts do not approximate their fair value (in thousands):

	As of March 31, 2023						As of December 31, 2022
	Face Value (1)		Carrying Amount (2)		Fair Value		Face Value (1)		Carrying Amount (2)		Fair Value
Financial assets:
Loans receivable	$	366,200	$	356,365	$	370,048	$	370,364	$	360,325	$	370,188
Preferred equity investments	52,551		52,714		54,156		50,902		51,071		51,995
Financial liabilities:
Senior Notes	1,750,000		1,734,644		1,436,036		1,750,000		1,734,431		1,463,041
Secured indebtedness	49,633		48,754		37,583		50,123		49,232		38,149

(1)    Face value represents amounts contractually due under the terms of the respective agreements.

(2)    Carrying amount represents the book value of financial instruments, including unamortized premiums/discounts and deferred financing costs.

The Company determined the fair value of financial instruments as of March 31, 2023 whose carrying amounts do not approximate their fair value with valuation methods utilizing the following types of inputs (in thousands):

			Fair Value Measurements Using
	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Financial assets:
Loans receivable	$	370,048	$	—	$	—	$	370,048
Preferred equity investments	54,156		—		—		54,156
Financial liabilities:
Senior Notes	1,436,036		—		1,436,036		—
Secured indebtedness	37,583		—		—		37,583

Disclosure of the fair value of financial instruments is based on pertinent information available to the Company at the applicable dates and requires a significant amount of judgment. Transaction volume for certain of the Company’s financial instruments remains relatively low, which has made the estimation of fair values difficult. Therefore, both the actual results and the Company’s estimate of fair value at a future date could be materially different.

Items Measured at Fair Value on a Recurring Basis

During the three months ended March 31, 2023, the Company recorded the following amounts measured at fair value (in thousands):

			Fair Value Measurements Using
	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Recurring Basis:
Financial assets:
Interest rate swaps	$	8,753	$	—	$	8,753	$	—
Interest rate collars	5,308		—		5,308		—
Forward starting interest rate swaps	1,977		—		1,977		—
Cross currency interest rate swaps	3,785		—		3,785		—

XML

EQUITY

3 Months Ended

Mar. 31, 2023

Equity [Abstract]

EQUITY

EQUITY

Common Stock

On February 23, 2023, the Company established an at-the-market equity offering program (the “ATM Program”) pursuant to which shares of its common stock having an aggregate gross sales price of up to $500.0 million may be sold from time to time (i) by the Company through a consortium of banks acting as sales agents or directly to the banks acting as principals or (ii) by a consortium of banks acting as forward sellers on behalf of any forward purchasers pursuant to a forward sale agreement. The use of a forward sale agreement would allow the Company to lock in a share price on the sale of shares at the time the agreement is effective, but defer receiving the proceeds from the sale of the shares until a later date. The Company may also elect to cash settle or net share settle all or a portion of its obligations under any forward sale agreement. The forward sale agreements have a one year term during which time the Company may settle the forward sales by delivery of physical shares of common stock to the forward purchasers or, at the Company’s election, in cash or net shares. The forward sale price that the Company expects to receive upon settlement will be the initial forward price established upon the effective date, subject to adjustments for (i) the forward purchasers’ stock borrowing costs and (ii) certain fixed price reductions during the term of the agreement.

During the three months ended March 31, 2023, no shares were sold under the ATM Program and the Company did not utilize the forward feature of the ATM Program. As of March 31, 2023, the Company had $500.0 million available under the ATM Program.

The following table lists the cash dividends on common stock declared and paid by the Company during the three months ended March 31, 2023:

Declaration Date	Record Date	Amount Per Share		Dividend Payable Date
February 1, 2023	February 13, 2023	$	0.30	February 28, 2022

During the three months ended March 31, 2023, the Company issued 0.2 million shares of common stock as a result of restricted stock unit vestings.

Upon any payment of shares to team members as a result of restricted stock unit vestings, the team members’ related tax withholding obligation will generally be satisfied by the Company reducing the number of shares to be delivered by a number of shares necessary to satisfy the related applicable tax withholding obligation. During the three months ended March 31, 2023 and 2022, the Company incurred $1.4 million and $3.3 million, respectively, in tax withholding obligations on behalf of its team members that were satisfied through a reduction in the number of shares delivered to those participants.

Accumulated Other Comprehensive Income

The following is a summary of the Company’s accumulated other comprehensive income (in thousands):

	March 31, 2023		December 31, 2022
Foreign currency translation (loss) gain	$	(455)	$	1,168
Unrealized gain on cash flow hedges	17,893		17,895
Total accumulated other comprehensive income	$	17,438	$	19,063

XML

EARNINGS PER COMMON SHARE

3 Months Ended

Mar. 31, 2023

Earnings Per Share [Abstract]

EARNINGS PER COMMON SHARE

EARNINGS PER COMMON SHARE

The following table illustrates the computation of basic and diluted earnings per share for the three months ended March 31, 2023 and 2022 (in thousands, except share and per share amounts):

	Three Months Ended March 31,
	2023		2022
Numerator
Net (loss) income	$	(9,487)	$	40,602
Denominator
Basic weighted average common shares and common equivalents	231,164,876		230,859,993
Dilutive restricted stock units	—		704,977
Diluted weighted average common shares	231,164,876		231,564,970
Net (loss) income, per:
Basic common share	$	(0.04)	$	0.18
Diluted common share	$	(0.04)	$	0.18

During the three months ended March 31, 2023 and 2022, approximately 0.7 million and 13,100 restricted stock units, respectively, were not included in computing diluted earnings per share because they were considered anti-dilutive.

XML

COMMITMENTS AND CONTINGENCIES

3 Months Ended

Mar. 31, 2023

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES

Environmental

As an owner of real estate, the Company is subject to various environmental laws of federal, state and local governments. The Company is not aware of any environmental liability that could have a material adverse effect on its financial condition or results of operations. However, changes in applicable environmental laws and regulations, the uses and conditions of properties in the vicinity of the Company’s properties, the activities of its tenants and other environmental conditions of which the Company is unaware with respect to the properties could result in future environmental liabilities. As of March 31, 2023, the Company does not expect that compliance with existing environmental laws will have a material adverse effect on the Company’s financial condition and results of operations.

Legal Matters

From time to time, the Company and its subsidiaries are party to legal proceedings that arise in the ordinary course of its business. Management is not aware of any legal proceedings where the likelihood of a loss contingency is reasonably possible and the amount or range of reasonably possible losses is material to the Company’s results of operations, financial condition or cash flows.

XML

SUBSEQUENT EVENTS

3 Months Ended

Mar. 31, 2023

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

SUBSEQUENT EVENTSThe Company evaluates subsequent events up until the date the consolidated financial statements are issued.

Dividend Declaration

On May 3, 2023, the Company’s board of directors declared a quarterly cash dividend of $0.30 per share of common stock. The dividend will be paid on May 31, 2023 to common stockholders of record as of the close of business on May 16, 2023.

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

Mar. 31, 2023

Accounting Policies [Abstract]

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Sabra and its wholly owned subsidiaries as of March 31, 2023 and December 31, 2022 and for the three month periods ended March 31, 2023 and 2022. All significant intercompany transactions and balances have been eliminated in consolidation.

Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information as contained within the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification and the rules and regulations of the SEC, including the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the unaudited consolidated financial statements do not include all of the information and footnotes required by GAAP for financial statements. In the opinion of management, the financial statements for the unaudited interim periods presented include all adjustments, which are of a normal and recurring nature, necessary for a fair statement of the results for such periods. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. For further information, refer to the Company’s consolidated financial statements and notes thereto for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC.

Variable Interest Entities

GAAP requires the Company to identify entities for which control is achieved through voting rights or other means and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). A VIE is broadly defined as an entity with one or more of the following characteristics: (a) the total equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (b) as a group, the holders of the equity investment at risk lack (i) the ability to make decisions about the entity’s activities through voting or similar rights, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity; or (c) the equity investors have voting rights that are not proportional to their economic interests, and substantially all of the entity’s activities either involve, or are conducted on behalf of, an investor that has disproportionately few voting rights. If the Company were determined to be the primary beneficiary of the VIE, the Company would consolidate investments in the VIE. The Company may change its original assessment of a VIE due to events such as modifications of contractual arrangements that affect the characteristics or adequacy of the entity’s equity investments at risk and the disposal of all or a portion of an interest held by the primary beneficiary.

The Company identifies the primary beneficiary of a VIE as the enterprise that has both: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance; and (ii) the obligation to absorb losses or

the right to receive benefits of the VIE that could be significant to the entity. The Company performs this analysis on an ongoing basis. As of March 31, 2023, the Company determined that it was not the primary beneficiary of any VIEs.

As it relates to investments in loans, in addition to the Company’s assessment of VIEs and whether the Company is the primary beneficiary of those VIEs, the Company evaluates the loan terms and other pertinent facts to determine whether the loan investment should be accounted for as a loan or as a real estate joint venture. If an investment has the characteristics of a real estate joint venture, including if the Company participates in the majority of the borrower’s expected residual profit, the Company would account for the investment as an investment in a real estate joint venture and not as a loan investment. Expected residual profit is defined as the amount of profit, whether called interest or another name, such as an equity kicker, above a reasonable amount of interest and fees expected to be earned by a lender. At March 31, 2023, none of the Company’s investments in loans were accounted for as real estate joint ventures.

As it relates to investments in joint ventures, the Company assesses any partners’ rights and their impact on the presumption of control of the partnership by any single partner. The Company also applies this guidance to managing member interests in limited liability companies. The Company reassesses its determination of which entity controls the joint venture if: there is a change to the terms or in the exercisability of the rights of any partners or members, the general partner or managing member increases or decreases its ownership interests, or there is an increase or decrease in the number of outstanding ownership interests.

Use of Estimates

The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.

Fair Value of Financial Instruments

Under GAAP, the Company is required to measure certain financial instruments at fair value on a recurring basis. In addition, the Company is required to measure other financial instruments and balances at fair value on a non-recurring basis (e.g., carrying value of impaired loans receivable and long-lived assets). Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The GAAP fair value framework uses a three-tiered approach. Fair value measurements are classified and disclosed in one of the following three categories:

•Level 1: unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets or liabilities;

•Level 2: quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which significant inputs and significant value drivers are observable in active markets; and

•Level 3: prices or valuation techniques where little or no market data is available that requires inputs that are both significant to the fair value measurement and unobservable.

Financial Instruments

The fair value for certain financial instruments is derived using a combination of market quotes, pricing models and other valuation techniques that involve significant management judgment. The price transparency of financial instruments is a key determinant of the degree of judgment involved in determining the fair value of the Company’s financial instruments.

Financial instruments for which actively quoted prices or pricing parameters are available and whose markets contain orderly transactions will generally have a higher degree of price transparency than financial instruments whose markets are inactive or consist of non-orderly trades. The Company evaluates several factors when determining if a market is inactive or when market transactions are not orderly. The carrying values of cash and cash equivalents, restricted cash, accounts payable, accrued liabilities and the Credit Agreement are reasonable estimates of fair value because of the short-term maturities of these instruments. Fair values for other financial instruments are derived as follows:

Loans receivable: These instruments are presented on the accompanying consolidated balance sheets at their amortized cost and not at fair value. The fair values of the loans receivable were estimated using an internal valuation model that considered the expected cash flows for the loans receivable, as well as the underlying collateral value and other credit enhancements as applicable. The Company utilized discount rates ranging from 7% to 16% with a weighted average rate of 7% in its fair value calculation. As such, the Company classifies these instruments as Level 3.

Preferred equity investments: These instruments are presented on the accompanying consolidated balance sheets at their cost and not at fair value. The fair values of the preferred equity investments were estimated using an internal valuation model that considered the expected future cash flows for the preferred equity investments, the underlying collateral value and other credit enhancements. The Company utilized discount rates ranging from 10% to 15% with a weighted average rate of 11% in its fair value calculation. As such, the Company classifies these instruments as Level 3.

Derivative instruments: The Company’s derivative instruments are presented at fair value on the accompanying consolidated balance sheets. The Company estimates the fair value of derivative instruments, including its interest rate swaps, interest rate collars and cross currency swaps, using the assistance of a third party using inputs that are observable in the market, which include forward yield curves and other relevant information. Although the Company has determined that the majority of the inputs used to value its derivative financial instruments fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with its derivative financial instruments utilize Level 3 inputs, such as estimates of current credit spreads, to evaluate the likelihood of default by itself and its counterparties. The Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of its derivative financial instruments. As a result, the

Company has determined that its derivative financial instruments valuations in their entirety are classified in Level 2 of the fair value hierarchy.

Senior Notes: These instruments are presented on the accompanying consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Senior Notes were determined using third-party market quotes derived from orderly trades. As such, the Company classifies these instruments as Level 2.

Secured indebtedness: These instruments are presented on the accompanying consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Company’s secured debt were estimated using a discounted cash flow analysis based on management’s estimates of current market interest rates for instruments with similar characteristics, including remaining loan term, loan-to-value ratio, type of collateral and other credit enhancements. The Company utilized a rate of 6% in its fair value calculation. As such, the Company classifies these instruments as Level 3.

XML

RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) (Tables)

3 Months Ended

Mar. 31, 2023

Business Combination and Asset Acquisition [Abstract]

Schedule of Purchase Price Allocation

The consideration was allocated as follows (in thousands):

	Three Months Ended March 31,
	2023		2022
Land	$	3,415	$	3,691
Building and improvements	45,333		21,168
Tenant origination and absorption costs intangible assets	2,706		1,337
Tenant relationship intangible assets	20		—
Total consideration	$	51,474	$	26,196

XML

INVESTMENT IN REAL ESTATE PROPERTIES (Tables)

3 Months Ended

Mar. 31, 2023

Real Estate [Abstract]

Schedule of Real Estate Properties Held for Investment

The Company’s real estate properties held for investment consisted of the following (dollars in thousands):

As of March 31, 2023

Property Type	Number of Properties	Number of Beds/Units	Total Real Estate at Cost		Accumulated Depreciation		Total Real Estate Investments, Net
Skilled Nursing/Transitional Care	258	28,334	$	3,212,202	$	(518,215)	$	2,693,987
Senior Housing - Leased	47	3,600	592,119		(101,303)		490,816
Senior Housing - Managed	59	5,973	1,245,066		(227,844)		1,017,222
Behavioral Health	17	965	474,079		(61,487)		412,592
Specialty Hospitals and Other	15	392	225,443		(43,392)		182,051
	396	39,264	5,748,909		(952,241)		4,796,668
Corporate Level			923		(550)		373
			$	5,749,832	$	(952,791)	$	4,797,041

As of December 31, 2022

Property Type	Number of Properties	Number of Beds/Units	Total Real Estate at Cost		Accumulated Depreciation		Total Real Estate Investments, Net
Skilled Nursing/Transitional Care	264	29,136	$	3,385,221	$	(492,495)	$	2,892,726
Senior Housing - Leased	47	3,550	590,694		(97,716)		492,978
Senior Housing - Managed	59	5,942	1,205,283		(222,089)		983,194
Behavioral Health	17	965	465,143		(58,481)		406,662
Specialty Hospitals and Other	15	392	225,443		(42,038)		183,405
	402	39,985	5,871,784		(912,819)		4,958,965
Corporate Level			904		(526)		378
			$	5,872,688	$	(913,345)	$	4,959,343

	March 31, 2023		December 31, 2022
Building and improvements	$	4,945,404	$	5,034,470
Furniture and equipment	236,032		262,644
Land improvements	9,499		7,085
Land	558,897		568,489
Total real estate at cost	5,749,832		5,872,688
Accumulated depreciation	(952,791)		(913,345)
Total real estate investments, net	$	4,797,041	$	4,959,343

Schedule of Future Minimum Rental Payments from Non-Cancelable Operating Leases

As of March 31, 2023, the future minimum rental payments from the Company’s properties held for investment under non-cancelable operating leases were as follows and may materially differ from actual future rental payments received (in thousands):

April 1 through December 31, 2023	$	279,989
2024	380,057
2025	375,286
2026	360,133
2027	337,235
Thereafter	1,535,962
	$	3,268,662

Schedule of Investment in Joint Ventures

The following is a summary of the Company’s investment in unconsolidated joint ventures (dollars in thousands):

	Property Type	Number of Properties as of March 31, 2023	Ownership as of March 31, 2023 (1)		Book Value
					March 31, 2023		December 31, 2022
Sienna Joint Venture	Senior Housing - Managed	12	50	%	$	119,824	$	120,269
Marlin Spring Joint Venture	Senior Housing - Managed	4	85	%	19,578		14,693
					$	139,402	$	134,962

(1)    These investments are not consolidated because the Company does not control, through voting rights or other means, the joint ventures.

XML

IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS (Tables)

3 Months Ended

Mar. 31, 2023

Discontinued Operations and Disposal Groups [Abstract]

Schedule of Dispositions

The following table summarizes the Company’s dispositions for the periods presented (dollars in millions):

	Three Months Ended March 31,
	2023		2022
Number of facilities	8		—
Consideration, net of closing costs	$	160.3	$	—
Net carrying value	181.8		—
Net loss on sale	$	(21.5)	$	—
Net (loss) income	$	(22.1)	$	0.1

XML

LOANS RECEIVABLE AND OTHER INVESTMENTS (Tables)

3 Months Ended

Mar. 31, 2023

Receivables [Abstract]

Schedule of Loans Receivable and Other Investments

As of March 31, 2023 and December 31, 2022, the Company’s loans receivable and other investments consisted of the following (dollars in thousands):

									As of March 31, 2023
Investment	Quantity as of March 31, 2023	Property Type	Principal Balance as of March 31, 2023 (1)		Book Value as of March 31, 2023		Book Value as of December 31, 2022		Weighted Average Contractual Interest Rate / Rate of Return		Weighted Average Annualized Effective Interest Rate / Rate of Return		Maturity Date as of March 31, 2023
Loans Receivable:
Mortgage	2	Behavioral Health	$	319,000	$	319,000	$	319,000	7.6	%	7.6	%	11/01/26 - 01/31/27
Other	11	Multiple	47,200		43,768		47,936		7.1	%	6.5	%	08/31/23 - 08/31/28
	13		366,200		362,768		366,936		7.6	%	7.5	%
Allowance for loan losses			—		(6,403)		(6,611)
			$	366,200	$	356,365	$	360,325
Other Investments:
Preferred Equity	6	Skilled Nursing / Senior Housing	52,551		52,714		51,071		10.9	%	10.8	%	N/A
Total	19		$	418,751	$	409,079	$	411,396	8.0	%	7.9	%

(1)    Principal balance includes amounts funded and accrued but unpaid interest / preferred return and excludes capitalizable fees.

Schedule of Additional Information Regarding the Company's Loans Receivable

Additional information regarding the Company’s loans receivable is as follows (dollars in thousands):

	Three Months Ended March 31,
	2023		2022
Allowance for loan losses:
Balance at beginning of the period	$	6,611	$	6,344
(Recovery of) provision for loan losses	(208)		507
Balance at end of the period	$	6,403	$	6,851
	March 31, 2023		December 31, 2022
Deteriorated credit quality:
Number of loans receivable investments	1		1
Principal balance	$	1,214	$	1,214
Book value	—		—
Nonaccrual status:
Number of loans receivable investments	3		3
Book value	$	—	$	—

XML

DEBT (Tables)

3 Months Ended

Mar. 31, 2023

Debt Disclosure [Abstract]

Schedule of Debt

The Company’s secured debt consists of the following (dollars in thousands):

					As of March 31, 2023
Interest Rate Type	Principal Balance as of March 31, 2023 (1)		Principal Balance as of December 31, 2022 (1)		Weighted Average Interest Rate		Weighted Average Effective Interest Rate (2)		Maturity Date
Fixed Rate	$	49,633	$	50,123	2.84	%	3.34	%	May 2031 -  August 2051

(1)     Principal balance does not include deferred financing costs, net of $0.9 million as of each of March 31, 2023 and December 31, 2022.

(2)     Weighted average interest rate includes private mortgage insurance.

The Company’s senior unsecured notes consist of the following (dollars in thousands):

		Principal Balance as of
Title	Maturity Date	March 31, 2023 (1)		December 31, 2022 (1)
5.125% senior unsecured notes due 2026 (“2026 Notes”)	August 15, 2026	$	500,000	$	500,000
5.88% senior unsecured notes due 2027 (“2027 Notes”)	May 17, 2027	100,000		100,000
3.90% senior unsecured notes due 2029 (“2029 Notes”)	October 15, 2029	350,000		350,000
3.20% senior unsecured notes due 2031 (“2031 Notes”)	December 1, 2031	800,000		800,000
		$	1,750,000	$	1,750,000

(1)    Principal balance does not include discount, net of $3.7 million and deferred financing costs, net of $11.6 million as of March 31, 2023 and does not include discount, net of $3.5 million and deferred financing costs, net of $12.0 million as of December 31, 2022. In addition, the weighted average effective interest rate as of March 31, 2023 was 4.01%.

Schedule of Maturities for Outstanding Debt

The following is a schedule of maturities for the Company’s outstanding debt as of March 31, 2023 (in thousands): 

	Secured Indebtedness		Revolving Credit     Facility (1)		Term Loans		Senior Notes		Total
April 1 through December 31, 2023	$	1,489	$	—	$	—	$	—	$	1,489
2024	2,034		—		—		—		2,034
2025	2,089		—		—		—		2,089
2026	2,147		—		—		500,000		502,147
2027	2,206		79,563		—		100,000		181,769
Thereafter	39,668		—		540,865		1,150,000		1,730,533
Total Debt	49,633		79,563		540,865		1,750,000		2,420,061
Discount, net	—		—		—		(3,719)		(3,719)
Deferred financing costs, net	(879)		—		(7,208)		(11,637)		(19,724)
Total Debt, Net	$	48,754	$	79,563	$	533,657	$	1,734,644	$	2,396,618

(1)    Revolving Credit Facility is subject to two six-month extension options.

XML

DERIVATIVE AND HEDGING INSTRUMENTS (Tables)

3 Months Ended

Mar. 31, 2023

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Notional Amount of Derivatives Instruments

The following presents the notional amount of derivative instruments as of the dates indicated (in thousands):

	March 31, 2023		December 31, 2022
Derivatives designated as cash flow hedges:
Denominated in U.S. Dollars (1)	$	753,750	$	436,250
Denominated in Canadian Dollars (2)	$	300,000	$	125,000
Derivatives designated as net investment hedges:
Denominated in Canadian Dollars	$	56,300	$	55,991
Financial instruments designated as net investment hedges:
Denominated in Canadian Dollars	$	236,000	$	329,500
Derivatives not designated as net investment hedges:
Denominated in Canadian Dollars	$	—	$	309

(1) Balance as of March 31, 2023 includes two forward starting interest rate swaps with an effective date of August 2024 and an aggregate notional amount of $323.8 million.

(2)    Balance as of March 31, 2023 includes two forward starting interest rate swaps with an effective date of September 2024 and an aggregate notional amount of CAD $150.0 million.

Schedule of Derivative and Financial Instruments Designated as Hedging Instruments

The following is a summary of the derivative and financial instruments designated as hedging instruments held by the Company at March 31, 2023 and December 31, 2022 (dollars in thousands):    

		Count as of March 31, 2023	Fair Value as of				Maturity Dates
Type	Designation		March 31, 2023		December 31, 2022			Balance Sheet Location
Assets:
Interest rate swaps	Cash flow	5	$	8,753	$	11,004	2024 - 2028	Accounts receivable, prepaid expenses and other assets, net
Interest rate collars	Cash flow	2	5,308		6,622		2024	Accounts receivable, prepaid expenses and other assets, net
Forward starting interest rate swaps	Cash flow	4	1,977		—		2028	Accounts receivable, prepaid expenses and other assets, net
Cross currency interest rate swaps	Net investment	2	3,785		3,851		2025	Accounts receivable, prepaid expenses and other assets, net
			$	19,823	$	21,477
Liabilities:
CAD borrowings under Revolving Credit Facility	Net investment	1	63,563		150,982		2027	Revolving credit facility
CAD Term Loan	Net investment	1	110,865		92,288		2028	Term loans, net
			$	174,428	$	243,270

Effect of Derivative Financial Instruments on the Condensed Consolidated Statements of (Loss) Income and Condensed Consolidated Statements of Equity

The following presents the effect of the Company’s derivative and financial instruments designated as hedging instruments on the consolidated statements of (loss) income and the consolidated statements of equity for the three months ended March 31, 2023 and 2022 (in thousands):

	Gain (Loss) Recognized in Other Comprehensive Income
	Three Months Ended March 31,
	2023		2022
Cash Flow Hedges:
Interest rate products	$	1,565	$	9,652
Net Investment Hedges:
Foreign currency products	(14)		(986)
CAD borrowings under Revolving Credit Facility	(1,026)		—
CAD term loan	(140)		(1,513)
	$	385	$	7,153

		Loss Reclassified from Accumulated Other Comprehensive Income into Income
		Three Months Ended March 31,
	Income Statement Location	2023		2022
Cash Flow Hedges:
Interest rate products	Interest expense	$	1,572	$	(2,704)

Gross Presentation, Effects of Offsetting, and Net Presentation of Derivatives - Assets

The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of March 31, 2023 and December 31, 2022 (in thousands):

	As of March 31, 2023
	Gross Amounts of Recognized Assets / Liabilities		Gross Amounts Offset in the Balance Sheet		Net Amounts of Assets / Liabilities presented in the Balance Sheet		Gross Amounts Not Offset in the Balance Sheet
							Financial Instruments		Cash Collateral Received		Net Amount
Offsetting Assets:
Derivatives	$	19,823	$	—	$	19,823	$	—	$	—	$	19,823
Offsetting Liabilities:
Derivatives	$	—	$	—	$	—	$	—	$	—	$	—

	As of December 31, 2022
	Gross Amounts of Recognized Assets / Liabilities		Gross Amounts Offset in the Balance Sheet		Net Amounts of Assets / Liabilities presented in the Balance Sheet		Gross Amounts Not Offset in the Balance Sheet
							Financial Instruments		Cash Collateral Received		Net Amount
Offsetting Assets:
Derivatives	$	21,477	$	—	$	21,477	$	—	$	—	$	21,477
Offsetting Liabilities:
Derivatives	$	—	$	—	$	—	$	—	$	—	$	—

Gross Presentation, Effects of Offsetting, and Net Presentation of Derivatives - Liabilities

The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of March 31, 2023 and December 31, 2022 (in thousands):

	As of March 31, 2023
	Gross Amounts of Recognized Assets / Liabilities		Gross Amounts Offset in the Balance Sheet		Net Amounts of Assets / Liabilities presented in the Balance Sheet		Gross Amounts Not Offset in the Balance Sheet
							Financial Instruments		Cash Collateral Received		Net Amount
Offsetting Assets:
Derivatives	$	19,823	$	—	$	19,823	$	—	$	—	$	19,823
Offsetting Liabilities:
Derivatives	$	—	$	—	$	—	$	—	$	—	$	—

	As of December 31, 2022
	Gross Amounts of Recognized Assets / Liabilities		Gross Amounts Offset in the Balance Sheet		Net Amounts of Assets / Liabilities presented in the Balance Sheet		Gross Amounts Not Offset in the Balance Sheet
							Financial Instruments		Cash Collateral Received		Net Amount
Offsetting Assets:
Derivatives	$	21,477	$	—	$	21,477	$	—	$	—	$	21,477
Offsetting Liabilities:
Derivatives	$	—	$	—	$	—	$	—	$	—	$	—

XML

FAIR VALUE DISCLOSURES (Tables)

3 Months Ended

Mar. 31, 2023

Fair Value Disclosures [Abstract]

Schedule of Face Values, Carrying Amounts and Fair Values of Financial Instruments

The following are the face values, carrying amounts and fair values of the Company’s financial instruments as of March 31, 2023 and December 31, 2022 whose carrying amounts do not approximate their fair value (in thousands):

	As of March 31, 2023						As of December 31, 2022
	Face Value (1)		Carrying Amount (2)		Fair Value		Face Value (1)		Carrying Amount (2)		Fair Value
Financial assets:
Loans receivable	$	366,200	$	356,365	$	370,048	$	370,364	$	360,325	$	370,188
Preferred equity investments	52,551		52,714		54,156		50,902		51,071		51,995
Financial liabilities:
Senior Notes	1,750,000		1,734,644		1,436,036		1,750,000		1,734,431		1,463,041
Secured indebtedness	49,633		48,754		37,583		50,123		49,232		38,149

(1)    Face value represents amounts contractually due under the terms of the respective agreements.

(2)    Carrying amount represents the book value of financial instruments, including unamortized premiums/discounts and deferred financing costs.

Schedule of Fair Value of Financial Instruments

The Company determined the fair value of financial instruments as of March 31, 2023 whose carrying amounts do not approximate their fair value with valuation methods utilizing the following types of inputs (in thousands):

			Fair Value Measurements Using
	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Financial assets:
Loans receivable	$	370,048	$	—	$	—	$	370,048
Preferred equity investments	54,156		—		—		54,156
Financial liabilities:
Senior Notes	1,436,036		—		1,436,036		—
Secured indebtedness	37,583		—		—		37,583

Schedule of Items Measured at Fair Value on a Recurring Basis

During the three months ended March 31, 2023, the Company recorded the following amounts measured at fair value (in thousands):

			Fair Value Measurements Using
	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Recurring Basis:
Financial assets:
Interest rate swaps	$	8,753	$	—	$	8,753	$	—
Interest rate collars	5,308		—		5,308		—
Forward starting interest rate swaps	1,977		—		1,977		—
Cross currency interest rate swaps	3,785		—		3,785		—

XML

EQUITY (Tables)

3 Months Ended

Mar. 31, 2023

Equity [Abstract]

Schedule of Cash Dividends on Common Stock Declared and Paid

The following table lists the cash dividends on common stock declared and paid by the Company during the three months ended March 31, 2023:

Declaration Date	Record Date	Amount Per Share		Dividend Payable Date
February 1, 2023	February 13, 2023	$	0.30	February 28, 2022

Schedule of Accumulated Other Comprehensive Income

The following is a summary of the Company’s accumulated other comprehensive income (in thousands):

	March 31, 2023		December 31, 2022
Foreign currency translation (loss) gain	$	(455)	$	1,168
Unrealized gain on cash flow hedges	17,893		17,895
Total accumulated other comprehensive income	$	17,438	$	19,063

XML

EARNINGS PER COMMON SHARE (Tables)

3 Months Ended

Mar. 31, 2023

Earnings Per Share [Abstract]

Computation of Basic and Diluted Earnings Per Share

The following table illustrates the computation of basic and diluted earnings per share for the three months ended March 31, 2023 and 2022 (in thousands, except share and per share amounts):

	Three Months Ended March 31,
	2023		2022
Numerator
Net (loss) income	$	(9,487)	$	40,602
Denominator
Basic weighted average common shares and common equivalents	231,164,876		230,859,993
Dilutive restricted stock units	—		704,977
Diluted weighted average common shares	231,164,876		231,564,970
Net (loss) income, per:
Basic common share	$	(0.04)	$	0.18
Diluted common share	$	(0.04)	$	0.18

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	Mar. 31, 2023 variableInterestEntity investment
Accounting Policies [Line Items]
Number of investments in loans accounted for as real estate joint ventures | investment	0
Primary beneficiary
Accounting Policies [Line Items]
Number of variable interest entities | variableInterestEntity	0

XML

RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) - Narrative (Details) - Recent Real Estate Acquisitions $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($) property	Mar. 31, 2022 USD ($) property
Business Acquisition [Line Items]
Total revenues	$ 1.7	$ 0.9
Net income	$ 0.2	$ 0.1
Tenant origination and absorption costs
Business Acquisition [Line Items]
Weighted-average amortization period of intangible assets	1 year	1 year
Tenant relationships
Business Acquisition [Line Items]
Weighted-average amortization period of intangible assets	22 years
Senior Housing - Leased
Business Acquisition [Line Items]
Number of acquired properties | property	1
Senior Housing - Managed
Business Acquisition [Line Items]
Number of acquired properties | property	1	1
Preferred equity investment book value at acquisition	$ 4.6	$ 5.6
Number of properties | property	2
Aggregate additional consideration	$ 17.4

XML

RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) - Purchase Price Allocation for Recent Real Estate Acquisitions (Details) - Recent Real Estate Acquisitions - USD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Business Acquisition [Line Items]
Land	$ 3,415	$ 3,691
Building and improvements	45,333	21,168
Total consideration	51,474	26,196
Tenant origination and absorption costs intangible assets
Business Acquisition [Line Items]
Tenant intangible assets	2,706	1,337
Tenant relationship intangible assets
Business Acquisition [Line Items]
Tenant intangible assets	$ 20	$ 0

XML

INVESTMENT IN REAL ESTATE PROPERTIES - Real Estate Properties Held for Investment (Details) $ in Thousands	Mar. 31, 2023 USD ($) bed facility	Dec. 31, 2022 USD ($) bed facility
Real Estate Properties [Line Items]
Building and improvements	$ 4,945,404	$ 5,034,470
Furniture and equipment	236,032	262,644
Land improvements	9,499	7,085
Land	558,897	568,489
Total Real Estate at Cost	5,749,832	5,872,688
Accumulated Depreciation	(952,791)	(913,345)
Total Real Estate Investments, Net	$ 4,797,041	$ 4,959,343
Operating Segments
Real Estate Properties [Line Items]
Number of Properties | facility	396	402
Number of Beds/Units | bed	39,264	39,985
Total Real Estate at Cost	$ 5,748,909	$ 5,871,784
Accumulated Depreciation	(952,241)	(912,819)
Total Real Estate Investments, Net	$ 4,796,668	$ 4,958,965
Operating Segments | Skilled Nursing/Transitional Care
Real Estate Properties [Line Items]
Number of Properties | facility	258	264
Number of Beds/Units | bed	28,334	29,136
Total Real Estate at Cost	$ 3,212,202	$ 3,385,221
Accumulated Depreciation	(518,215)	(492,495)
Total Real Estate Investments, Net	$ 2,693,987	$ 2,892,726
Operating Segments | Senior Housing - Leased
Real Estate Properties [Line Items]
Number of Properties | facility	47	47
Number of Beds/Units | bed	3,600	3,550
Total Real Estate at Cost	$ 592,119	$ 590,694
Accumulated Depreciation	(101,303)	(97,716)
Total Real Estate Investments, Net	$ 490,816	$ 492,978
Operating Segments | Senior Housing - Managed
Real Estate Properties [Line Items]
Number of Properties | facility	59	59
Number of Beds/Units | bed	5,973	5,942
Total Real Estate at Cost	$ 1,245,066	$ 1,205,283
Accumulated Depreciation	(227,844)	(222,089)
Total Real Estate Investments, Net	$ 1,017,222	$ 983,194
Operating Segments | Behavioral Health
Real Estate Properties [Line Items]
Number of Properties | facility	17	17
Number of Beds/Units | bed	965	965
Total Real Estate at Cost	$ 474,079	$ 465,143
Accumulated Depreciation	(61,487)	(58,481)
Total Real Estate Investments, Net	$ 412,592	$ 406,662
Operating Segments | Specialty Hospitals and Other
Real Estate Properties [Line Items]
Number of Properties | facility	15	15
Number of Beds/Units | bed	392	392
Total Real Estate at Cost	$ 225,443	$ 225,443
Accumulated Depreciation	(43,392)	(42,038)
Total Real Estate Investments, Net	182,051	183,405
Corporate Level
Real Estate Properties [Line Items]
Total Real Estate at Cost	923	904
Accumulated Depreciation	(550)	(526)
Total Real Estate Investments, Net	$ 373	$ 378

XML

INVESTMENT IN REAL ESTATE PROPERTIES - Operating Leases Narrative (Details) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($) facility	Sep. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($) facility
Real Estate Properties [Line Items]
Weighted-average remaining term of operating leases	8 years
Security deposit liability	$ 14.0			$ 13.1
Letters of credit deposited	59.0			57.0
Tenant deposits for future real estate taxes, insurance expenditures, and tenant improvements	13.6			$ 13.3
Variable lease revenue	$ 3.8		$ 5.1
North American Health Care, Inc
Real Estate Properties [Line Items]
Write-off of non-cash rent receivable		$ 15.6
Minimum
Real Estate Properties [Line Items]
Operating lease expiration term	1 year
Maximum
Real Estate Properties [Line Items]
Operating lease expiration term	20 years
Operating Segments
Real Estate Properties [Line Items]
Number of properties | facility	396			402
Operating Segments | Senior Housing - Managed
Real Estate Properties [Line Items]
Number of properties | facility	59			59

XML

INVESTMENT IN REAL ESTATE PROPERTIES - Future Minimum Rental Payments Receivable for Properties Held for Investment Under Non-Cancelable Operating Leases (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Future minimum rental payments from the Company’s properties held for investment under non-cancelable operating leases:
April 1 through December 31, 2023	$ 279,989
2024	380,057
2025	375,286
2026	360,133
2027	337,235
Thereafter	1,535,962
Total	$ 3,268,662

XML

INVESTMENT IN REAL ESTATE PROPERTIES - Senior Housing - Managed Communities Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Disaggregation of Revenue [Line Items]
Resident fees and services	$ 56,721	$ 42,227
Ancillary services
Disaggregation of Revenue [Line Items]
Resident fees and services	$ 500	$ 300

XML

INVESTMENT IN REAL ESTATE PROPERTIES - Capital and Other Expenditures Narrative (Details) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($)
Real Estate [Abstract]
Future capital expenditures	$ 65

XML

INVESTMENT IN REAL ESTATE PROPERTIES - Schedule of Investment in Joint Ventures (Details) $ in Thousands	Mar. 31, 2023 USD ($) property	Dec. 31, 2022 USD ($)
Unconsolidated Joint Venture
Book value	$ 139,402	$ 134,962
Sienna Joint Venture
Unconsolidated Joint Venture
Ownership	50.00%
Book value	$ 119,824	120,269
Marlin Spring Joint Venture
Unconsolidated Joint Venture
Ownership	85.00%
Book value	$ 19,578	$ 14,693
Senior Housing - Managed | Sienna Joint Venture
Unconsolidated Joint Venture
Number of properties | property	12
Senior Housing - Managed | Marlin Spring Joint Venture
Unconsolidated Joint Venture
Number of properties | property	4

XML

INVESTMENT IN REAL ESTATE PROPERTIES - Investment in Unconsolidated Joint Venture Narrative (Details) $ in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2023 CAD ($) property	Dec. 31, 2022 USD ($)	Mar. 31, 2022
Marlin Spring Joint Venture
Unconsolidated Joint Venture
Equity interest in joint venture	85.00%
Marlin Spring Joint Venture | Senior Housing - Managed
Unconsolidated Joint Venture
Number of acquired properties | property	1
Payments to acquire buildings	$ 30.0
Enlivant Joint Venture
Unconsolidated Joint Venture
Equity interest, investment basis amount		$ 0.0
Other-than-temporary impairment of unconsolidated joint ventures		$ 57.8
Equity interest in joint venture			49.00%
Marlin Spring Joint Venture | Marlin Spring Joint Venture | Senior Housing - Managed
Unconsolidated Joint Venture
Debt assumed	$ 23.6

XML

INVESTMENT IN REAL ESTATE PROPERTIES - Net Investment in Sales-Type Lease Narrative (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($) property
Real Estate Properties [Line Items]
Net proceeds from sales-type lease	$ 25,490	$ 0
Skilled nursing transitional care facility
Real Estate Properties [Line Items]
Net investment in sales type lease			$ 25,500
Properties in sales-type | property			1
Net proceeds from sales-type lease	$ 25,500

XML

IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS - Narrative (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($) facility	Mar. 31, 2022 USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment of real estate | $	$ 7,064	$ 0
Held-for-sale or sold | Skilled nursing transitional care facility
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of properties | facility	1

XML

IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS - Dispositions (Details) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($) facility	Mar. 31, 2022 USD ($) facility
Dispositions:
Number of facilities | facility	8	0
Consideration, net of closing costs	$ 160.3	$ 0.0
Net carrying value	181.8	0.0
Net loss on sale	(21.5)	0.0
Net (loss) income	$ (22.1)	$ 0.1

XML

LOANS RECEIVABLE AND OTHER INVESTMENTS - Composition of Loans Receivable and Other Investments (Details) $ in Thousands	Mar. 31, 2023 USD ($) investment loan preferredEquityInvestment	Dec. 31, 2022 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Loans Receivable:
Quantity | loan	13
Principal balance	$ 366,200	$ 370,364
Book value	362,768	366,936
Allowance for loan losses	(6,403)	(6,611)	$ (6,851)	$ (6,344)
Book value	$ 356,365	360,325
Weighted Average Contractual Interest Rate / Rate of Return	7.60%
Weighted Average Annualized Effective Interest Rate / Rate of Return	7.50%
Other Investments:
Quantity | preferredEquityInvestment	6
Principal balance	$ 52,551	50,902
Book value	$ 52,714	51,071
Weighted Average Contractual Interest Rate / Rate of Return	10.90%
Weighted Average Annualized Effective Interest Rate / Rate of Return	10.80%
Total quantity | investment	19
Total principal balance	$ 418,751
Total book value	$ 409,079	411,396
Total weighted average contractual interest rate / rate of return	8.00%
Total weighted average annualized effective interest rate / rate of return	7.90%
Mortgage
Loans Receivable:
Quantity | loan	2
Principal balance	$ 319,000
Book value	$ 319,000	319,000
Weighted Average Contractual Interest Rate / Rate of Return	7.60%
Weighted Average Annualized Effective Interest Rate / Rate of Return	7.60%
Other
Loans Receivable:
Quantity | loan	11
Principal balance	$ 47,200
Book value	$ 43,768	$ 47,936
Weighted Average Contractual Interest Rate / Rate of Return	7.10%
Weighted Average Annualized Effective Interest Rate / Rate of Return	6.50%

XML

LOANS RECEIVABLE AND OTHER INVESTMENTS - Narrative (Details) - Future funding on investment $ in Millions	Mar. 31, 2023 USD ($) investment
Accounts, Notes, Loans and Financing Receivable [Line Items]
Future funding commitment | $	$ 28.0
Number of preferred equity investments for funding commitment	2
Number of loan receivable investments for funding commitment	1

XML

LOANS RECEIVABLE AND OTHER INVESTMENTS - Schedule of Additional Information Regarding the Company's Loans Receivable (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($) loan	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($) loan
Financing Receivable, Allowance for Credit Loss [Roll Forward]
Balance at beginning of the period	$ 6,611	$ 6,344
(Recovery of) provision for loan losses	(208)	507
Balance at end of the period	6,403	$ 6,851
Accounts, Notes, Loans and Financing Receivable [Line Items]
Principal balance	366,200		$ 370,364
Book value	$ 356,365		$ 360,325
Nonaccrual status
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of loans receivable investments | loan	3		3
Book value	$ 0		$ 0
Receivables with deteriorated credit quality
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of loans receivable investments | loan	1		1
Principal balance	$ 1,214		$ 1,214
Book value	$ 0		$ 0

XML

DEBT - Secured Indebtedness (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Deferred financing costs	$ 19,724
Secured Debt
Debt Instrument [Line Items]
Deferred financing costs	879	$ 900
Secured Debt | Fixed Rate
Debt Instrument [Line Items]
Principal balance	$ 49,633	$ 50,123
Weighted average interest rate (percent)	2.84%
Weighted average effective interest rate (percent)	3.34%

XML

DEBT - Senior Unsecured Notes (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Discount, net	$ 3,719
Deferred financing costs	19,724
Senior Notes
Debt Instrument [Line Items]
Principal balance	1,750,000	$ 1,750,000
Discount, net	3,719	3,500
Deferred financing costs	$ 11,637	12,000
Weighted average effective interest rate (percent)	4.01%
Senior Notes | 5.125% senior unsecured notes due 2026 (“2026 Notes”)
Debt Instrument [Line Items]
Interest rate (percent)	5.125%
Principal balance	$ 500,000	500,000
Senior Notes | 5.88% senior unsecured notes due 2027 (“2027 Notes”)
Debt Instrument [Line Items]
Interest rate (percent)	5.88%
Principal balance	$ 100,000	100,000
Senior Notes | 3.90% senior unsecured notes due 2029 (“2029 Notes”)
Debt Instrument [Line Items]
Interest rate (percent)	3.90%
Principal balance	$ 350,000	350,000
Senior Notes | 3.20% senior unsecured notes due 2031 (“2031 Notes”)
Debt Instrument [Line Items]
Interest rate (percent)	3.20%
Principal balance	$ 800,000	$ 800,000

XML

DEBT - Senior Unsecured Notes Narrative (Details) - Senior Notes	Mar. 31, 2023
5.125% senior unsecured notes due 2026 (“2026 Notes”)
Debt Instrument [Line Items]
Interest rate (percent)	5.125%
5.88% senior unsecured notes due 2027 (“2027 Notes”)
Debt Instrument [Line Items]
Interest rate (percent)	5.88%
5.375% Senior Unsecured Notes Due 2023
Debt Instrument [Line Items]
Interest rate (percent)	5.375%
3.90% senior unsecured notes due 2029 (“2029 Notes”)
Debt Instrument [Line Items]
Interest rate (percent)	3.90%
3.20% senior unsecured notes due 2031 (“2031 Notes”)
Debt Instrument [Line Items]
Interest rate (percent)	3.20%

XML

DEBT - Credit Agreement Narrative (Details)		3 Months Ended
	Jan. 04, 2023 USD ($) extensionOption	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Mar. 31, 2023 CAD ($)	Jan. 04, 2023 CAD ($) extensionOption	Dec. 31, 2022 USD ($)	Sep. 09, 2019 USD ($)	Sep. 09, 2019 CAD ($)
Debt Instrument [Line Items]
Loss on extinguishment of debt		$ 1,541,000	$ 271,000
Amount outstanding under credit facility		79,563,000				$ 196,982,000
Credit Agreement
Debt Instrument [Line Items]
Loss on extinguishment of debt		1,500,000
Deferred finance costs		18,100,000
Credit Agreement | Revolving Credit Facility
Debt Instrument [Line Items]
Borrowing capacity	$ 1,000,000,000						$ 1,000,000,000
Borrowing capacity in certain foreign currencies	$ 350,000,000						175,000,000
Basis spread on variable rate	1.00%
Number of extension options | extensionOption	2				2
Extension period	6 months
Amount outstanding under credit facility		79,600,000		$ 86,000,000
Available borrowing capacity		$ 920,400,000
Interest rate		6.05%		6.05%
Credit Agreement | Revolving Credit Facility | Minimum
Debt Instrument [Line Items]
Annum percent unused borrowing fee	0.125%	0.125%
Credit Agreement | Revolving Credit Facility | Maximum
Debt Instrument [Line Items]
Annum percent unused borrowing fee	0.30%	0.30%
Credit Agreement | Revolving Credit Facility | Prime Rate
Debt Instrument [Line Items]
Basis spread on variable rate	0.50%	0.50%
Credit Agreement | Revolving Credit Facility | Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate	1.00%	1.00%
Credit Agreement | Revolving Credit Facility | Base Rate | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate	0.00%	0.00%
Credit Agreement | Revolving Credit Facility | Base Rate | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate	0.45%	0.45%
Credit Agreement | Revolving Credit Facility | LIBOR | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate		0.775%
Credit Agreement | Revolving Credit Facility | LIBOR | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate		1.45%
Credit Agreement | Revolving Credit Facility | SOFR | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate	0.775%
Credit Agreement | Revolving Credit Facility | SOFR | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate	1.45%
Credit Agreement | Line of Credit
Debt Instrument [Line Items]
Borrowing capacity	$ 2,750,000,000						2,750,000,000
U.S. dollar Term Loan | Credit Agreement
Debt Instrument [Line Items]
Aggregate principal amount	$ 430,000,000						$ 436,300,000
Loss on extinguishment of debt		$ 300,000
Interest rate		6.22%		6.22%
Effective interest rate		3.85%		3.85%
U.S. dollar Term Loan | Credit Agreement | Interest rate swaps
Debt Instrument [Line Items]
Aggregate principal amount		$ 430,000,000
Fixed interest rate under swap		1.51%		1.51%
U.S. dollar Term Loan | Credit Agreement | Base Rate | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate	0.00%	0.00%
U.S. dollar Term Loan | Credit Agreement | Base Rate | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate	0.65%	0.65%
U.S. dollar Term Loan | Credit Agreement | LIBOR | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate		0.85%
U.S. dollar Term Loan | Credit Agreement | LIBOR | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate		1.65%
U.S. dollar Term Loan | Credit Agreement | SOFR | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate	0.85%
U.S. dollar Term Loan | Credit Agreement | SOFR | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate	1.65%
Canadian dollar Term Loan | Credit Agreement
Debt Instrument [Line Items]
Aggregate principal amount					$ 150,000,000			$ 125,000,000
Interest rate		6.20%		6.20%
Effective interest rate		2.88%		2.88%
Canadian dollar Term Loan | Credit Agreement | Interest rate swaps
Debt Instrument [Line Items]
Aggregate principal amount				$ 150,000,000
Fixed interest rate under swap		1.63%		1.63%
Canadian dollar Term Loan | Credit Agreement | CDOR | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate	0.85%	0.85%
Canadian dollar Term Loan | Credit Agreement | CDOR | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate	1.65%	1.65%

XML

DEBT - Interest Expense Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Debt Disclosure [Abstract]
Interest expense	$ 28,540	$ 24,972
Non-cash interest expense	3,014	$ 2,698
Accrued interest	$ 21,400		$ 18,200

XML

DEBT - Schedule of Maturities for Outstanding Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
April 1 through December 31, 2023	$ 1,489
2024	2,034
2025	2,089
2026	502,147
2027	181,769
Thereafter	1,730,533
Total Debt	2,420,061
Discount, net	(3,719)
Deferred financing costs, net	(19,724)
Total Debt, Net	2,396,618
Secured Indebtedness
Debt Instrument [Line Items]
April 1 through December 31, 2023	1,489
2024	2,034
2025	2,089
2026	2,147
2027	2,206
Thereafter	39,668
Total Debt	49,633
Discount, net	0
Deferred financing costs, net	(879)	$ (900)
Total Debt, Net	48,754
Revolving Credit Facility
Debt Instrument [Line Items]
April 1 through December 31, 2023	0
2024	0
2025	0
2026	0
2027	79,563
Thereafter	0
Total Debt	79,563
Discount, net	0
Deferred financing costs, net	0
Total Debt, Net	79,563
Term Loans
Debt Instrument [Line Items]
April 1 through December 31, 2023	0
2024	0
2025	0
2026	0
2027	0
Thereafter	540,865
Total Debt	540,865
Discount, net	0
Deferred financing costs, net	(7,208)
Total Debt, Net	533,657
Senior Notes
Debt Instrument [Line Items]
April 1 through December 31, 2023	0
2024	0
2025	0
2026	500,000
2027	100,000
Thereafter	1,150,000
Total Debt	1,750,000
Discount, net	(3,719)	(3,500)
Deferred financing costs, net	(11,637)	$ (12,000)
Total Debt, Net	$ 1,734,644

XML

DERIVATIVE AND HEDGING INSTRUMENTS - Narrative (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Derivative [Line Items]
Fair value of derivatives in a net liability position	$ 0		$ 0
Credit risk-related contingent features
Derivative [Line Items]
Fair value of derivatives in a net liability position	0
Cash flow hedges | Interest rate swaps
Derivative [Line Items]
Ineffectiveness on cash flow hedges	0	$ 0
Designated as Hedging Instrument
Derivative [Line Items]
Fair value of derivatives in a net liability position	174,428,000		$ 243,270,000
Designated as Hedging Instrument | Cash flow hedges
Derivative [Line Items]
Gains included in accumulated other comprehensive income expected to be reclassified into retained earnings in the next 12 months	5,400,000
Not Designated as Hedging Instrument | Cross currency interest rate swaps
Derivative [Line Items]
Other expense related to derivatives	$ 0	$ 100,000

XML

DERIVATIVE AND HEDGING INSTRUMENTS - Notional Amount of Derivatives Instruments (Details)	Mar. 31, 2023 USD ($) derivative	Mar. 31, 2023 CAD ($) derivative	Dec. 31, 2022 USD ($)	Dec. 31, 2022 CAD ($)
Cash flow hedges | Designated as hedging instrument
Derivative [Line Items]
Notional amount	$ 753,750,000		$ 436,250,000
Cash flow hedges | Designated as hedging instrument | Cross currency interest rate swaps
Derivative [Line Items]
Notional amount		$ 300,000,000		$ 125,000,000
Cash flow hedges | Designated as hedging instrument | Interest Rate Swap
Derivative [Line Items]
Number of interest rate swaps | derivative	2	2
Cash flow hedges | Designated as hedging instrument | Interest Rate Swap One
Derivative [Line Items]
Notional amount	$ 323,800,000
Cash flow hedges | Designated as hedging instrument | Interest Rate Swap Two
Derivative [Line Items]
Notional amount		$ 150,000,000
Net Investment Hedges | Designated as hedging instrument
Derivative [Line Items]
Notional amount		236,000,000		329,500,000
Net Investment Hedges | Designated as hedging instrument | Cross currency interest rate swaps
Derivative [Line Items]
Notional amount		56,300,000		55,991,000
Net Investment Hedges | Not designated as hedging instrument | Cross currency interest rate swaps
Derivative [Line Items]
Notional amount		$ 0		$ 309,000

XML

DERIVATIVE AND HEDGING INSTRUMENTS - Derivative and Financial Instruments Designated as Hedging Instruments (Details) $ in Thousands	Mar. 31, 2023 USD ($) instrument	Dec. 31, 2022 USD ($)
Assets:
Fair value	$ 19,823	$ 21,477
Liabilities:
Fair value	$ 0	$ 0
Derivative liability, statement of financial position		Accounts payable and accrued liabilities, Revolving credit facility, Term loans, net
Derivative asset, statement of financial position	Accounts receivable, prepaid expenses and other assets, net
Designated as hedging instrument
Assets:
Fair value	$ 19,823	$ 21,477
Liabilities:
Fair value	$ 174,428	243,270
Designated as hedging instrument | Interest rate swaps | Cash flow
Assets:
Count | instrument	5
Fair value	$ 8,753	11,004
Designated as hedging instrument | Interest rate collars | Cash flow
Assets:
Count | instrument	2
Fair value	$ 5,308	6,622
Designated as hedging instrument | Forward starting interest rate swaps | Cash flow
Assets:
Count | instrument	4
Fair value	$ 1,977	0
Designated as hedging instrument | Cross currency interest rate swaps | Net investment
Assets:
Count | instrument	2
Fair value	$ 3,785	3,851
Designated as hedging instrument | Currency Swap | Net investment | Revolving credit facility
Liabilities:
Count | instrument	1
Fair value	$ 63,563	150,982
Designated as hedging instrument | Currency Swap | Net investment | Term loans, net
Liabilities:
Count | instrument	1
Fair value	$ 110,865	$ 92,288

XML

DERIVATIVE AND HEDGING INSTRUMENTS - Effect of Derivative Financial Instruments on the Condensed Consolidated Statements of (Loss) Income and Condensed Consolidated Statements of Equity (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in other comprehensive income, cash flow hedges and net investment hedges	$ 385	$ 7,153
Interest rate products
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in other comprehensive income, cash flow hedges	1,565	9,652
Interest rate products | Interest expense
Derivative Instruments, Gain (Loss) [Line Items]
Loss reclassified from accumulated other comprehensive income into income, cash flow hedges	1,572	(2,704)
Foreign currency products
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in other comprehensive income, net investment hedges	(14)	(986)
Currency Swap
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in other comprehensive income, net investment hedges	(140)	(1,513)
Currency Swap | Revolving Credit Facility
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in other comprehensive income, net investment hedges	$ (1,026)	$ 0

XML

DERIVATIVE AND HEDGING INSTRUMENTS - Gross Presentation, Effects of Offsetting, and Net Presentation of Derivatives (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Offsetting Assets:
Gross Amounts of Recognized Assets / Liabilities	$ 19,823	$ 21,477
Gross Amounts Offset in the Balance Sheet	0	0
Net Amounts of Assets / Liabilities presented in the Balance Sheet	19,823	21,477
Financial Instruments	0	0
Cash Collateral Received	0	0
Net Amount	19,823	21,477
Offsetting Liabilities:
Gross Amounts of Recognized Assets / Liabilities	0	0
Gross Amounts Offset in the Balance Sheet	0	0
Net Amounts of Assets / Liabilities presented in the Balance Sheet	0	0
Financial Instruments	0	0
Cash Collateral Received	0	0
Net Amount	$ 0	$ 0

XML

FAIR VALUE DISCLOSURES - Narrative (Details) - Discount Rate	Mar. 31, 2023
Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Loans receivable, measurement input	0.07
Preferred equity investments, measurement input	0.10
Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Loans receivable, measurement input	0.16
Preferred equity investments, measurement input	0.15
Weighted Average
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Loans receivable, measurement input	0.07
Preferred equity investments, measurement input	0.11
Weighted Average | Secured Indebtedness
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt, measurement input	0.06

XML

FAIR VALUE DISCLOSURES - Face Values, Carrying Amounts and Fair Values of Financial Instruments (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Financial assets:
Loans receivable	$ 366,200	$ 370,364
Preferred equity investments	52,551	50,902
Senior Notes
Financial liabilities:
Financial liabilities	1,750,000	1,750,000
Secured Indebtedness
Financial liabilities:
Financial liabilities	49,633	50,123
Carrying Amount
Financial assets:
Loans receivable	356,365	360,325
Preferred equity investments	52,714	51,071
Carrying Amount | Senior Notes
Financial liabilities:
Financial liabilities	1,734,644	1,734,431
Carrying Amount | Secured Indebtedness
Financial liabilities:
Financial liabilities	48,754	49,232
Fair Value
Financial assets:
Loans receivable	370,048	370,188
Preferred equity investments	54,156	51,995
Fair Value | Senior Notes
Financial liabilities:
Financial liabilities	1,436,036	1,463,041
Fair Value | Secured Indebtedness
Financial liabilities:
Financial liabilities	$ 37,583	$ 38,149

XML

FAIR VALUE DISCLOSURES - Fair Value of Financial Instruments (Details) - Recurring $ in Thousands	Mar. 31, 2023 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loans receivable	$ 370,048
Preferred equity investments	54,156
Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	1,436,036
Secured Indebtedness
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	37,583
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loans receivable	0
Preferred equity investments	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Secured Indebtedness
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	0
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loans receivable	0
Preferred equity investments	0
Significant Other Observable Inputs (Level 2) | Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	1,436,036
Significant Other Observable Inputs (Level 2) | Secured Indebtedness
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	0
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loans receivable	370,048
Preferred equity investments	54,156
Significant Unobservable Inputs (Level 3) | Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	0
Significant Unobservable Inputs (Level 3) | Secured Indebtedness
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	$ 37,583

XML

FAIR VALUE DISCLOSURES - Items Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	$ 19,823	$ 21,477
Recurring | Interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	8,753
Recurring | Interest rate collars
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	5,308
Recurring | Forward starting interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	1,977
Recurring | Cross currency interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	3,785
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Interest rate collars
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Forward starting interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Cross currency interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0
Recurring | Significant Other Observable Inputs (Level 2) | Interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	8,753
Recurring | Significant Other Observable Inputs (Level 2) | Interest rate collars
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	5,308
Recurring | Significant Other Observable Inputs (Level 2) | Forward starting interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	1,977
Recurring | Significant Other Observable Inputs (Level 2) | Cross currency interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	3,785
Recurring | Significant Unobservable Inputs (Level 3) | Interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0
Recurring | Significant Unobservable Inputs (Level 3) | Interest rate collars
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0
Recurring | Significant Unobservable Inputs (Level 3) | Forward starting interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0
Recurring | Significant Unobservable Inputs (Level 3) | Cross currency interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	$ 0

XML

EQUITY - Common Stock (Details) - USD ($)		3 Months Ended
	Feb. 23, 2023	Mar. 31, 2023	Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Tax withholding obligations incurred on behalf of employees		$ 1,400,000	$ 3,300,000
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued upon vesting (in shares)		200,000
ATM Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate gross proceeds possible from sales of common stock under equity offering program	$ 500,000,000
Forward sale agreements term	1 year
Shares issued (in shares)		0
Amount available for issuance		$ 500,000,000

XML

EQUITY - Cash Dividends on Common Stock Declared and Paid (Details) - $ / shares		3 Months Ended
	Feb. 01, 2023	Mar. 31, 2023	Mar. 31, 2022
Equity [Abstract]
Common dividends (in dollars per share)	$ 0.30	$ 0.30	$ 0.30

XML

EQUITY - Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022	Dec. 31, 2021
Total Equity [Line Items]
Accumulated other comprehensive income (loss)	$ 2,976,227	$ 3,056,395	$ 3,361,523	$ 3,379,530
Total accumulated other comprehensive income
Total Equity [Line Items]
Accumulated other comprehensive income (loss)	17,438	19,063	$ 1,674	$ (10,021)
Foreign currency translation (loss) gain
Total Equity [Line Items]
Accumulated other comprehensive income (loss)	(455)	1,168
Unrealized gain on cash flow hedges
Total Equity [Line Items]
Accumulated other comprehensive income (loss)	$ 17,893	$ 17,895

XML

EARNINGS PER COMMON SHARE - Computation of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Numerator
Net (loss) income	$ (9,487)	$ 40,602
Denominator
Basic weighted average common shares and common equivalents (in shares)	231,164,876	230,859,993
Dilutive restricted stock units (in shares)	0	704,977
Diluted weighted average common shares (in shares)	231,164,876	231,564,970
Net (loss) income, per:
Basic common share (in dollars per share)	$ (0.04)	$ 0.18
Diluted common share (in dollars per share)	$ (0.04)	$ 0.18

XML

EARNINGS PER COMMON SHARE - Narrative (Details) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities not included in computation of diluted earnings per share (in shares)	700,000	13,100

XML

SUBSEQUENT EVENTS (Details) - $ / shares			3 Months Ended
	May 03, 2023	Feb. 01, 2023	Mar. 31, 2023	Mar. 31, 2022
Subsequent Event [Line Items]
Quarterly cash dividend declared on common stock (in dollars per share)		$ 0.30	$ 0.30	$ 0.30
Subsequent event
Subsequent Event [Line Items]
Quarterly cash dividend declared on common stock (in dollars per share)	$ 0.30